0000818479-26-000075 | 10-K | XBRL Viewer

Print Document

LEASES - SUPPLEMENTAL CASH FLOW INFORMATION (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows paid for operating leases	$ 62	$ 67	$ 68
Right-of-use assets obtained in exchange for new lease liabilities (non-cash investing activity):
Operating leases	$ 51	$ 19	$ 36

BENEFIT PLANS - ADDITIONAL INFORMATION (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Defined Benefit Plan Disclosure [Line Items]
Employer matching contribution of first 1% of contribution	100.00%
Employer matching contribution of next 5% of contribution	50.00%
Employer maximum matching contribution	5.00%
Defined contribution plan, cost recognized	$ 38	$ 34	$ 43
Gain (loss) attributable to discount rates	34	9
Loss attributable to plan experience different than anticipated	$ 13	4
Loss on lump sum participation rate for the Swiss plan		$ 1
Expected return on plan assets	2.00%
Percentage of total plan assets categorized as level 1	83.00%	83.00%
Expected contributions to defined benefit pension plans in 2026	$ 21
Minimum \| Defined Benefit Plan, Equity Securities
Defined Benefit Plan Disclosure [Line Items]
Target allocation for plan asset of equity securities	30.00%
Minimum \| Fixed Income Securities
Defined Benefit Plan Disclosure [Line Items]
Target allocation for plan asset of equity securities	30.00%
Minimum \| Real Estate
Defined Benefit Plan Disclosure [Line Items]
Target allocation for plan asset of equity securities	0.00%
Minimum \| Other Investments
Defined Benefit Plan Disclosure [Line Items]
Target allocation for plan asset of equity securities	0.00%
Maximum \| Defined Benefit Plan, Equity Securities
Defined Benefit Plan Disclosure [Line Items]
Target allocation for plan asset of equity securities	65.00%
Maximum \| Fixed Income Securities
Defined Benefit Plan Disclosure [Line Items]
Target allocation for plan asset of equity securities	65.00%
Maximum \| Real Estate
Defined Benefit Plan Disclosure [Line Items]
Target allocation for plan asset of equity securities	15.00%
Maximum \| Other Investments
Defined Benefit Plan Disclosure [Line Items]
Target allocation for plan asset of equity securities	25.00%

PROPERTY, PLANT AND EQUIPMENT, NET (Details) - USD ($) $ in Millions	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 2,433	$ 2,107
Less: Accumulated depreciation and amortization	1,572	1,341
Property, plant and equipment, net	861	766	$ 800
Land
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	52	46
Buildings and improvements
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	638	571
Machinery and equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	995	887
Capitalized software
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	614	516
Construction in progress
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 134	$ 87

ACCRUED LIABILITIES (Tables)

12 Months Ended

Dec. 31, 2025

Other Liabilities Disclosure [Abstract]

Schedule of Accrued Liabilities

Accrued liabilities were as follows:


	Year Ended December 31,
(in millions)	2025		2024

Compensation, benefits, and other employee-related liabilities	$	171	$	155
Sales and marketing programs	50		86
Reserve for distributor rebates	118		116
Restructuring costs	12		31

Professional and legal costs	52		105
Current portion of derivatives	30		12
Insurance	10		11
Warranty liabilities	18		21

Deferred income	74		95
Accrued interest	44		8


Current operating lease liabilities	47		46

Other	74		68
Accrued liabilities	$	700	$	754

FINANCING ARRANGEMENTS - ADDITIONAL INFORMATION (Details)		12 Months Ended
	Dec. 24, 2025	Dec. 31, 2025 USD ($)	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)
Debt Instrument [Line Items]
Notes payable and current portion of long-term debt		$ 313,000,000	$ 549,000,000
Total unused lines of credit		637,000,000
Debt Covenant Period One
Debt Instrument [Line Items]
Total leverage ratio, maximum	4.25
Debt Covenant Period Two
Debt Instrument [Line Items]
Total leverage ratio, maximum	2.50
Interest expense, net
Debt Instrument [Line Items]
Interest income		14,000,000	20,000,000	$ 16,000,000
Corporate commercial paper facility
Debt Instrument [Line Items]
Notes payable and current portion of long-term debt		82,000,000	410,000,000
Uncommitted Short-Term Financing
Debt Instrument [Line Items]
Notes payable and current portion of long-term debt		22,000,000
Other short-term borrowings
Debt Instrument [Line Items]
Notes payable and current portion of long-term debt		3,000,000	11,000,000
Line of Credit
Debt Instrument [Line Items]
Credit facilities, maximum borrowing capacity		$ 700,000,000
Revolving Credit Facility \| Line of Credit
Debt Instrument [Line Items]
Long-term debt, term		5 years
Credit facilities, maximum borrowing capacity		$ 700,000,000
Notes payable and current portion of long-term debt		0	$ 0
Corporate commercial paper facility \| Line of Credit
Debt Instrument [Line Items]
Credit facilities, maximum borrowing capacity		700,000,000
Notes payable and current portion of long-term debt		$ 82,000,000

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (Parenthetical) - $ / shares	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Statement of Stockholders' Equity [Abstract]
Cash dividends declared per common share (in dollars per share)	$ 0.64	$ 0.64	$ 0.56

STOCK COMPENSATION - INFORMATION ABOUT NON-QUALIFIED STOCK OPTIONS OUTSTANDING (Details) - $ / shares shares in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Remaining Contractual Life (in years)	8 years 8 months 12 days
Nonqualified Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number Outstanding (in shares)	6.2	2.2
Weighted Average Exercise Price (in dollars per share)	$ 19.88	$ 45.37
Number Exercisable (in shares)	1.1	1.4
Weighted Average Exercise Price Exercisable (in dollars per share)	$ 48.74	$ 50.27
Nonqualified Stock Options \| Exercise Prices:$5.01 - $10.00
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Exercise Prices, lower range limit (in dollars per share)	5.01
Range of Exercise Prices, upper range limit (in dollars per share)	$ 10.00
Number Outstanding (in shares)	0.0
Weighted Average Remaining Contractual Life (in years)	0 years
Weighted Average Exercise Price (in dollars per share)	$ 0
Number Exercisable (in shares)	0.0
Weighted Average Exercise Price Exercisable (in dollars per share)	$ 0
Nonqualified Stock Options \| Exercise Prices: $10.01 - $20.00
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Exercise Prices, lower range limit (in dollars per share)	10.01
Range of Exercise Prices, upper range limit (in dollars per share)	$ 20.00
Number Outstanding (in shares)	5.0
Weighted Average Remaining Contractual Life (in years)	9 years 7 months 6 days
Weighted Average Exercise Price (in dollars per share)	$ 13.09
Number Exercisable (in shares)	0.0
Weighted Average Exercise Price Exercisable (in dollars per share)	$ 0
Nonqualified Stock Options \| Exercise Prices: $20.01 - $30.00
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Exercise Prices, lower range limit (in dollars per share)	20.01
Range of Exercise Prices, upper range limit (in dollars per share)	$ 30.00
Number Outstanding (in shares)	0.0
Weighted Average Remaining Contractual Life (in years)	7 years 10 months 24 days
Weighted Average Exercise Price (in dollars per share)	$ 28.39
Number Exercisable (in shares)	0.0
Weighted Average Exercise Price Exercisable (in dollars per share)	$ 28.39
Nonqualified Stock Options \| Exercise Prices: $30.01 - $40.00
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Exercise Prices, lower range limit (in dollars per share)	30.01
Range of Exercise Prices, upper range limit (in dollars per share)	$ 40.00
Number Outstanding (in shares)	0.5
Weighted Average Remaining Contractual Life (in years)	7 years 8 months 12 days
Weighted Average Exercise Price (in dollars per share)	$ 36.99
Number Exercisable (in shares)	0.4
Weighted Average Exercise Price Exercisable (in dollars per share)	$ 37.49
Nonqualified Stock Options \| Exercise Prices: $40.01 - $50.00
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Exercise Prices, lower range limit (in dollars per share)	40.01
Range of Exercise Prices, upper range limit (in dollars per share)	$ 50.00
Number Outstanding (in shares)	0.3
Weighted Average Remaining Contractual Life (in years)	3 years 3 months 18 days
Weighted Average Exercise Price (in dollars per share)	$ 47.53
Number Exercisable (in shares)	0.3
Weighted Average Exercise Price Exercisable (in dollars per share)	$ 47.60
Nonqualified Stock Options \| Exercise Prices: $50.01 - $60.00
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Exercise Prices, lower range limit (in dollars per share)	50.01
Range of Exercise Prices, upper range limit (in dollars per share)	$ 60.00
Number Outstanding (in shares)	0.3
Weighted Average Remaining Contractual Life (in years)	4 years 1 month 6 days
Weighted Average Exercise Price (in dollars per share)	$ 55.69
Number Exercisable (in shares)	0.3
Weighted Average Exercise Price Exercisable (in dollars per share)	$ 55.69
Nonqualified Stock Options \| Exercise Prices: $60.01 - $70.00
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Exercise Prices, lower range limit (in dollars per share)	60.01
Range of Exercise Prices, upper range limit (in dollars per share)	$ 70.00
Number Outstanding (in shares)	0.1
Weighted Average Remaining Contractual Life (in years)	1 year
Weighted Average Exercise Price (in dollars per share)	$ 62.37
Number Exercisable (in shares)	0.1
Weighted Average Exercise Price Exercisable (in dollars per share)	$ 62.37

COMPREHENSIVE LOSS - CHANGES IN AOCI (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Accumulated other comprehensive income (loss) rollforward [Roll Forward]
Beginning balance	$ 1,943	$ 3,294	$ 3,812
Total other comprehensive income (loss)	91	(94)	(8)
Ending balance	1,340	1,943	3,294
Total
Accumulated other comprehensive income (loss) rollforward [Roll Forward]
Beginning balance	(730)	(636)	(628)
Other comprehensive income (loss) before reclassifications and tax impact	27	(50)
Tax benefit (expense)	60	(48)
Other comprehensive income (loss), net of tax, before reclassifications	87	(98)
Amounts reclassified from accumulated other comprehensive income, net of tax	4	4
Total other comprehensive income (loss)	91	(94)	(8)
Ending balance	(639)	(730)	(636)
Foreign Currency Translation (Loss) Gain
Accumulated other comprehensive income (loss) rollforward [Roll Forward]
Beginning balance	(619)	(473)
Other comprehensive income (loss) before reclassifications and tax impact	152	(113)
Tax benefit (expense)	33	(33)
Other comprehensive income (loss), net of tax, before reclassifications	185	(146)
Amounts reclassified from accumulated other comprehensive income, net of tax	0	0
Total other comprehensive income (loss)	185	(146)
Ending balance	(434)	(619)	(473)
(Loss) Gain on Cash Flow Hedges
Accumulated other comprehensive income (loss) rollforward [Roll Forward]
Beginning balance	(10)	(13)
Other comprehensive income (loss) before reclassifications and tax impact	0	0
Tax benefit (expense)	0	0
Other comprehensive income (loss), net of tax, before reclassifications	0	0
Amounts reclassified from accumulated other comprehensive income, net of tax	3	3
Total other comprehensive income (loss)	3	3
Ending balance	(7)	(10)	(13)
(Loss) Gain on Net Investment and Fair Value Hedges
Accumulated other comprehensive income (loss) rollforward [Roll Forward]
Beginning balance	(70)	(107)
Other comprehensive income (loss) before reclassifications and tax impact	(151)	48
Tax benefit (expense)	33	(11)
Other comprehensive income (loss), net of tax, before reclassifications	(118)	37
Amounts reclassified from accumulated other comprehensive income, net of tax	0	0
Total other comprehensive income (loss)	(118)	37
Ending balance	(188)	(70)	(107)
Pension Liability (Loss) Gain
Accumulated other comprehensive income (loss) rollforward [Roll Forward]
Beginning balance	(31)	(43)
Other comprehensive income (loss) before reclassifications and tax impact	26	15
Tax benefit (expense)	(6)	(4)
Other comprehensive income (loss), net of tax, before reclassifications	20	11
Amounts reclassified from accumulated other comprehensive income, net of tax	1	1
Total other comprehensive income (loss)	21	12
Ending balance	$ (10)	$ (31)	$ (43)

FINANCIAL INSTRUMENTS AND DERIVATIVES - SCHEDULE OF GAIN (LOSS) RECORDED IN AOCI IN THE CONSOLIDATED STATEMENTS OF OPERATIONS (Details) - Designated as Hedging Instrument - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Cross currency basis swaps \| Hedges of Net Investments
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain or (Loss) Recognized in AOCI	$ (49)	$ 11	$ (18)
Amount of Gain or (Loss) Reclassified from AOCI into Income	0	0	0
Foreign exchange forward contracts \| Hedges of Net Investments
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain or (Loss) Recognized in AOCI	(102)	37	(29)
Amount of Gain or (Loss) Reclassified from AOCI into Income	0	0	0
Foreign exchange forward contracts \| Fair Value Hedges
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain or (Loss) Recognized in AOCI	0	0	2
Amount of Gain or (Loss) Reclassified from AOCI into Income	0	0	0
Interest rate swaps \| Fair Value Hedges
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain or (Loss) Recognized in AOCI	0	0	0
Amount of Gain or (Loss) Reclassified from AOCI into Income	$ 0	$ 0	$ 0

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4C
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 182
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480401/815-10-55-182

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4D
-Subparagraph (a)(5)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4D

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4D
-Subparagraph (a)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4D

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4D
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4D

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4D
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4D

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4A
-Subparagraph (b)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4D
-Subparagraph (a)(6)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4D

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4D
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4D

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4A
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4C
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4CCC
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4CCC
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4CCC
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4CC
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4CC

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4C
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4C
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4C
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4C
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4C
-Subparagraph (bb)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4D
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4D

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4E
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4E

+ Details

LOSS PER COMMON SHARE

12 Months Ended

Dec. 31, 2025

Earnings Per Share [Abstract]

LOSS PER COMMON SHARE

The computations of basic and diluted loss per common share were as follows:


Basic Loss Per Common Share	Year Ended December 31,
(in millions, except per share amounts)	2025		2024		2023

Net loss attributable to Dentsply Sirona	$	(598)	$	(910)	$	(132)

Weighted average common shares outstanding	199.4		203.2		212.0

Basic loss per common share	$	(3.00)	$	(4.48)	$	(0.62)

Diluted Loss Per Common Share	Year Ended December 31,
(in millions, except per share amounts)	2025		2024		2023

Net loss attributable to Dentsply Sirona	$	(598)	$	(910)	$	(132)

Weighted average common shares outstanding	199.4		203.2		212.0
Incremental weighted average shares from assumed exercise of dilutive options from stock-based compensation awards	—		—		—
Total weighted average diluted shares outstanding	199.4		203.2		212.0

Diluted loss per common share	$	(3.00)	$	(4.48)	$	(0.62)

Weighted average shares excluded from diluted common shares outstanding due to reported net loss	0.8		0.6		1.1

Weighted average shares excluded from diluted common shares outstanding due to antidilutive nature	4.5		3.7		3.0

REVENUE RECOGNITION - NET SALES DISAGGREGATED BY PRODUCT CATEGORY (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Disaggregation of Revenue [Line Items]
Net sales	$ 3,680	$ 3,793	$ 3,965
Operating Segments
Disaggregation of Revenue [Line Items]
Net sales	3,680	3,793	3,965
Operating Segments \| Connected Technology Solutions
Disaggregation of Revenue [Line Items]
Net sales	1,036	1,062	1,169
Operating Segments \| Essential Dental Solutions
Disaggregation of Revenue [Line Items]
Net sales	1,469	1,454	1,468
Operating Segments \| Orthodontic and Implant Solutions
Disaggregation of Revenue [Line Items]
Net sales	850	973	1,040
Operating Segments \| Wellspect Healthcare
Disaggregation of Revenue [Line Items]
Net sales	325	304	288
Operating Segments \| Equipment & Instruments \| Connected Technology Solutions
Disaggregation of Revenue [Line Items]
Net sales	578	553	628
Operating Segments \| CAD/CAM \| Connected Technology Solutions
Disaggregation of Revenue [Line Items]
Net sales	458	509	541
Operating Segments \| Orthodontics \| Orthodontic and Implant Solutions
Disaggregation of Revenue [Line Items]
Net sales	227	299	339
Operating Segments \| Implants & Prosthetics \| Orthodontic and Implant Solutions
Disaggregation of Revenue [Line Items]
Net sales	$ 623	$ 674	$ 701

ACCRUED LIABILITIES

12 Months Ended

Dec. 31, 2025

Other Liabilities Disclosure [Abstract]

ACCRUED LIABILITIES

Accrued liabilities were as follows:


	Year Ended December 31,
(in millions)	2025		2024

Compensation, benefits, and other employee-related liabilities	$	171	$	155
Sales and marketing programs	50		86
Reserve for distributor rebates	118		116
Restructuring costs	12		31

Professional and legal costs	52		105
Current portion of derivatives	30		12
Insurance	10		11
Warranty liabilities	18		21

Deferred income	74		95
Accrued interest	44		8


Current operating lease liabilities	47		46

Other	74		68
Accrued liabilities	$	700	$	754

BENEFIT PLANS - SCHEDULE OF COMPONENETS OF NET PERIODIC BENEFIT COST (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Defined Benefit Plan Disclosure [Line Items]
Service cost	$ 11	$ 11
Interest cost	12	12	$ 14
Expected return on plan assets	(6)	(5)	(6)
Amortization of prior service credit	(1)	(1)	(1)
Amortization of net actuarial loss	1	2	0
Curtailment and settlement gains	2	0	0
Net periodic benefit cost	$ 19	19	17
Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Interest Cost, Statement of Income or Comprehensive Income [Extensible Enumeration]	Other Nonoperating Income (Expense)
Defined Benefit Plan, Net Periodic Benefit (Cost) Credit, Expected Return (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Other Nonoperating Income (Expense)
Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Amortization of Prior Service Cost (Credit), Statement of Income or Comprehensive Income [Extensible Enumeration]	Other Nonoperating Income (Expense)
Defined Benefit Plan, Net Periodic Benefit (Cost) Credit, Amortization of Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Other Nonoperating Income (Expense)
Defined Benefit Plan, Net Periodic Benefit (Cost) Credit, Curtailment Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Other Nonoperating Income (Expense)
Cost of products sold
Defined Benefit Plan Disclosure [Line Items]
Service cost	$ 4	4	4
Selling, general and administrative expenses
Defined Benefit Plan Disclosure [Line Items]
Service cost	$ 7	$ 7	$ 6

ACCRUED LIABILITIES (Details) - USD ($) $ in Millions	Dec. 31, 2025	Dec. 31, 2024
Other Liabilities Disclosure [Abstract]
Compensation, benefits, and other employee-related liabilities	$ 171	$ 155
Sales and marketing programs	50	86
Reserve for distributor rebates	118	116
Restructuring costs	12	31
Professional and legal costs	52	105
Current portion of derivatives	30	12
Insurance	10	11
Warranty liabilities	18	21
Deferred income	74	95
Accrued interest	44	8
Current operating lease liabilities	47	46
Other	74	68
Accrued liabilities	$ 700	$ 754

STOCK COMPENSATION - ASSUMPTIONS USED TO DETERMINE COMPENSATION COST FOR THE COMPANY'S NON-QUALIFIED STOCK OPTIONS ISSUED (Details) - Nonqualified Stock Options - $ / shares	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average fair value per NQSO (in dollars per share)	$ 3.14	$ 9.91	$ 12.64
Expected dividend yield	4.77%	1.92%	1.45%
Risk-free interest rate	3.81%	4.28%	4.27%
Expected volatility	36.30%	35.70%	35.80%
Expected life (years)	4 years 1 month 13 days	4 years 3 months 3 days	4 years 9 months 3 days

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(v)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (l)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 1D
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480483/718-10-35-3

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

LOSS PER COMMON SHARE (Tables)

12 Months Ended

Dec. 31, 2025

Earnings Per Share [Abstract]

Schedule of Computation of Basic and Diluted Loss Per Common Share

The computations of basic and diluted loss per common share were as follows:


Basic Loss Per Common Share	Year Ended December 31,
(in millions, except per share amounts)	2025		2024		2023

Net loss attributable to Dentsply Sirona	$	(598)	$	(910)	$	(132)

Weighted average common shares outstanding	199.4		203.2		212.0

Basic loss per common share	$	(3.00)	$	(4.48)	$	(0.62)

Diluted Loss Per Common Share	Year Ended December 31,
(in millions, except per share amounts)	2025		2024		2023

Net loss attributable to Dentsply Sirona	$	(598)	$	(910)	$	(132)

Weighted average common shares outstanding	199.4		203.2		212.0
Incremental weighted average shares from assumed exercise of dilutive options from stock-based compensation awards	—		—		—
Total weighted average diluted shares outstanding	199.4		203.2		212.0

Diluted loss per common share	$	(3.00)	$	(4.48)	$	(0.62)

Weighted average shares excluded from diluted common shares outstanding due to reported net loss	0.8		0.6		1.1

Weighted average shares excluded from diluted common shares outstanding due to antidilutive nature	4.5		3.7		3.0

INCOME TAXES - SCHEDULE OF THE TAX EFFECT OF SIGNIFICANT TEMPORARY DIFFERENCES GIVING RISE TO DEFERRED TAX ASSETS AND LIABILITIES (Details) - USD ($) $ in Millions	Dec. 31, 2025	Dec. 31, 2024
Deferred tax assets
Employee benefit accruals	$ 38	$ 40
Inventory	12	19
Miscellaneous accruals	36	50
Other	35	44
Lease right-of-use liability	33	39
Net unrealized gains/losses included in AOCI	57	0
Foreign tax credit and R&D carryforward	11	41
Tax loss carryforwards and other tax attributes	2,132	1,554
Total deferred tax assets	2,354	1,787
Less: Valuation allowances	(2,103)	(1,503)
Total deferred tax assets, net	251	284
Deferred tax liabilities
Identifiable intangible assets	(60)	(110)
Property, plant and equipment	(35)	(28)
Lease right-of-use asset	(32)	(38)
Net unrealized gains/losses included in AOCI	0	(9)
Taxes on unremitted earnings of foreign subsidiaries	(7)	(6)
Total deferred tax liabilities	(134)	(191)
Net deferred tax assets (liabilities)	$ 117	$ 93

INCOME TAXES - SCHEDULE OF THE RECONCILIATION OF THE U.S. FEDERAL STATUTORY TAX RATE TO THE EFFECTIVE RATE (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]
Statutory U.S. federal income tax rate	$ (102)	$ (197)	$ (37)
State income taxes, net of federal benefit / Cantonal tax		0	(2)
Changes in valuation allowances		(13)	5
Goodwill impairment		106	60
Global Intangible Low Taxed Income (GILTI)	7	9	12
Subpart F	8
Other cross-border	2
Tax credits	2
Share-based payment awards	6
Other non-taxable or non-deductible items	7
Changes in unrecognized tax benefits	2
Federal benefit of R&D and foreign tax credits		(7)	(17)
U.S. other permanent differences		3	5
Tax effect of international operations		42	(65)
Foreign Derived Intangible Income (FDII)		0	(9)
Net effect of tax audit activity		23	(6)
Tax effect of enacted statutory rate changes on Non-U.S. jurisdictions		3	1
Federal tax on unremitted earnings of certain foreign subsidiaries		(1)	2
Other		6	8
Total expense (benefit) for income taxes	$ 112	$ (26)	$ (43)
Effective Income Tax Rate Reconciliation, Percent [Abstract]
Statutory U.S. federal income tax rate	21.00%	21.00%	21.00%
State income taxes, net of federal benefit		0.00%	1.40%
Valuation allowance adjustments		1.30%	(3.20%)
Goodwill impairment		(11.30%)	(34.60%)
Global Intangible Low Taxed Income (GILTI)	(1.50%)	(1.00%)	(7.00%)
Subpart F	(0.017)
Other cross-border	(0.40%)
Tax credits	(0.40%)
Share-based payment awards	(1.20%)
Other non-taxable or non-deductible items	(1.50%)
Changes in unrecognized tax benefits	(0.40%)
Federal benefit of R&D and foreign tax credits		0.80%	10.00%
U.S. other permanent differences		(0.003)	(0.027)
Tax effect of international operations		(4.50%)	37.20%
Foreign Derived Intangible Income (FDII)		0.00%	5.20%
Net effect of tax audit activity		(2.50%)	3.20%
Tax effect of enacted statutory rate changes on Non-U.S. jurisdictions		(0.30%)	(0.40%)
Federal tax on unremitted earnings of certain foreign subsidiaries		0.10%	(0.90%)
Other		(0.50%)	(4.40%)
Effective income tax rate on operations	(23.10%)	2.80%	24.80%
United States
Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]
State income taxes, net of federal benefit / Cantonal tax	$ 3
Goodwill impairment	24
Other	$ 10
Effective Income Tax Rate Reconciliation, Percent [Abstract]
State income taxes, net of federal benefit	(0.60%)
Goodwill impairment	(4.90%)
Other	(2.10%)
Germany
Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]
Statutory income tax rate differential	$ 16
Trade tax	(18)
Changes in valuation allowances	16
Goodwill impairment	8
Other	$ 2
Effective Income Tax Rate Reconciliation, Percent [Abstract]
Statutory income tax rate differential	(3.30%)
Trade tax	0.037
Valuation allowance adjustments	(3.30%)
Goodwill impairment	(1.60%)
Other	(0.40%)
Israel
Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]
Statutory income tax rate differential	$ 16
Goodwill impairment	18
Other	$ (4)
Effective Income Tax Rate Reconciliation, Percent [Abstract]
Statutory income tax rate differential	(3.30%)
Goodwill impairment	(3.70%)
Other	0.80%
Luxembourg
Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]
Changes in valuation allowances	$ 238
Other	3
Local impairment losses	(250)
Foreign exchange differences	$ 11
Effective Income Tax Rate Reconciliation, Percent [Abstract]
Valuation allowance adjustments	(48.90%)
Other	(0.60%)
Local impairment losses	0.513
Foreign exchange differences	(2.30%)
Sweden
Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]
Goodwill impairment	$ 26
Other	$ 2
Effective Income Tax Rate Reconciliation, Percent [Abstract]
Goodwill impairment	(5.30%)
Other	(0.40%)
Switzerland
Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]
State income taxes, net of federal benefit / Cantonal tax	$ 28
Statutory income tax rate differential	(21)
Changes in valuation allowances	55
Local impairment losses	(38)
Foreign exchange differences	$ (4)
Effective Income Tax Rate Reconciliation, Percent [Abstract]
State income taxes, net of federal benefit	(5.70%)
Statutory income tax rate differential	4.30%
Valuation allowance adjustments	(11.30%)
Local impairment losses	0.078
Foreign exchange differences	0.80%
Other
Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]
Statutory income tax rate differential	$ 39
Effective Income Tax Rate Reconciliation, Percent [Abstract]
Statutory income tax rate differential	(8.00%)

LEASES (Tables)

12 Months Ended

Dec. 31, 2025

Leases [Abstract]

Schedule of Assets and Liabilities, Leases

The net present value of finance and operating lease right-of-use assets and liabilities was as follows:


		Year Ended December 31,
(in millions, except percentages)	Location in the Consolidated Balance Sheets	2025			2024

Assets
Finance leases	Property, plant, and equipment, net	$	—		$	—
Operating leases	Operating lease right-of-use assets, net	139			136
Total right-of-use assets		$	139		$	136

Liabilities
Current liabilities

Operating leases	Accrued liabilities	47			46
Noncurrent liabilities
Finance leases	Long-term debt	—			—
Operating leases	Operating lease liabilities	93			91
Total lease liabilities		$	140		$	137

Supplemental information:
Weighted-average discount rate

Operating leases		4.6		%	4.1		%

Weighted-average remaining lease term in years

Operating leases		4.0			4.1

Schedule of Lease Costs and Supplemental Cash Flow Information For Leases

The lease costs recognized in the Consolidated Statements of Operations were as follows:


	Year Ended December 31,
(in millions)	2025		2024




Operating lease cost	$	65	$	67

Variable lease cost	17		16
Total lease cost	$	82	$	83

The supplemental cash flow information for leases was as follows:


	Year Ended December 31,
(in millions)	2025		2024		2023

Cash paid for amounts included in the measurement of lease liabilities:

Operating cash flows paid for operating leases	$	62	$	67	$	68


Right-of-use assets obtained in exchange for new lease liabilities (non-cash investing activity):

Operating leases	51		19		36

Schedule of Contractual Maturity Dates, Operating Lease

The contractual maturity dates of the remaining lease liabilities as of December 31, 2025 were as follows:


(in millions)	Operating Leases

2026	$	52
2027	38
2028	26
2029	17
2030	9
2031 and beyond	12
Total lease payments	$	154
Less imputed interest	14
Present value of lease liabilities	$	140

RESTRUCTURING AND OTHER COSTS (Tables)

12 Months Ended

Dec. 31, 2025

Restructuring and Related Activities [Abstract]

Schedule of Restructuring and Related Costs

Restructuring and other costs for the years ended December 31, 2025, 2024 and 2023 were recorded in the Consolidated Statements of Operations as follows:


Affected Line Item in the Consolidated Statements of Operations	Year Ended December 31,
(in millions)	2025		2024		2023

Cost of products sold	$	—	$	10	$	4
Selling, general, and administrative expenses	1		32		3
Restructuring costs	24		53		67

Total Restructuring and other costs	$	25	$	95	$	74

Schedule of Restructuring Accruals

The liabilities associated with the Company’s restructuring plans are recorded in Accrued liabilities and Other noncurrent liabilities in the Consolidated Balance Sheets. Activity in the Company’s restructuring accruals at December 31, 2025 was as follows:


	Severance
(in millions)	2023 and Prior Plans		2024 Plans		Other Actions		Total

Balance at December 31, 2024	$	13	$	19	$	—	$	32
Provisions and adjustments	1		4		16		21
Amounts applied	(11)		(19)		(7)		(37)
Change in estimates	(2)		(2)		(2)		(6)
Balance at December 31, 2025	$	1	$	2	$	7	$	10


	Other Restructuring Costs
(in millions)	2023 and Prior Plans		2024 Plans		Other Actions		Total

Balance at December 31, 2024	$	1	$	—	$	—	$	1
Provisions and adjustments	1		1		2		4
Amounts applied	(2)		(1)		—		(3)

Balance at December 31, 2025	$	—	$	—	$	2	$	2

The Company’s restructuring accruals at December 31, 2024 were as follows:


	Severances
(in millions)	2022 and Prior Plans		2023 Plans		2024 Plans		Total

Balance at December 31, 2023	$	2	$	37	$	—	$	39
Provisions and adjustments	1		23		30		54
Amounts applied	(2)		(44)		(11)		(57)
Change in estimates	—		(4)		—		(4)
Balance at December 31, 2024	$	1	$	12	$	19	$	32


	Other Restructuring Costs
(in millions)	2022 and Prior Plans		2023 Plans		2024 Plans		Total

Balance at December 31, 2023	$	1	$	—	$	—	$	1
Provisions and adjustments	—		3		—		3
Amounts applied	—		(3)		—		(3)
Change in estimates	—		—		—		—
Balance at December 31, 2024	$	1	$	—	$	—	$	1

The impact of the 2024 charges related to changes to the Company’s Byte clear aligners business was as follows:


Location in the Consolidated Statements of Operations
(in millions)	December 31, 2024

Net sales
Change in refund estimate	$	(35)
Cost of products sold
Inventory reserve	(8)
Selling, general, and administrative expenses
Intangible asset impairment - trademark	(152)
Property, plant and equipment write-off	(17)
Accounts receivable reserve and prepaid write-off	(10)
Total impact on operating loss	$	(222)

Schedule of Segment Information

The Company’s segment financial information was as follows:


	Year Ended December 31,
	2025
(in millions)	Connected Technology Solutions	Essential Dental Solutions	Orthodontic and Implant Solutions	Wellspect Healthcare	Total

Net sales	1,036	1,469	850	325	3,680

Adjusted cost of products sold (a)	614	555	392	131




Adjusted selling expenses (b)	221	301	222	55
Adjusted G&A expenses (b)	81	76	80	27

Adjusted R&D expenses (c)	68	23	48	10

Segment adjusted operating income	52	514	108	102	776

Reconciling items (income) expense:
Unallocated corporate costs (d)					311
Interest expense, net					88
Other (income) expense, net					(24)
Goodwill and intangible asset impairments					650
Restructuring and other costs					24
Amortization of intangibles					211
Depreciation resulting from the fair value step-up of property, plant, and equipment from business combinations					2
Loss before income taxes					(486)

(a) Adjusted cost of products sold represents expenses adjusted to exclude intangible amortization expense, step-up depreciation expense, and other restructuring costs.

(b) Adjusted selling and adjusted G&A expenses represent expenses adjusted to exclude intangible amortization expense, other acquisition costs, step-up depreciation expense, and other restructuring costs.

(d) Unallocated corporate costs consist of general corporate expenses including corporate headcount costs, depreciation and amortization, certain professional service fees, and other operating costs which are not assigned to a specific segment.


	Year Ended December 31,
	2024
(in millions)	Connected Technology Solutions	Essential Dental Solutions	Orthodontic and Implant Solutions	Wellspect Healthcare	Total

Net sales	1,062	1,454	973	304	3,793

Adjusted cost of products sold (a)	602	565	407	117




Adjusted selling expenses (b)	242	313	301	52
Adjusted G&A expenses (b)	74	74	133	27

Adjusted R&D expenses (c)	74	23	52	10

Segment adjusted operating income	70	479	80	98	727

Reconciling items (income) expense:
Unallocated corporate costs (d)					320
Interest expense, net					69
Other (income) expense, net					(12)
Goodwill and intangible asset impairments					1,014
Restructuring and other costs					53
Amortization of intangibles					216
Depreciation resulting from the fair value step-up of property, plant, and equipment from business combinations					3
Loss before income taxes					(936)

(a) Adjusted cost of products sold represents expenses adjusted to exclude intangible amortization expense, step-up depreciation expense, and other restructuring costs.


	Year Ended December 31,
	2023
(in millions)	Connected Technology Solutions	Essential Dental Solutions	Orthodontic and Implant Solutions	Wellspect Healthcare	Total

Net sales	1,169	1,468	1,040	288	3,965

Adjusted cost of products sold (a)	645	560	402	114




Adjusted selling expenses (b)	264	313	305	51
Adjusted G&A expenses (b)	77	94	119	25

Adjusted R&D expenses (c)	82	23	58	11

Segment adjusted operating income	101	478	156	87	822

Reconciling items (income) expense:
Unallocated corporate costs (d)					319
Interest expense, net					81
Other (income) expense, net					9
Goodwill and intangible asset impairments					307
Restructuring and other costs					67
Amortization of intangibles					211
Depreciation resulting from the fair value step-up of property, plant, and equipment from business combinations					3
Loss before income taxes					(175)

(a) Adjusted cost of products sold represents expenses adjusted to exclude intangible amortization expense, step-up depreciation expense, and other restructuring costs.


Depreciation and Amortization	Year Ended December 31,
(in millions)	2025		2024		2023

Connected Technology Solutions	$	186	$	175	$	176
Essential Dental Solutions	34		35		33
Orthodontic and Implant Solutions	90		98		97
Wellspect Healthcare	18		19		18
All Other (a)	24		22		19
Total	$	352	$	349	$	343

(a) Includes unallocated corporate costs for depreciation and amortization

The cumulative amounts for the provisions and adjustments and amounts applied for all the plans by segment were as follows:


(in millions)	December 31, 2024		Provisions and Adjustments		Amounts Applied		Change in Estimates		December 31, 2025

Connected Technology Solutions	$	9	$	6	$	(10)	$	(4)	$	1
Essential Dental Solutions	11		3		(9)		(1)		4
Orthodontic and Implant Solutions	9		7		(12)		(1)		3
Wellspect Healthcare	3		1		(2)		—		2
All Other	1		8		(7)		—		2
Total	$	33	$	25	$	(40)	$	(6)	$	12

The cumulative amounts for the provisions and adjustments and amounts applied for all the plans by segment were as follows:


(in millions)	December 31, 2023		Provisions and Adjustments		Amounts Applied		Change in Estimates		December 31, 2024

Connected Technology Solutions	$	13	$	23	$	(25)	$	(2)	$	9
Essential Dental Solutions	17		15		(20)		(1)		11
Orthodontic and Implant Solutions	9		11		(11)		—		9
Wellspect Healthcare	1		5		(2)		(1)		3
All Other	—		3		(2)		—		1
Total	$	40	$	57	$	(60)	$	(4)	$	33

FINANCING ARRANGEMENTS - SCHEDULE OF NOTES PAYABLE AND CURRENT PORTIONS OF LONG-TERM DEBT (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Short-term Debt [Line Items]
Total notes payable and current portion of long-term debt	$ 313	$ 549
Add: Current portion of long-term debt	228	128
Average amount of short-term debt outstanding during the year	$ 136	$ 344
Weighted-average interest rate on short-term debt at year-end	4.40%	5.30%
Corporate commercial paper facility
Short-term Debt [Line Items]
Total notes payable and current portion of long-term debt	$ 82	$ 410
Fixed interest rate	4.40%	5.30%
Other short-term borrowings
Short-term Debt [Line Items]
Total notes payable and current portion of long-term debt	$ 3	$ 11
Fixed interest rate	4.50%	4.90%

BENEFIT PLANS - SCHEDULE OF ESTIMATED FUTURE BENEFIT PAYMENTS (Details) $ in Millions	Dec. 31, 2025 USD ($)
Retirement Benefits [Abstract]
2026	$ 31
2027	31
2028	30
2029	30
2030	30
2031-2035	$ 145

REVENUE RECOGNITION

12 Months Ended

Dec. 31, 2025

Revenue from Contract with Customer [Abstract]

REVENUE RECOGNITION

Revenues are derived primarily from the sale of dental equipment and dental and healthcare consumable products. Revenues are measured as the amount of consideration the Company expects to receive in exchange for transferring goods or providing services.

Net sales disaggregated by product category were as follows:


	Year Ended December 31,
(in millions)	2025		2024		2023

Equipment & Instruments	$	578	$	553	$	628
CAD/CAM	458		509		541
Connected Technology Solutions	$	1,036	$	1,062	$	1,169



Essential Dental Solutions	$	1,469	$	1,454	$	1,468

Orthodontics	$	227	$	299	$	339
Implants & Prosthetics	623		674		701
Orthodontic and Implant Solutions	$	850	$	973	$	1,040

Wellspect Healthcare	$	325	$	304	$	288

Total net sales	$	3,680	$	3,793	$	3,965

Net sales disaggregated by geographic region were as follows:


	Year Ended December 31,
(in millions)	2025		2024		2023

United States	$	1,182	$	1,348	$	1,437
Europe	1,576		1,518		1,550
Rest of World	922		927		978

Total net sales	$	3,680	$	3,793	$	3,965

Contract Assets and Liabilities

The Company does not typically have contract assets in the course of its business. Contract liabilities, which represent billings in excess of revenue recognized, are primarily related to deferred revenue associated with loyalty points earned but not yet redeemed by customers under the Company’s loyalty point program and advanced billings for customer orthodontic treatments where the performance obligation has not yet been satisfied. The Company had deferred revenue of $74 million and $33 million presented in Accrued liabilities and Other noncurrent liabilities, respectively, in the Consolidated Balance Sheets at December 31, 2025. The Company recorded deferred revenue of $95 million and $49 million presented in Accrued liabilities and Other noncurrent liabilities, respectively, in the Consolidated Balance Sheets at December 31, 2024. The Company recognized $111 million of revenue for the year ended December 31, 2025 which was previously deferred as of December 31, 2024. The Company recognized $79 million of revenue for the year ended December 31, 2024 which was previously deferred as of December 31, 2023. The Company expects to recognize most of the remaining deferred revenue in net sales within the next twelve months.

Allowance for Doubtful Accounts

Accounts and notes receivable-trade, net are stated net of allowances for doubtful accounts and trade discounts, which were $12 million and $14 million at December 31, 2025 and 2024, respectively. For the years ended December 31, 2025 and 2024, changes to the allowance for doubtful accounts, including write-offs of accounts receivable that were previously reserved, were not significant. Changes to the allowance for doubtful accounts are presented in Selling, general, and administrative expenses in the Consolidated Statements of Operations.

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-7

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-9

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-10

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-15

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-13

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Topic 606
-Publisher FASB
-URI https://asc.fasb.org/606/tableOfContent

+ Details

Cybersecurity Risk Management and Strategy Disclosure	12 Months Ended
Cybersecurity Risk Management and Strategy Disclosure	Dec. 31, 2025
Cybersecurity Risk Management, Strategy, and Governance [Line Items]
Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]	Risk Management and Strategy The Company maintains a comprehensive process for assessing, identifying, and managing material risks from cybersecurity threats. These include risks relating to disruption of business operations or financial reporting systems, intellectual property theft, exposure to fraud or extortion, harm to employees or customers, violation of privacy laws or other regulatory and compliance lapses, reputational risk, and inability to consistently deliver digital technologies. For more information on the Company’s risks related to cybersecurity, refer to “Risk Factors” in Item 1A of this Annual Report on Form 10-K. Identifying and assessing cybersecurity risk is fully integrated into our overall risk management systems and processes. The Company has established a cybersecurity and information security program that includes risk assessment and mitigation through a threat intelligence-driven approach, application controls, and enhanced security with ransomware defense. We leverage the standards set by the National Institute of Standards and Technology (“NIST”) Cybersecurity Framework as well as industry best practices to measure our security posture and manage risk. Our security program under this framework utilizes policies, software, training programs and hardware solutions to protect and monitor our environment, including multi-factor authentication on all critical systems, firewalls, intrusion detection and prevention systems, vulnerability and penetration testing and identity management systems. With oversight from our Board of Directors, the Company has formally adopted and annually updates a Security Incident Response Plan which coordinates the activities we undertake to prepare for, detect, respond to and recover from cybersecurity incidents. These activities include processes to triage, assess the severity of, escalate, contain, investigate, and remediate incidents, as well as to comply with potentially applicable legal obligations and mitigate brand and reputational damage. Our incident response plan establishes a framework for measuring the severity of security incidents and provides for a post-market response program including protocols for coordination and communication between security response teams, designated leaders within the Company, internal and outside legal counsel, and the Audit and Finance Committee (“AFC”) of the Company’s Board of Directors in responding to any such incidents. Our cybersecurity and information security program also includes review and assessment by external, independent third parties, with whom we periodically consult on threat assessments and security enhancements, and incident response preparedness. We share threat intelligence and collaborate with organizations across different industries to share best practices, fight cybercrime, enhance privacy, discuss new technologies, better understand the evolving regulatory environment, and advance capabilities in these areas. Additionally, the Company uses a third-party risk management program that assesses risks from vendors and suppliers. In response to these assessments, we have developed contingency plans for business continuity if our vendors are subject to a cyberattack that impacts our use of their systems. Our Information Security team conducts annual information security awareness training for employees involved in our systems and processes that handle customer data and audits of our systems and conducts enhanced training for specialized personnel. We also conduct cyber awareness training and simulate responses to cybersecurity incidents and use the findings to improve our practices, procedures, and technologies. The Company provides security awareness education and training for all employees and consultants, conducts monthly internal “phishing” testing and mandatory training for “clickers,” and publishes periodic cybersecurity newsletters to highlight any emerging or urgent security threats. Our business strategy, results of operations and financial condition have not been materially affected by risks from cybersecurity threats, including the impact of previous cybersecurity incidents, but we cannot provide assurance that they will not be materially affected in the future by such risks and any future material incidents. In the last three years, we are not aware of having experienced any material information security breach incidents. The Company maintains cybersecurity insurance, and as part of management oversight we regularly review our policy and levels of coverage based on current risks.
Cybersecurity Risk Management Processes Integrated [Flag]	true
Cybersecurity Risk Management Processes Integrated [Text Block]	Identifying and assessing cybersecurity risk is fully integrated into our overall risk management systems and processes. The Company has established a cybersecurity and information security program that includes risk assessment and mitigation through a threat intelligence-driven approach, application controls, and enhanced security with ransomware defense.
Cybersecurity Risk Management Third Party Engaged [Flag]	true
Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]	true
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]	false
Cybersecurity Risk Board of Directors Oversight [Text Block]	Board of Directors Oversight Our Board of Directors is committed to mitigating data privacy and cybersecurity risks and has charged the AFC with oversight of data privacy and cybersecurity risks. Our CISO provides updates to either the AFC or to the full Board of Directors on a quarterly basis on a broad range of topics, including: •current cybersecurity landscape and emerging threats; •the status of ongoing cybersecurity initiatives and strategies; •compliance with regulatory requirements and industry standards; and •updates on the Company’s performance preparing for, preventing, detecting, responding to and recovering from cyber incidents. The CISO also promptly informs and updates the Company’s Board of Directors about any information security incidents that may pose significant risk to the Company. Our guidelines require that any significant cybersecurity matters, including strategic risk management decisions, are escalated to the Board of Directors to ensure that they have comprehensive oversight. The AFC conducts an annual review of the Company’s cybersecurity posture and the effectiveness of its risk management strategies, including input from external experts, and the results of those reviews are reported to the Company’s Board of Directors.
Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]	Our Board of Directors is committed to mitigating data privacy and cybersecurity risks and has charged the AFC with oversight of data privacy and cybersecurity risks.
Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]	Our CISO provides updates to either the AFC or to the full Board of Directors on a quarterly basis on a broad range of topics, including: •current cybersecurity landscape and emerging threats; •the status of ongoing cybersecurity initiatives and strategies; •compliance with regulatory requirements and industry standards; and •updates on the Company’s performance preparing for, preventing, detecting, responding to and recovering from cyber incidents.
Cybersecurity Risk Role of Management [Text Block]	Management’s Role Managing Risk The cybersecurity risk management processes described above are managed by our Chief Information Security Officer (“CISO”), who has over 20 years of experience in matters of cybersecurity and information systems including senior roles at other global publicly traded companies in various industries. His in-depth knowledge and experience are instrumental in developing and executing our cybersecurity strategies. Our CISO oversees our governance programs, tests our compliance with standards, remediates known risks, and leads our employee training program.
Cybersecurity Risk Management Positions or Committees Responsible [Flag]	true
Cybersecurity Risk Management Positions or Committees Responsible [Text Block]	The cybersecurity risk management processes described above are managed by our Chief Information Security Officer (“CISO”), who has over 20 years of experience in matters of cybersecurity and information systems including senior roles at other global publicly traded companies in various industries.
Cybersecurity Risk Management Expertise of Management Responsible [Text Block]	The cybersecurity risk management processes described above are managed by our Chief Information Security Officer (“CISO”), who has over 20 years of experience in matters of cybersecurity and information systems including senior roles at other global publicly traded companies in various industries.
Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]	Our CISO oversees our governance programs, tests our compliance with standards, remediates known risks, and leads our employee training program.
Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]	true

SEGMENT AND GEOGRAPHIC INFORMATION (Tables)

12 Months Ended

Dec. 31, 2025

Segment Reporting [Abstract]

Schedule of Segment Information

The Company’s segment financial information was as follows:


	Year Ended December 31,
	2025
(in millions)	Connected Technology Solutions	Essential Dental Solutions	Orthodontic and Implant Solutions	Wellspect Healthcare	Total

Net sales	1,036	1,469	850	325	3,680

Adjusted cost of products sold (a)	614	555	392	131




Adjusted selling expenses (b)	221	301	222	55
Adjusted G&A expenses (b)	81	76	80	27

Adjusted R&D expenses (c)	68	23	48	10

Segment adjusted operating income	52	514	108	102	776

Reconciling items (income) expense:
Unallocated corporate costs (d)					311
Interest expense, net					88
Other (income) expense, net					(24)
Goodwill and intangible asset impairments					650
Restructuring and other costs					24
Amortization of intangibles					211
Depreciation resulting from the fair value step-up of property, plant, and equipment from business combinations					2
Loss before income taxes					(486)

(a) Adjusted cost of products sold represents expenses adjusted to exclude intangible amortization expense, step-up depreciation expense, and other restructuring costs.


	Year Ended December 31,
	2024
(in millions)	Connected Technology Solutions	Essential Dental Solutions	Orthodontic and Implant Solutions	Wellspect Healthcare	Total

Net sales	1,062	1,454	973	304	3,793

Adjusted cost of products sold (a)	602	565	407	117




Adjusted selling expenses (b)	242	313	301	52
Adjusted G&A expenses (b)	74	74	133	27

Adjusted R&D expenses (c)	74	23	52	10

Segment adjusted operating income	70	479	80	98	727

Reconciling items (income) expense:
Unallocated corporate costs (d)					320
Interest expense, net					69
Other (income) expense, net					(12)
Goodwill and intangible asset impairments					1,014
Restructuring and other costs					53
Amortization of intangibles					216
Depreciation resulting from the fair value step-up of property, plant, and equipment from business combinations					3
Loss before income taxes					(936)

(a) Adjusted cost of products sold represents expenses adjusted to exclude intangible amortization expense, step-up depreciation expense, and other restructuring costs.


	Year Ended December 31,
	2023
(in millions)	Connected Technology Solutions	Essential Dental Solutions	Orthodontic and Implant Solutions	Wellspect Healthcare	Total

Net sales	1,169	1,468	1,040	288	3,965

Adjusted cost of products sold (a)	645	560	402	114




Adjusted selling expenses (b)	264	313	305	51
Adjusted G&A expenses (b)	77	94	119	25

Adjusted R&D expenses (c)	82	23	58	11

Segment adjusted operating income	101	478	156	87	822

Reconciling items (income) expense:
Unallocated corporate costs (d)					319
Interest expense, net					81
Other (income) expense, net					9
Goodwill and intangible asset impairments					307
Restructuring and other costs					67
Amortization of intangibles					211
Depreciation resulting from the fair value step-up of property, plant, and equipment from business combinations					3
Loss before income taxes					(175)

(a) Adjusted cost of products sold represents expenses adjusted to exclude intangible amortization expense, step-up depreciation expense, and other restructuring costs.


Depreciation and Amortization	Year Ended December 31,
(in millions)	2025		2024		2023

Connected Technology Solutions	$	186	$	175	$	176
Essential Dental Solutions	34		35		33
Orthodontic and Implant Solutions	90		98		97
Wellspect Healthcare	18		19		18
All Other (a)	24		22		19
Total	$	352	$	349	$	343

(a) Includes unallocated corporate costs for depreciation and amortization

The cumulative amounts for the provisions and adjustments and amounts applied for all the plans by segment were as follows:


(in millions)	December 31, 2024		Provisions and Adjustments		Amounts Applied		Change in Estimates		December 31, 2025

Connected Technology Solutions	$	9	$	6	$	(10)	$	(4)	$	1
Essential Dental Solutions	11		3		(9)		(1)		4
Orthodontic and Implant Solutions	9		7		(12)		(1)		3
Wellspect Healthcare	3		1		(2)		—		2
All Other	1		8		(7)		—		2
Total	$	33	$	25	$	(40)	$	(6)	$	12

The cumulative amounts for the provisions and adjustments and amounts applied for all the plans by segment were as follows:


(in millions)	December 31, 2023		Provisions and Adjustments		Amounts Applied		Change in Estimates		December 31, 2024

Connected Technology Solutions	$	13	$	23	$	(25)	$	(2)	$	9
Essential Dental Solutions	17		15		(20)		(1)		11
Orthodontic and Implant Solutions	9		11		(11)		—		9
Wellspect Healthcare	1		5		(2)		(1)		3
All Other	—		3		(2)		—		1
Total	$	40	$	57	$	(60)	$	(4)	$	33

Schedule of Net Sales and Long Lived Assets by Geographic Location

The following tables set forth information about the Company’s significant operations by geographic areas, for the years ended December 31, 2025, 2024, and 2023. Net sales reported below represent revenues from external customers in those respective countries based on the destination of shipments.


	Year Ended December 31,
(in millions)	2025		2024		2023

Net sales
United States	$	1,182	$	1,348	$	1,437
Germany	422		410		431

Other Foreign	2,076		2,035		2,097
Total net sales	$	3,680	$	3,793	$	3,965

Property, plant and equipment, net, represents those long-lived assets held by the operating businesses located in the respective geographic areas.


	Year Ended December 31,
(in millions)	2025		2024		2023

Property, plant, and equipment, net
United States	$	206	$	210	$	194
Germany	247		230		260
Sweden	124		101		105
Other Foreign	284		225		241
Total property, plant, and equipment, net	$	861	$	766	$	800

Schedules of Concentration Risk

Customers that accounted for 10% or more of net sales or accounts receivable for the year ended December 31, 2025 were as follows:


		Year Ended December 31,
	2025
			% of net sales		% of accounts receivable

Henry Schein, Inc.			13	%	Less than 10%
Patterson Companies, Inc.			Less than 10%		11	%

Customers that accounted for 10% or more of net sales or accounts receivable for the year ended December 31, 2023 were as follows:


		Year Ended December 31,
	2023
			% of net sales		% of accounts receivable

Henry Schein, Inc.			14	%	11	%
Patterson Companies, Inc.			Less than 10%		10	%

EQUITY - ADDITIONAL INFORMATION (Details) - USD ($) $ / shares in Units, shares in Millions				1 Months Ended	2 Months Ended	12 Months Ended
	Apr. 28, 2023	Mar. 31, 2023	Mar. 03, 2023	Mar. 31, 2023	Apr. 30, 2023	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023	Nov. 07, 2023	Mar. 06, 2023
Equity [Abstract]
Stock repurchase program, authorized amount									$ 1,000,000,000.0
Share repurchase program, remaining authorization						$ 1,200,000,000
Shares received (in shares)		3.1	3.1	3.1	0.8
Price per share (in dollars per share)			$ 38.74	$ 38.74
Amount Paid	$ 150,000,000	$ 120,000,000		$ 120,000,000
Total shares received (in shares)	3.9				3.9		9.4	8.8
Accelerated share repurchases, delivery of common shares										$ 121,000,000
Accelerated share repurchase		$ 30,000,000
Treasury shares purchased						$ 0	$ 250,000,000	$ 300,000,000
Excise tax amount							$ 2,000,000

GOODWILL AND INTANGIBLE ASSETS - SCHEDULE OF IDENTIFIABLE DEFINITE-LIVED AND INDEFINITE-LIVED INTANGIBLE ASSETS (Details) - USD ($) $ in Millions	Dec. 31, 2025	Dec. 31, 2024
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 3,007.0	$ 2,766.0
Accumulated Amortization	(2,289.0)	(1,896.0)
Net Carrying Amount	718.0	870.0
Indefinite-lived Intangible Assets [Line Items]
Total indefinite-lived	256.0	337.0
Total identifiable intangible assets
Identifiable intangible assets, gross carrying amount	3,263.0	3,103.0
Identifiable intangible assets, net carrying amount	974.0	1,207.0
Indefinite-lived trade names and trademarks
Indefinite-lived Intangible Assets [Line Items]
Total indefinite-lived	251.0	332.0
In-process R&D
Indefinite-lived Intangible Assets [Line Items]
Total indefinite-lived	5.0	5.0
Developed technology and patents
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	1,783.0	1,639.0
Accumulated Amortization	(1,334.0)	(1,079.0)
Net Carrying Amount	449.0	560.0
Total identifiable intangible assets
Identifiable intangible assets, net carrying amount	3.8
Indefinite-lived trade names and trademarks
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	84.0	79.0
Accumulated Amortization	(79.0)	(73.0)
Net Carrying Amount	5.0	6.0
Licensing agreements
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	42.0	29.0
Accumulated Amortization	(29.0)	(28.0)
Net Carrying Amount	13.0	1.0
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	1,098.0	1,019.0
Accumulated Amortization	(847.0)	(716.0)
Net Carrying Amount	$ 251.0	$ 303.0

INCOME TAXES - SCHEDULE OF COMPONENTS OF (LOSS) INCOME BEFORE INCOME TAXES FROM OPERATIONS (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Income Tax Disclosure [Abstract]
United States	$ (120)	$ (307)	$ (6)
Foreign	(366)	(629)	(169)
Loss before income taxes	$ (486)	$ (936)	$ (175)

- Definition

Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-4

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-21

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(11))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 14: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(10))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(15))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

+ Details

COMMITMENTS AND CONTINGENCIES - SCHEDULE OF NON-CANCELABLE PURCHASE COMMITMENTS (Details) $ in Millions	Dec. 31, 2025 USD ($)
Commitments and Contingencies Disclosure [Abstract]
2026	$ 141
2027	70
2028	35
2029	0
2030	0
Thereafter	0
Total	$ 246

BENEFIT PLANS - SCHEDULE OF OTHER CHANGES IN PLAN ASSETS AND BENEFIT OBLIGATIONS RECOGNIZED IN AOCI (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Retirement Benefits [Abstract]
Net actuarial (gains) losses	$ (24)	$ (17)	$ 37
Amortization	0	(1)	1
Total recognized in AOCI	(24)	(18)	38
Total recognized in net periodic benefit cost and AOCI	$ (5)	$ 1	$ 55

- Definition

Amount, before tax, after reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.

+ References + Details

Insider Trading Policies and Procedures	12 Months Ended
Insider Trading Policies and Procedures	Dec. 31, 2025
Insider Trading Policies and Procedures [Line Items]
Insider Trading Policies and Procedures Adopted	true

FINANCIAL INSTRUMENTS AND DERIVATIVES - ADDITIONAL INFORMATION (Details) € in Millions, SFr in Millions, $ in Millions			1 Months Ended	12 Months Ended
	Feb. 13, 2024 USD ($)	Jul. 01, 2021 USD ($)	Sep. 30, 2023 USD ($)	Dec. 31, 2025 USD ($)	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2025 EUR (€)	Jul. 01, 2025 EUR (€)	Oct. 01, 2023 CHF (SFr)	Jul. 20, 2023 CHF (SFr)	Jul. 02, 2021 USD ($)	May 25, 2021 EUR (€) derivative_instrument
Derivative [Line Items]
Cash received on derivative contracts				$ 10	$ 1	$ 39
Senior Unsecured Notes Maturing June 1, 2030 \| Senior Notes
Derivative [Line Items]
Debt instrument face amount		$ 750
Debt instrument, interest rate, stated percentage		3.30%									1.70%
Loss on derivative	$ 8
Hedges of Net Investments \| Designated as Hedging Instrument
Derivative [Line Items]
Notional amount				2,217
Foreign exchange forward contracts \| Hedges of Net Investments \| Designated as Hedging Instrument
Derivative [Line Items]
Notional amount \| €							€ 804
Cross Currency Interest Rate Contract
Derivative [Line Items]
Notional amount											$ 300
Foreign exchange forward contracts \| Hedges of Net Investments \| Designated as Hedging Instrument
Derivative [Line Items]
Notional amount							€ 40		SFr 600	SFr 600		€ 10
Loss recognized in OCI				102	(37)	29
Derivative, number of instruments held \| derivative_instrument												8
Cash received on derivative contracts			$ 32
Cross currency basis swaps \| Hedges of Net Investments \| Designated as Hedging Instrument
Derivative [Line Items]
Notional amount				1,413				€ 1,100
Loss recognized in OCI				$ 49	$ (11)	$ 18
Cross Currency Basis Swap Maturing 2030 \| Hedges of Net Investments \| Designated as Hedging Instrument
Derivative [Line Items]
Notional amount \| €								550
Cross Currency Basis Swap Maturing 2032 \| Hedges of Net Investments \| Designated as Hedging Instrument
Derivative [Line Items]
Notional amount \| €								275
Cross Currency Basis Swap Maturing 2035 \| Hedges of Net Investments \| Designated as Hedging Instrument
Derivative [Line Items]
Notional amount \| €								€ 275
Interest rate swaps
Derivative [Line Items]
Notional amount		$ 250
Payment made to settle variable interest swaps	9
Interest Rate Swap Maturing June 1, 2026
Derivative [Line Items]
Notional amount	$ 100	$ 100
Derivative, term of contract		5 years
Interest Rate Swap Maturing March 1, 2030
Derivative [Line Items]
Notional amount		$ 150
Derivative, term of contract		9 years

SEGMENT AND GEOGRAPHIC INFORMATION - NET SALES AND LONG LIVED ASSETS BY GEOGRAPHIC LOCATION (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	$ 3,680	$ 3,793	$ 3,965
Property, plant, and equipment, net	861	766	800
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	1,182	1,348	1,437
Property, plant, and equipment, net	206	210	194
Germany
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	422	410	431
Property, plant, and equipment, net	247	230	260
Sweden
Revenues from External Customers and Long-Lived Assets [Line Items]
Property, plant, and equipment, net	124	101	105
Other Foreign
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	2,076	2,035	2,097
Property, plant, and equipment, net	$ 284	$ 225	$ 241

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-4

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-7

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 924
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-4

+ Details

COMMITMENTS AND CONTINGENCIES (Tables)

12 Months Ended

Dec. 31, 2025

Commitments and Contingencies Disclosure [Abstract]

Schedule of Non-Cancelable Purchase Commitments

The Company has certain non-cancelable future commitments primarily related to long-term supply contracts for key components and raw materials. At December 31, 2025, non-cancelable purchase commitments were as follows:


(in millions)


2026	$	141
2027	70
2028	35
2029	—
2030	—
Thereafter	—
Total	$	246

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY - USD ($) $ in Millions	Total	Total Dentsply Sirona Equity	Common Stock	Capital in Excess of Par Value	(Accumulated Deficit) Retained Earnings	Accumulated Other Comprehensive Loss	Treasury Stock	Noncontrolling Interests
Beginning balance at Dec. 31, 2022	$ 3,812	$ 3,811	$ 3	$ 6,629	$ 456	$ (628)	$ (2,649)	$ 1
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(132)	(132)			(132)
Other comprehensive (loss) income	(8)	(8)				(8)
Exercise of stock options	0			(1)			1
Stock-based compensation expense	46	46		46
Funding of employee stock purchase plan	6	6					6
Treasury shares purchased	(303)	(303)					(303)
Restricted stock unit distributions	(9)	(9)		(32)			23
Restricted stock unit dividends	0			1	(1)
Cash dividends declared	(118)	(118)			(118)
Ending balance at Dec. 31, 2023	3,294	3,293	3	6,643	205	(636)	(2,922)	1
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(910)	(910)			(910)
Other comprehensive (loss) income	(94)	(94)				(94)
Stock-based compensation expense	39	39		39
Funding of employee stock purchase plan	6	6		(2)			8
Treasury shares purchased	(252)	(252)					(252)
Restricted stock unit distributions	(12)	(12)		(42)			30
Restricted stock unit dividends	0			2	(2)
Cash dividends declared	(128)	(128)			(128)
Ending balance at Dec. 31, 2024	1,943	1,942	3	6,640	(835)	(730)	(3,136)	1
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(598)	(598)			(598)
Other comprehensive (loss) income	91	91				91
Exercise of stock options	0			(1)			1
Stock-based compensation expense	33	33		33
Funding of employee stock purchase plan	4	4		(7)			11
Restricted stock unit distributions	(5)	(5)		(24)			19
Restricted stock unit dividends	0			3	(3)
Cash dividends declared	(128)	(128)			(128)
Ending balance at Dec. 31, 2025	$ 1,340	$ 1,339	$ 3	$ 6,644	$ (1,564)	$ (639)	$ (3,105)	$ 1

SUBSEQUENT EVENTS	12 Months Ended
SUBSEQUENT EVENTS	Dec. 31, 2025
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	SUBSEQUENT EVENTS On February 23, 2026, the Company’s Board of Directors eliminated the declaration of quarterly dividends on the Company’s common stock starting in the quarter ending March 31, 2026. On February 24, 2026, the Company’s Board of Directors approved a restructuring plan (the “2026 Plan”) to improve operational performance and drive stockholder value creation. In connection with the 2026 Plan, the Company expects to incur non-recurring charges in the approximate range of $55 million to $65 million, the majority of which will be expensed and paid in cash in 2026 and 2027.

FINANCIAL INSTRUMENTS AND DERIVATIVES - SCHEDULE OF DERIVATIVE INSTRUMENTS (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Derivative Instruments, Gain (Loss) [Line Items]
Cost of products sold	$ 1,840	$ 1,835	$ 1,879
Interest expense, net	88	69	81
Other (income) expense, net	(24)	(12)	9
Cross currency basis swaps \| Gain on Hedges of Net Investment \| Designated as Hedging Instrument
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain or (Loss) Reclassified from AOCI into Income	0	0	0
Cross currency basis swaps \| Gain on Hedges of Net Investment \| Designated as Hedging Instrument \| Cost of products sold
Derivative Instruments, Gain (Loss) [Line Items]
(Gain) loss on hedges of net investment and fair value hedges	0	0	0
Cross currency basis swaps \| Gain on Hedges of Net Investment \| Designated as Hedging Instrument \| Interest expense, net
Derivative Instruments, Gain (Loss) [Line Items]
(Gain) loss on hedges of net investment and fair value hedges	0	0	0
Cross currency basis swaps \| Gain on Hedges of Net Investment \| Designated as Hedging Instrument \| Other (income) expense, net
Derivative Instruments, Gain (Loss) [Line Items]
(Gain) loss on hedges of net investment and fair value hedges	(23)	(5)	(5)
Foreign exchange forward contracts \| Gain on Hedges of Net Investment \| Designated as Hedging Instrument
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain or (Loss) Reclassified from AOCI into Income	0	0	0
Foreign exchange forward contracts \| Gain on Hedges of Net Investment \| Designated as Hedging Instrument \| Cost of products sold
Derivative Instruments, Gain (Loss) [Line Items]
(Gain) loss on hedges of net investment and fair value hedges	0	0	0
Foreign exchange forward contracts \| Gain on Hedges of Net Investment \| Designated as Hedging Instrument \| Interest expense, net
Derivative Instruments, Gain (Loss) [Line Items]
(Gain) loss on hedges of net investment and fair value hedges	0	0	0
Foreign exchange forward contracts \| Gain on Hedges of Net Investment \| Designated as Hedging Instrument \| Other (income) expense, net
Derivative Instruments, Gain (Loss) [Line Items]
(Gain) loss on hedges of net investment and fair value hedges	(25)	(25)	(12)
Foreign exchange forward contracts \| Loss on Fair Value Hedges: \| Designated as Hedging Instrument
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain or (Loss) Reclassified from AOCI into Income	0	0	0
Foreign exchange forward contracts \| Loss on Fair Value Hedges: \| Designated as Hedging Instrument \| Cost of products sold
Derivative Instruments, Gain (Loss) [Line Items]
(Gain) loss on hedges of net investment and fair value hedges	0	0	0
Foreign exchange forward contracts \| Loss on Fair Value Hedges: \| Designated as Hedging Instrument \| Interest expense, net
Derivative Instruments, Gain (Loss) [Line Items]
(Gain) loss on hedges of net investment and fair value hedges	0	0	0
Foreign exchange forward contracts \| Loss on Fair Value Hedges: \| Designated as Hedging Instrument \| Other (income) expense, net
Derivative Instruments, Gain (Loss) [Line Items]
(Gain) loss on hedges of net investment and fair value hedges	0	0	0
Foreign exchange forward contracts \| Loss on Fair Value Hedges: \| Not Designated as Hedging Instrument \| Cost of products sold
Derivative Instruments, Gain (Loss) [Line Items]
(Gain) loss on hedges of net investment and fair value hedges	0	0	0
Foreign exchange forward contracts \| Loss on Fair Value Hedges: \| Not Designated as Hedging Instrument \| Interest expense, net
Derivative Instruments, Gain (Loss) [Line Items]
(Gain) loss on hedges of net investment and fair value hedges	0	0	0
Foreign exchange forward contracts \| Loss on Fair Value Hedges: \| Not Designated as Hedging Instrument \| Other (income) expense, net
Derivative Instruments, Gain (Loss) [Line Items]
(Gain) loss on hedges of net investment and fair value hedges	12	2	8
Interest rate swaps \| Loss on Fair Value Hedges: \| Designated as Hedging Instrument
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain or (Loss) Reclassified from AOCI into Income	0	0	0
Interest rate swaps \| Loss on Fair Value Hedges: \| Designated as Hedging Instrument \| Cost of products sold
Derivative Instruments, Gain (Loss) [Line Items]
(Gain) loss on hedges of net investment and fair value hedges	0	0	0
Interest rate swaps \| Loss on Fair Value Hedges: \| Designated as Hedging Instrument \| Interest expense, net
Derivative Instruments, Gain (Loss) [Line Items]
(Gain) loss on hedges of net investment and fair value hedges	6	8	11
Interest rate swaps \| Loss on Fair Value Hedges: \| Designated as Hedging Instrument \| Other (income) expense, net
Derivative Instruments, Gain (Loss) [Line Items]
(Gain) loss on hedges of net investment and fair value hedges	$ 0	$ 0	$ 0

SIGNIFICANT ACCOUNTING POLICIES (Policies)

12 Months Ended

Dec. 31, 2025

Accounting Policies [Abstract]

Basis of Presentation

The consolidated financial statements include the results of the Company and its consolidated subsidiaries. All significant intercompany accounts and transactions are eliminated in consolidation. Certain prior period amounts have been reclassified to conform to current year presentation.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“US GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expense during the reporting period. Actual results could differ materially from those estimates.

Cash and Cash Equivalents

Cash and cash equivalents include deposits with banks as well as highly liquid time deposits with original maturities of ninety days or less. The balance as of December 31, 2025 includes $56 million of cash and cash equivalents located in Russia which is available for use in local operations but limited in its ability to be transferred out of the country due to control measures currently in place by the Russian government.

Accounts Receivable

The Company recognizes a receivable when it has an unconditional right to payment, which represents the amount the Company expects to collect in a transaction. Our standard payment terms are typically 30 days in the United States but may be longer in markets outside the United States. In general, contracts containing significant financing components are not material to the Company’s financial statements.

The Company establishes an allowance for doubtful accounts based on an estimate of current expected credit losses resulting from the inability of its customers to make required payments. The allowance is determined based on a combination of factors, including the length of time that the receivable is past due, history of write-offs, and the Company’s knowledge of circumstances relating to specific customers’ ability to meet their financial obligations. The provision for doubtful accounts is included in Selling, general and administrative expenses (“SG&A”) in the Consolidated Statements of Operations. For customers on credit terms, the Company performs ongoing credit evaluation of those customers’ financial condition and generally does not require collateral from them.

Inventories

Inventories are stated at the lower of cost and net realizable value. The cost of inventories is based upon the first-in, first-out method (“FIFO”) or average cost methods.

The Company establishes reserves for inventory estimated to be excess, obsolete or unmarketable based upon assumptions about future demand, market conditions, and expiration of products.

Valuation of Goodwill and Indefinite-Lived and Definite-Lived Intangible Assets

Goodwill

Goodwill is the excess of the purchase price over the fair value of identifiable net assets acquired and liabilities assumed in a business combination. Goodwill is not subject to amortization but is tested for impairment at the reporting unit level annually in accordance with US GAAP as of April 1 of each year, or more frequently if events or circumstances indicate that the carrying value of goodwill may be impaired. The Company performs impairment tests by comparing the fair value of each reporting unit to its carrying amount to determine if there is a potential impairment. If the carrying value of a reporting unit with goodwill exceeds its respective fair value, an impairment charge is recognized for the excess amount. Additional information related to the testing for goodwill impairment, including results of the annual test performed as of April 1, 2025 and the interim impairment assessments performed in the third and fourth quarters of 2025, is provided in Note 11, Goodwill and Intangible Assets.

Indefinite-Lived Intangible Assets

Indefinite-lived intangible assets consist primarily of trade names and trademarks and in-process research and development (“R&D”) acquired in business combinations, and these are not subject to amortization. Valuations of indefinite-lived intangible assets acquired in business combinations are based on information and assumptions available at the time of their acquisition, using income and market approaches to determine fair value. The Company conducts an impairment test in accordance with US GAAP as of April 1 of each year, or more frequently if events or circumstances indicate that the carrying value of indefinite-lived intangible assets may be impaired. Potential impairment is identified by comparing the fair value of an intangible asset to its carrying value. Additional information related to the testing for indefinite-lived intangible asset impairment, including results of the annual test performed as of April 1, 2025 and the interim impairment assessments performed in the first, third, and fourth quarters of 2025, is provided in Note 11, Goodwill and Intangible Assets.

Definite-Lived Intangible Assets

Definite-lived intangible assets primarily consist of patents, trade names, trademarks, licensing agreements, developed technology, and customer relationships. The valuation of definite-lived intangible assets acquired in business combinations is based on information and assumptions available at the time of acquisition, using income and market model approaches to determine fair value.

Identifiable definite-lived intangible assets are amortized on a basis that best reflects how their economic benefits are utilized over the life of the asset or on a straight-line basis if not materially different from actual utilization. The useful life is the period over which the asset is expected to contribute to the future cash flows of the Company. The Company uses the following useful lives for its definite-lived intangible assets:


Definite-Lived Intangible Asset Type						Useful Life

Patents						Up to the date the patent expires
Trade names and trademarks						Up to 20 years
Licensing agreements						Up to 20 years
Customer relationships						Up to 15 years
Developed technology						Up to 15 years

When the expected useful life of an intangible is not known, the Company will estimate its useful life based on similar assets or asset groups, any legal, regulatory, or contractual provision that limits the useful life, the effect of economic factors, including obsolescence, demand, competition, and the level of maintenance expenditures required to obtain the expected future economic benefit from the asset.

These assets are reviewed for impairment whenever events or circumstances suggest that the carrying amount of the asset may not be recoverable. The Company closely monitors all intangible assets, including those related to new and existing technologies, for indicators of impairment as these assets have more risk of becoming impaired. Impairment is based upon an initial evaluation of the identifiable undiscounted cash flows. If the initial evaluation identifies a potential impairment, a fair value of the asset is determined by using a discounted cash flow valuation. If impaired, the resulting charge reflects the excess of the asset’s carrying cost over its fair value.

Property, Plant and Equipment

Property, plant and equipment are stated at cost, net of accumulated depreciation. Assets acquired through acquisitions are recorded at fair value. The Company capitalizes costs incurred in the development or acquisition of software, whether for internal or external use, and expenses costs incurred in the preliminary project planning stage. Except for leasehold improvements, depreciation and amortization is computed by the straight-line method over the assets estimated useful lives:


Property, Plant and Equipment Assets Type						Useful Life

Buildings						25 to 40 years
Machinery and Equipment						2 to 20 years
Capitalized Software						3 to 10 years
Leasehold Improvements						Shorter of the estimated useful life or the term of the lease

Maintenance and repairs are expensed as incurred; replacements and major improvements are capitalized. If events or circumstances exist which suggest that the carrying amount of the asset group may not be recoverable, the identifiable undiscounted cash flows of the asset group are compared to the carrying value of the asset. If the carrying value is in excess of the identifiable undiscounted cash flows, the excess of the asset group’s carrying cost over its fair value is recorded as an impairment charge.

Leases

The Company leases real estate, automobiles and equipment under various operating and finance leases. The Company determines if an arrangement is a lease or contains a lease at inception. Operating lease right-of-use assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As the implicit rate is not readily determinable in most of the Company’s lease agreements, the Company uses its estimated secured incremental borrowing rate, based on the information available at commencement of the lease, to determine the present value of lease payments. Lease expense is recognized on a straight-line basis over the lease term. Leases with an initial term of 12 months or less are not recorded on the balance sheet. Any new real estate and equipment operating lease agreements with lease and non-lease components, are accounted for as a single lease component; auto leases are accounted for as separate lease components.

The Company’s leases have remaining lease terms of approximately 1 year to 8 years. Many of the Company’s real estate and equipment leases have one or more options to renew, with terms that can extend primarily from 1 year to 3 years, which are not included in the initial lease term until considered reasonably certain of renewal. The Company does not have lease agreements with residual value guarantees, sale-and-leaseback terms, or material restrictive covenants. The Company does not have any material sublease arrangements.

Derivative Financial Instruments

The Company employs derivative financial instruments to hedge certain anticipated transactions, firm commitments, and assets and liabilities denominated in foreign currencies. Additionally, the Company manages exposure to changes in interest rates by utilizing interest rate swaps that have the effect of converting floating rate debt to fixed rate, or vice versa. The benefit or loss from interest rate swaps is recorded in Interest expense, net in the Company’s Consolidated Statements of Operations consistent with the classification of interest expense attributable to the underlying debt.

The Company records all derivative instruments at fair value and changes in fair value are recorded each period in the consolidated statements of operations or accumulated other comprehensive income (“AOCI”). The Company classifies derivative assets and liabilities as current when the remaining term of the derivative contract is one year or less. The Company has elected to classify the cash flows from derivative instruments in the same category as the cash flows from the items being hedged. Should the Company enter into a derivative instrument that includes an other-than-insignificant financing element then all cash flows will be classified as financing activities in the Consolidated Statements of Cash Flows as required by US GAAP.

Pension and Other Postemployment Benefits

Some of the employees of the Company and its subsidiaries are covered by government or Company-sponsored defined benefit plans and defined contribution plans. Additionally, certain salaried employee groups in the United States are covered by postemployment healthcare plans. Projected benefit obligations and net periodic costs for Company-sponsored defined benefit and postemployment benefit plans are based on an annual actuarial valuation that includes assessment of key assumptions relating to expected return on plan assets, discount rates, employee compensation increase rates and health care cost trends. Expected return on plan assets, discount rates and health care cost trend assumptions are particularly important when determining the Company’s benefit obligations and net periodic benefit costs associated with postemployment benefits. Changes in these assumptions can impact the Company’s earnings. In determining the cost of postemployment benefits, certain assumptions are established annually to reflect market conditions and plan experience to appropriately reflect the expected costs as determined by actuaries. These assumptions include medical inflation trend rates, discount rates, employee turnover and mortality rates. The Company predominantly uses liability durations in establishing its discount rates, which are observed from indices of high-grade corporate bond yields in the respective economic regions of the plans. The expected return on plan assets is the weighted average long-term expected return based upon asset allocations and historic average returns for the markets where the assets are invested, principally in foreign locations. The Company reports the funded status of its defined benefit pension and other postemployment benefit plans on its consolidated balance sheets as a net liability or asset.

Accruals for Self-Insured Losses

The Company maintains insurance for certain risks, including workers’ compensation, and is self-insured for employee-related healthcare benefits. The Company accrues for the expected costs associated with these risks by considering historical claims experience, demographic factors, severity factors and other relevant information. Costs are recognized in the period the claim is incurred, and the financial statement accruals include an estimate of claims incurred but not yet reported. The Company has stop-loss coverage to limit its exposure to any significant exposure on a per claim basis.

Litigation

The Company and its subsidiaries, from time to time, are parties to lawsuits arising from operations. The Company records liabilities when a loss is probable and can be reasonably estimated. If these estimates are in the form of ranges, the Company records the liabilities at the most likely outcome within the range. If no point within the range represents a better estimate of the probable loss, then the low point in the range is accrued. The ranges established by management are based on analysis made by internal and external legal counsel who consider the best information known at the time. If the Company determines that a contingency is reasonably possible, it considers the same information to estimate the possible exposure and discloses any material potential liability. These loss contingencies are monitored regularly for a change in fact or circumstance that would require an accrual adjustment. Legal costs related to these lawsuits are expensed as incurred.

Foreign Currency Translation

The local currency of foreign operations is generally considered to be their functional currency. In the case of operations within highly inflationary economies, which for the Company include Argentina and Turkey, the Company remeasures the financial statements of entities in those countries with the U.S. dollar as the functional currency.

Adjustments resulting from the process of translating the financial statements of entities with foreign functional currencies into U.S. dollars are included in AOCI in the Consolidated Balance Sheets. During the year ended December 31, 2025, the Company had a translation gain of $263 million and a loss on its loans designated as hedges of net investments of $78 million. During the year ended December 31, 2024, the Company had a translation loss of $192 million and a gain on its loans designated as hedges of net investments of $46 million. During the year ended December 31, 2023, the Company had a translation gain of $78 million and a loss on its loans designated as hedges of net investments of $29 million.

Revenue Recognition

Revenues are derived primarily from the sale of dental equipment and dental and healthcare consumable products. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring goods or providing services in accordance with ASC 606-10, Revenues from Contracts with Customers. Revenue is recognized when performance obligations under the terms of a contract with a customer are satisfied; this occurs with the transfer of control of products and services to the Company’s customers, which for products generally occurs when title and risk of loss transfers to the customer, and for services generally occurs as the customer receives and consumes the benefit. Sales, value-added, and other taxes collected concurrent with revenue-producing activities are excluded from revenue.

Certain contracts with the Company’s customers include promises to transfer multiple products and services to a customer. Determining whether products and services are considered distinct performance obligations that should be accounted for separately may require significant judgment. The Company generally uses an observable price, typically average selling price, to determine the stand-alone selling price for separate performance obligations. The Company determines the stand-alone selling prices based on its database of pricing and discounting practices from among the Company’s varied geographic sales locations and for specific products or services when sold separately, and the Company utilizes this data to arrive at average selling prices by product. In cases where an average selling price is not observable, the Company determines the stand-alone selling price using relevant information and applies suitable estimation methods including, but not limited to, the cost plus a margin approach. Revenue is then allocated proportionately, based on the determined stand-alone selling price, to each distinct performance obligation.

The Company exercises judgment in estimating variable consideration, which primarily includes volume discounts, sales rebates, product returns, and certain extended warranty arrangements. The Company adjusts the estimate of revenue at the earlier of when the most likely amount of consideration can be estimated, the amount expected to be received changes, or when the consideration becomes fixed. The Company estimates volume discounts by evaluating specific inputs and assumptions, including the individual customer’s historical and estimated future product purchases. Discounts are deducted from revenue at the time of sale or when the discount is offered, whichever is later. In estimating sales rebates, the Company evaluates inputs such as customer-specific trends, terms of the customers’ contracted rebate program, historical experience, and the forecasted performance of a customer and their expected level of achievement within the rebate programs. The accruals for these rebate programs are updated as actual results and updated forecasts impact the estimated achievement for customers within the rebate programs. When the Company gives customers the right to return eligible products and receive credit, returns are estimated based on an analysis of historical experience. However, returns of products, excluding warranty-related returns, are not material.

To the extent the transaction price includes variable consideration, the Company applies judgment in constraining the estimated variable consideration due to factors that may cause reversal of cumulative revenue recognized. The Company evaluates constraints based on its historical and projected experience with similar customer contracts.

For most of its products, the Company transfers control and recognizes revenue when products are shipped from the Company’s manufacturing facility or warehouse to the customer. For contracts with customers that contain destination shipping terms, revenue is not recognized until the goods are delivered to the agreed-upon destination. As such, the Company’s performance obligations related to product sales are satisfied at a point in time when customers obtain the use of, and substantially all of the benefit of, the products.

The Company recognizes revenue from support and maintenance contracts, extended warranties, and certain other contract performance obligations over time based on the period of the contracts or as the services are performed, as the customer simultaneously receives and consumes the benefits provided by the Company’s performance of the services. In general, the total amount of revenue recognized over time is not material to the Company’s financial statements.

Depending on the terms of its contracts, the Company defers the recognition of a portion of revenue on a relative stand-alone selling price basis when certain performance obligations are not yet satisfied. Consideration received from customers in advance of revenue recognition is classified as deferred revenue. For certain locations, the Company offers a loyalty points program to customers. A portion of the revenue generated in a sale is allocated to the loyalty points earned and is deferred until the loyalty points are redeemed or expire.

The Company has elected to account for shipping and handling activities as a fulfillment cost within the cost of products sold, and records shipping and handling costs collected from customers in net sales. The Company has adopted one practical expedient: relief from considering the existence of a significant financing component when the payment for the good or service is expected to be one year or less.

Cost of Products Sold

Cost of products sold represents costs directly related to the manufacture and distribution of the Company’s products, and include costs of raw materials, packaging, direct labor, overhead, shipping and handling, warehousing and the depreciation of manufacturing, warehousing and distribution facilities and amortization of intangible assets. Overhead and related expenses include salaries, wages, employee benefits, utilities, lease costs, maintenance and property taxes.

Warranties

The Company provides manufacturers’ warranties on certain equipment products. Estimated warranty costs are accrued when sales are made to customers. Estimates for warranty costs are based primarily on historical warranty claim experience. Warranty costs are included in Cost of products sold in the Consolidated Statements of Operations.

Selling, General and Administrative Expenses

SG&A represents indirect costs associated with generating revenues and managing the operations of the Company. Such costs include advertising and marketing expenses, salaries, employee benefits, incentive compensation, travel, office expenses, lease costs, amortization of capitalized software developed for internal use, and depreciation of administrative facilities. Advertising costs are expensed as incurred.

Research and Development Costs

R&D costs, including internal labor costs, material costs, consulting expenses, and certain overhead expenses, such as facilities and information technology costs directly attributable to R&D activities, are expensed in the period in which they are incurred. Software development costs related to software to be sold, leased, or otherwise marketed that are incurred prior to the attainment of technological feasibility are considered R&D and are expensed as incurred. Once technological feasibility is established, the cost of software developed for external use is capitalized until the product is available for general release to customers. Amortization of these costs are included in Cost of products sold over the estimated life of the products.

Stock-Based Compensation

Stock-based compensation is measured at the grant date at fair value and is recognized as an expense over the employee’s requisite service period (generally the vesting period of the equity awards). The compensation cost is only recognized for the portion of the awards that are expected to vest.

Stock options granted become exercisable as determined by the grant agreement and expire ten years after the date of grant under the Company’s stock-based compensation plans. Restricted Stock Units (“RSUs”) vest as determined by the grant agreement and are subject to a service condition, which requires grantees to remain employed by the Company during the period following the date of grant. Under the terms of the RSUs, the vesting period is referred to as the restricted period. In addition to the service condition, certain RSUs are subject to performance requirements that can vary between the first year and the final year of the RSU award. For a given RSU award which is subject to performance requirements, the number of shares which vest may be adjusted upward or downward from the target amount to reflect the achievement level, and no shares shall vest unless a threshold achievement level is met. Upon the expiration of the applicable restricted period and the satisfaction of any applicable performance conditions imposed, the restrictions on RSUs will lapse, and shares of common stock will be issued for each vested RSU. Upon death, disability or qualified retirement, awards continue to vest per the remaining grant term and are pro-rated if the grant date is less than twelve months from the date of separation. Awards are expensed as compensation

over their respective vesting periods or to the eligible retirement date if shorter. The Company records forfeitures on stock-based compensation as the participant terminates rather than estimating forfeitures.

Income Taxes

The Company’s income tax expense or benefit includes U.S. and international income taxes plus the provision for U.S. income taxes on undistributed earnings of international subsidiaries not considered to be permanently reinvested. Tax credits and other incentives reduce income tax expense in the year the credits are claimed. Certain items of income and expense are not reported in tax returns and financial statements in the same year. The tax effect of such temporary differences is reported as deferred income taxes. Deferred tax assets are recognized if it is more likely than not that the assets will be realized in future years. The Company establishes a valuation allowance for deferred tax assets for which realization is not likely.

The Company applies a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The Company recognizes in the consolidated financial statements the impact of a tax position if that position is more likely than not to be sustained upon examination by taxing authorities based on the technical merits of the position.

The Company’s tax positions are subject to ongoing examinations by tax authorities. The Company operates within multiple taxing jurisdictions throughout the world and in the normal course of business is examined by taxing authorities in those jurisdictions. Adjustments to uncertain tax positions are recorded when taxing authority examinations are completed, statutes of limitation are closed, changes in tax laws occur or as new information comes to light regarding the technical merits of a given tax position.

Earnings Per Share

Basic earnings per share are calculated by dividing net earnings (loss) attributable to the Company’s stockholders by the weighted average number of shares outstanding for the period. Diluted earnings per share is calculated by dividing net earnings attributable to the Company’s stockholders by the weighted average number of shares outstanding for the period, adjusted for the effect of an assumed exercise of all dilutive options outstanding at the end of the period, unless the impact of including these options is anti-dilutive.

Investments in Unconsolidated Affiliates

Investments in non-consolidated affiliates, joint ventures, and partnerships where the Company maintains significant influence over an entity but does not have control are accounted for using the equity method. The Company records the carrying value of these investments within other noncurrent assets in the Consolidated Balance Sheets and records the Company’s proportional share of the investees’ net earnings or losses within other (income) expense. Investments in which the Company does not exercise significant influence are recorded at cost and assessed for any other-than-temporary impairment when events or changes in circumstances indicate the carrying amount of the investment might not be recoverable.

Noncontrolling Interests

The Company reports noncontrolling interest (“NCI”) in a subsidiary as a separate component of Equity in the Consolidated Balance Sheets. Additionally, the Company reports the portion of net loss and comprehensive loss attributed to the Company and NCI separately in the Consolidated Statements of Operations, and in the Consolidated Statements of Comprehensive Income.

Fair Value Measurement

Recurring Basis

The Company records certain financial assets and liabilities at fair value in accordance with the accounting guidance, which defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date in current markets. The accounting guidance establishes a hierarchical disclosure framework associated with the level of observable pricing utilized in measuring financial instruments at fair value. The three broad levels defined by the fair value hierarchy are as follows:

Level 1 - Quoted prices are available in active markets for identical assets or liabilities as of the reported date.

Level 2 - Pricing inputs are other than quoted prices in active markets, which are either directly or indirectly observable as of the reported date. These financial instruments include derivative instruments whose fair values have been derived using a model where inputs to the model are directly observable in the market or can be derived principally from, or corroborated by, observable market data.

Level 3 - Instruments that have little to no observable pricing as of the reported date. These financial instruments do not have two-way markets and are measured using management’s best estimate of fair value, where the inputs into the determination of fair value require significant management judgment or estimation.

The degree of judgment utilized in measuring the fair value of certain financial assets and liabilities generally correlates to the level of observable pricing. Observable pricing is impacted by a number of factors, including the type of financial instrument. Financial assets and liabilities with readily available active quoted prices or for which fair value can be measured from actively quoted prices generally will have a higher degree of pricing observability and a lesser degree of judgment utilized in measuring fair value. Conversely, financial assets and liabilities rarely traded or not quoted will generally have less, or no pricing observability and a higher degree of judgment utilized in measuring fair value.

The Company primarily applies the market approach for recurring fair value measurements and endeavors to utilize the best available information. Accordingly, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. Additionally, the Company considers its credit risks and its counterparties’ credit risks when determining the fair values of its financial assets and liabilities. The Company records its derivatives and contingent considerations on a recurring fair value basis.

The Company believes the carrying amounts of cash and cash equivalents, accounts receivable (net of allowance for doubtful accounts), prepaid expenses and other current assets, accounts payable, accrued liabilities, income taxes payable and notes payable approximate fair value due to the short-term nature of these instruments.

Non-Recurring Basis

When events or circumstances require an asset or liability to be measured at fair value that otherwise is generally recorded based on another valuation method, such as, net realizable value, the Company will utilize the valuation techniques described above. The Company records its business combinations and impairments on a non-recurring basis.

Recently Adopted Accounting Pronouncements and Accounting Pronouncements Not Yet Adopted

Recently Adopted Accounting Pronouncements

In December 2023, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures,” which requires public entities to disclose additional income tax information, primarily related to the income tax rate reconciliation and income taxes paid on an annual basis. The amendments are intended to enhance the transparency and decision-usefulness of income tax disclosures. The Company has adopted this accounting standard as of January 1, 2025, which impacts annual disclosures only and does not impact results of operations, financial position, or cash flow, and the related disclosures are included in Note 16, Income Taxes in the Notes to the Consolidated Financial Statements.

In November 2023, the FASB issued ASU No. 2023-07, “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures,” which requires disclosure of information about significant expenses in a public company’s reportable segment results on both an interim and annual basis. Public companies are required to disclose significant expense categories and amounts for each reportable segment. Significant expense categories are derived from expenses that are regularly reported

to an entity’s chief operating decision-maker (“CODM”) and included in a segment’s reported measures of profit or loss. Public entities are also required to disclose the title and position of the CODM and explain how the CODM uses the reported measures of profit or loss to assess segment performance. This standard was effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The Company has adopted this accounting standard, and the related disclosures are included in Note 6, Segment and Geographic Information in the Notes to Consolidated Financial Statements.

Accounting Pronouncements Not Yet Adopted

In November 2024, the FASB issued ASU No. 2024-03, “Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40) Disaggregation of Income Statement Expenses,” which requires disaggregated disclosure of income statement expenses for public business entities (“PBEs”). In January 2025, the FASB issued ASU No. 2025-01 “Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40),” which clarified the effective date for ASU No. 2024-03. These amendments are intended to provide more information about types of expenses in commonly presented expense captions. The amendments in this update are effective for annual periods beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027, and early adoption is permitted. The Company is currently evaluating the impact on its consolidated financial statements and related disclosures.

In September 2025, the FASB issued ASU No. 2025-06, “Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40),” which amends certain aspects of ASC 350-40 related to the accounting and disclosure of internally developed software costs. This amendment is intended to provide further guidance on how to evaluate whether the probable-to-complete recognition threshold has been met to capitalize costs for internal-use software. The amendments in this update are effective for annual periods beginning after December 15, 2027, and interim periods within those annual reporting periods. Early adoption is permitted in an interim or annual reporting period in which financial statements have not yet been issued or made available for issuance. Entities may apply the guidance prospectively, retrospectively, or via a modified prospective transition method. The Company is currently evaluating the impact on its consolidated financial statements and related disclosures.

In September 2025, the FASB issued ASU No. 2025-07, “Derivatives and Hedging (Topic 815) and Revenue from Contracts with Customers (Topic 606),” which refines the scope of the guidance on derivatives in ASC 815 and clarifies the guidance on share-based payments from a customer in ASC 606. The amendments in this update are effective for annual reporting periods beginning after December 15, 2026, including interim reporting periods within those annual reporting periods. Early adoption is permitted in an interim or annual reporting period for which financial statements have not been issued or made available for issuance. Entities may apply the guidance prospectively or on a modified retrospective basis. The Company is currently evaluating the impact on its consolidated financial statements and related disclosures.

In November 2025, the FASB issued ASU No. 2025-09, “Derivatives and Hedging (Topic 815),” which amends certain aspects of the hedge accounting guidance in ASC 815. The amendments are intended to more closely align hedge accounting with the economics of an entity’s risk management activities. The amendments in this update are effective for fiscal years beginning after December 15, 2026, and interim periods therein. Early adoption is permitted in any interim or annual period after the ASU’s issuance. Entities should apply the guidance prospectively. The Company is currently evaluating the impact on its consolidated financial statements and related disclosures.

FINANCING ARRANGEMENTS - SCHEDULE OF LONG TERM BORROWINGS (Details)	Dec. 31, 2025 USD ($)	Dec. 31, 2025 CHF (SFr)	Dec. 31, 2025 EUR (€)	Dec. 31, 2025 JPY (¥)	Dec. 31, 2024 USD ($)
Debt Instrument [Line Items]
Principal balance	$ 2,276,000,000
Hedge accounting fair value adjustment	(19,000,000)				$ (28,000,000)
Long-term debt, net of hedging activities	2,257,000,000				1,720,000,000
Less: Current portion (included in notes payable and current portion of long-term debt)	228,000,000				128,000,000
Less: Long-term portion of deferred financing costs	14,000,000				6,000,000
Long-term debt	2,015,000,000				$ 1,586,000,000
Private Placement Notes \| 0.9% Private placement notes 25 million Swiss franc
Debt Instrument [Line Items]
Debt, fixed rate					0.90%
Debt instrument face amount \| SFr		SFr 25,000,000
Principal balance	0				$ 28,000,000
Private Placement Notes \| 2.1% Private placement notes 97 million euros
Debt Instrument [Line Items]
Debt, fixed rate					2.10%
Debt instrument face amount \| €			€ 97,000,000
Principal balance	$ 0				$ 100,000,000
Private Placement Notes \| 2.1% Private placement notes 26 million euros
Debt Instrument [Line Items]
Debt, fixed rate	2.10%	2.10%	2.10%	2.10%
Debt instrument face amount \| €			€ 26,000,000
Principal balance	$ 31,000,000				27,000,000
Private Placement Notes \| 1.0% Private placement notes 58 million Swiss franc
Debt Instrument [Line Items]
Debt, fixed rate	1.00%	1.00%	1.00%	1.00%
Debt instrument face amount \| SFr		SFr 58,000,000
Principal balance	$ 73,000,000				64,000,000
Private Placement Notes \| 2.3% Private placement notes 106 million euros
Debt Instrument [Line Items]
Debt, fixed rate	2.30%	2.30%	2.30%	2.30%
Debt instrument face amount \| €			€ 106,000,000
Principal balance	$ 125,000,000				110,000,000
Private Placement Notes \| 1.3% Private placement notes 70 million euros
Debt Instrument [Line Items]
Debt, fixed rate	1.30%	1.30%	1.30%	1.30%
Debt instrument face amount \| €			€ 70,000,000
Principal balance	$ 82,000,000				72,000,000
Private Placement Notes \| 1.0% Private placement notes 8 million Swiss franc
Debt Instrument [Line Items]
Debt, fixed rate	1.00%	1.00%	1.00%	1.00%
Debt instrument face amount \| SFr		SFr 8,000,000
Principal balance	$ 9,000,000				8,000,000
Private Placement Notes \| 2.2% Private placement notes 15 million euros
Debt Instrument [Line Items]
Debt, fixed rate	2.20%	2.20%	2.20%	2.20%
Debt instrument face amount \| €			€ 15,000,000
Principal balance	$ 18,000,000				16,000,000
Private Placement Notes \| 1.2% Private placement notes 140 million Swiss franc
Debt Instrument [Line Items]
Debt, fixed rate	1.20%	1.20%	1.20%	1.20%
Debt instrument face amount \| SFr		SFr 140,000,000
Principal balance	$ 177,000,000				154,000,000
Private Placement Notes \| 1.5% Private placement notes 70 million euros
Debt Instrument [Line Items]
Debt, fixed rate	1.50%	1.50%	1.50%	1.50%
Debt instrument face amount \| €			€ 70,000,000
Principal balance	$ 82,000,000				72,000,000
Private Placement Notes \| 1.6% Private placement notes 70 million euros
Debt Instrument [Line Items]
Debt, fixed rate	1.60%	1.60%	1.60%	1.60%
Debt instrument face amount \| €			€ 70,000,000
Principal balance	$ 82,000,000				72,000,000
Private Placement Notes \| 2.5% Private placement notes 45 million euros
Debt Instrument [Line Items]
Debt, fixed rate	2.50%	2.50%	2.50%	2.50%
Debt instrument face amount \| €			€ 45,000,000
Principal balance	$ 53,000,000				47,000,000
Private Placement Notes \| 1.3% Private placement notes 65 million Swiss franc
Debt Instrument [Line Items]
Debt, fixed rate	1.30%	1.30%	1.30%	1.30%
Debt instrument face amount \| SFr		SFr 65,000,000
Principal balance	$ 82,000,000				72,000,000
Private Placement Notes \| 1.0% Private placement notes 12.6 billion Japanese yen
Debt Instrument [Line Items]
Debt, fixed rate	1.00%	1.00%	1.00%	1.00%
Debt instrument face amount \| ¥				¥ 12,600,000,000
Principal balance	$ 80,000,000				80,000,000
Private Placement Notes \| 1.7% Private placement notes 70 million euros
Debt Instrument [Line Items]
Debt, fixed rate	1.70%	1.70%	1.70%	1.70%
Debt instrument face amount \| €			€ 70,000,000
Principal balance	$ 82,000,000				72,000,000
Private Placement Notes \| 8.4% Private placement notes 550000000 million U.S. dollars
Debt Instrument [Line Items]
Debt, fixed rate	8.40%	8.40%	8.40%	8.40%
Debt instrument face amount	$ 550,000,000
Principal balance	$ 550,000,000				0
Senior Notes \| 3.3% Fixed rate senior notes 750 million
Debt Instrument [Line Items]
Debt, fixed rate	3.30%	3.30%	3.30%	3.30%
Debt instrument face amount	$ 750,000,000
Principal balance	749,000,000				750,000,000
Other borrowings, various currencies and rates
Debt Instrument [Line Items]
Principal balance	$ 1,000,000				$ 4,000,000

OTHER (INCOME) EXPENSE, NET - ADDITIONAL INFORMATION (Details) - USD ($) $ in Millions		12 Months Ended
	Dec. 06, 2023	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Other Income and Expenses [Abstract]
Equity-method net losses	$ 4	$ 0	$ 0	$ 4

- Definition

Amount of income (loss) for proportionate share of equity method investee's income (loss).

+ References + Details

COMMITMENTS AND CONTINGENCIES - ADDITIONAL INFORMATION (Details) € in Millions, $ in Millions		1 Months Ended	12 Months Ended
	Mar. 21, 2023 EUR (€)	Jan. 31, 2025 USD ($)	Dec. 31, 2024 USD ($)	Dec. 31, 2016 USD ($)	Dec. 31, 2025 USD ($)
Commitments and Contingencies [Line Items]
Litigation settlement, amount awarded to other party		$ 84
Insurance settlements receivable		$ 78
Legal expense			$ 6
Distribution amount				$ 451
Cloud Services
Commitments and Contingencies [Line Items]
Purchase commitment					$ 69
Mr. Carlo Gobbetti
Commitments and Contingencies [Line Items]
Loss contingency, damages sought, value \| €	€ 28
Escrow deposit \| €	7
Loss contingency, punitive damages sought \| €	€ 21

RESTRUCTURING AND OTHER COSTS - ADDITIONAL INFORMATION (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Restructuring Cost and Reserve [Line Items]
Total Restructuring and other costs		$ 25	$ 95	$ 74
Payments for restructuring		40	60
Byte Aligner Systems
Restructuring Cost and Reserve [Line Items]
Contract refund reserve	$ 43		43
Net sales \| Byte Aligner Systems
Restructuring Cost and Reserve [Line Items]
Payments for restructuring		16	13
Restructuring (reduction) increase to net sales	$ (35)	14	$ (35)
Increase in deferred income		8
Non-Recurring Restructuring Activity \| 2024 Plan
Restructuring Cost and Reserve [Line Items]
Cost incurred to date		$ 29

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions	Dec. 31, 2025	Dec. 31, 2024
Current Assets:
Cash and cash equivalents	$ 326	$ 272
Accounts and notes receivable-trade, net	688	556
Inventories, net	642	564
Prepaid expenses and other current assets	367	354
Total Current Assets	2,023	1,746
Property, plant and equipment, net	861	766
Operating lease right-of-use assets, net	139	136
Identifiable intangible assets, net	974	1,207
Goodwill, net	1,148	1,597
Other noncurrent assets	284	301
Total Assets	5,429	5,753
Current Liabilities:
Accounts payable	300	241
Accrued liabilities	700	754
Income taxes payable	30	45
Notes payable and current portion of long-term debt	313	549
Total Current Liabilities	1,343	1,589
Long-term debt	2,015	1,586
Operating lease liabilities	93	91
Deferred income taxes	94	129
Other noncurrent liabilities	544	415
Total Liabilities	4,089	3,810
Commitments and contingencies (Note 21)
Equity:
Preferred stock, $1.00 par value; 0.25 million shares authorized; no shares issued	0	0
Common stock, $0.01 par value; 400.0 million shares authorized at December 31, 2024 and 2023 264.5 million shares issued at December 31, 2024 and 2023 198.8 million and 207.2 million shares outstanding at December 31, 2024 and 2023, respectively	3	3
Capital in excess of par value	6,644	6,640
Accumulated deficit	(1,564)	(835)
Accumulated other comprehensive loss	(639)	(730)
Treasury stock, at cost, 64.9 million and 65.7 million shares at December 31, 2025 and 2024, respectively	(3,105)	(3,136)
Total Dentsply Sirona Equity	1,339	1,942
Noncontrolling interests	1	1
Total Equity	1,340	1,943
Total Liabilities and Equity	$ 5,429	$ 5,753

COMMITMENTS AND CONTINGENCIES

12 Months Ended

Dec. 31, 2025

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES

Contingencies

On December 19, 2018, a putative class action was filed in the U.S. District Court for the Eastern District of New York (the “EDNY Court”) against the Company and certain individual defendants. The case was narrowed following its inception. The plaintiff’s claims which, as discussed below, have now been approved for final settlement, were that the Company and certain individual defendants violated U.S. securities laws by making material misrepresentations and omitting required information in the December 4, 2015 registration statement filed with the SEC in connection with the 2016 merger of Sirona Dental Systems Inc. (“Sirona”) with DENTSPLY International Inc. (the “Merger”) and that the defendants failed to disclose, among other things, that a distributor had purchased excessive inventory of legacy Sirona products. In addition, the plaintiff alleged that the defendants violated U.S. securities laws by making false and misleading statements in quarterly and annual reports and other public statements between May 6, 2016 and August 7, 2018. The plaintiff asserted claims on behalf of a putative class consisting of all purchasers of the Company’s stock during the period from December 8, 2015 through August 6, 2018. The Company moved to dismiss the amended complaint on August 15, 2019. The plaintiff filed its second amended complaint on January 22, 2021, and the Company filed a motion to dismiss the second amended complaint on March 8, 2021, with briefing on the motion fully submitted on May 21, 2021. The Company’s motion to dismiss was denied in a ruling by the EDNY Court on March 29, 2023, and the Company’s answer to the second amended complaint was filed on May 12, 2023. Following additional motion practice—which remained outstanding with the EDNY Court—and discovery, the parties engaged in settlement discussions with the assistance of a mediator, and, in January 2025, reached a settlement in principle to resolve the case in full for $84 million. In connection with the settlement, the Company received an offsetting insurance policy receivable of approximately $78 million and paid the rest in cash. The excess of the settlement liability over the corresponding insurance policy receivable resulted in $6 million of legal expense which was recorded during the year ended December 31, 2024. The settlement agreement, which was negotiated and signed in January, was approved by the EDNY Court following a final approval hearing held on September 10, 2025.

On June 2, 2022, the Company was named as a defendant in a putative class action filed in the U.S. District Court for the Southern District of Ohio captioned City of Miami General Employees’ & Sanitation Employees’ Retirement Trust v. Casey, Jr.

et al., No. 2:22-cv-02371, and on July 28, 2022, the Company was named as a defendant in a putative class action filed in the U.S. District Court for the Southern District of New York (the “SDNY Court”) captioned San Antonio Fire and Police Pension Fund v. Dentsply Sirona Inc. et al., No. 1:22-cv-06339 (together, the “Securities Litigation”). The complaints in the Securities Litigation are substantially similar and both allege that, during the period from June 9, 2021 through May 9, 2022, the Company, Mr. Donald M. Casey Jr., the Company’s former Chief Executive Officer, and Mr. Jorge Gomez, the Company’s former Chief Financial Officer, violated U.S. securities laws by, among other things, making materially false and misleading statements or omissions, including regarding the manner in which the Company recognized revenue tied to distributor rebate and incentive programs. On March 27, 2023, the Court in the Southern District of Ohio ordered the transfer of the putative class action to the SDNY Court. On June 1, 2023, the SDNY Court consolidated the two separate actions under case No. 1:22-cv-06339 and appointed as lead plaintiffs for the putative class the City of Birmingham Retirement and Relief System, the El Paso Firemen & Policemen’s Pension Fund, and the Wayne County Employees’ Retirement System (collectively, the “Lead Plaintiffs”). Lead Plaintiffs filed an amended class action complaint on July 28, 2023 (the “Amended Complaint”). In addition to asserting the same claims against the Company, Mr. Casey, and Mr. Gomez, the Amended Complaint added the Company’s former Chief Accounting Officer, Mr. Ranjit S. Chadha, as a defendant (collectively, “Defendants”). On October 10, 2023, Defendants filed a motion to dismiss the Amended Complaint. Lead Plaintiffs opposed the motion. On May 1, 2024, the SDNY Court granted the motion to dismiss as to Mr. Chadha and granted in part and denied in part the motion to dismiss as to the Company, Mr. Casey, and Mr. Gomez. The Company’s answer to the Amended Complaint was filed on May 21, 2024. On November 15, 2024, Lead Plaintiffs filed a motion to certify the matter as a class action, to appoint Lead Plaintiffs as class representatives, and to appoint class counsel. Defendants opposed the motion. On July 10, 2025, the SDNY Court granted Lead Plaintiffs’ motion for class certification, appointed the Lead Plaintiffs as class representatives, and appointed counsel for Lead Plaintiffs as class counsel. On November 3, 2025, Defendants and Lead Plaintiffs cross-moved for partial summary judgment. The motions for partial summary judgment were fully briefed on January 19, 2026. The Company has recognized a liability as of December 31, 2025, with an offsetting insurance receivable, resulting in no impact to the Consolidated Statements of Operations in the three and twelve months ended December 31, 2025.

In addition to the Securities Litigation, as previously disclosed, the Company voluntarily contacted the SEC following the Company’s announcement on May 10, 2022 of the internal investigation by the Audit and Finance Committee of the Company’s Board of Directors. On October 14, 2025, the Company announced that the Division of Enforcement of the SEC has concluded its investigation of the Company and does not intend to recommend any enforcement action against the Company.

Separately, on July 13, 2023, Company stockholder George Presura filed a stockholder derivative suit in the Delaware Court of Chancery captioned George Presura, Derivatively on Behalf of Nominal Defendant Dentsply Sirona Inc. v. Donald M. Casey Jr. et al. and Dentsply Sirona, Inc., No. 2023-0708-NAC (the “Presura Derivative Litigation”). The complaint, filed derivatively on behalf of the Company, asserts claims against current and former members of the Company’s Board of Directors and current and former executive officers, including Messrs. Casey and Gomez. The derivative complaint in this case contains allegations similar to those in the Securities Litigation, and it alleges that during the period from June 9, 2021 through July 13, 2023, various of the defendants breached fiduciary duties, committed corporate waste, and misappropriated information to conduct insider trading by making materially false and misleading statements or omissions regarding the Company’s recognition of revenue tied to distributor rebate and incentive programs and distributor inventory levels. On August 4, 2023, the Delaware Court of Chancery stayed the Presura Derivative Litigation until the earlier of public announcement of a settlement of the Securities Litigation or resolution of the pending motion to dismiss in the Securities Litigation.

Additionally, on March 26, 2024, Company stockholder Calvin Snee filed a stockholder derivative suit in the Delaware Court of Chancery captioned Calvin Snee, derivatively on behalf of Dentsply Sirona Inc. v. Donald M. Casey Jr., et al. and Dentsply Sirona Inc, No. 2024-0308 (the “Snee Derivative Litigation”). The complaint, filed derivatively on behalf of the Company, asserts claims against current and former members of the Company’s Board of Directors and current and former executive officers, including Messrs. Casey and Gomez. The derivative complaint in this case contains allegations similar to those in the Presura Derivative Litigation and the Securities Litigation, and it alleges that beginning in 2021, various of the defendants breached fiduciary duties, misappropriated information to conduct insider trading, and were unjustly enriched by making materially false and misleading statements or omissions regarding the Company’s recognition of revenue tied to distributor rebate and incentive programs and distributor inventory levels.

On May 2, 2024, the Delaware Court of Chancery issued an order consolidating and staying the Presura Derivative Litigation and Snee Derivative Litigation.

On July 19, 2024, Company stockholder Frank Manfre filed a stockholder derivative suit in the Delaware Court of Chancery captioned Frank Manfre, derivatively on behalf of nominal defendant Dentsply Sirona Inc. v. Donald M. Casey Jr. et al. and Dentsply Sirona Inc., No. 2024-0763 (the “Manfre Derivative Litigation”). The complaint asserts claims against current

and former members of the Company’s Board of Directors and current and former executive officers, including Messrs. Casey and Gomez. The complaint in this case contains allegations similar to those in the Snee Derivative Litigation, the Presura Derivative Litigation, and the Securities Litigation, and it alleges that beginning in 2021, various of the defendants breached fiduciary duties, misappropriated information to conduct insider trading, and were unjustly enriched by making materially false and misleading statements or omissions regarding the Company’s recognition of revenue tied to distributor rebate and incentive programs and distributor inventory levels.

On September 19, 2024, the Delaware Court of Chancery issued an order consolidating and staying the Manfre Derivative Litigation, Presura Derivative Litigation, and Snee Derivative Litigation.

On November 26, 2024, the Company was named as a defendant in a putative class action filed in the SDNY Court captioned North Collier Fire Control and Rescue District Firefighters’ Retirement Plan v. Dentsply Sirona Inc., et al., No. 1:24-cv-09083 (the “North Collier Action”). On December 18, 2024, the Company was named as a defendant in a putative class action filed in the SDNY Court captioned Calvin v. Dentsply Sirona Inc., et al., No. 1:24-cv-09764 (the “Calvin Action”), and on December 19, 2024, the Company was named as a defendant in a putative class action filed in the SDNY Court captioned Key West Police & Fire Pension Fund v. Dentsply Sirona Inc., et al., No. 1:24-cv-09819 (the “Key West Action”). The complaints in these three cases allege that, for different alleged class periods over the period from May 6, 2021 through November 6, 2024, the Company and certain then-current and former officers violated U.S. securities laws by, among other things, making materially false and misleading statements or omissions, including regarding the performance of the Company’s Byte aligners business, following the Company’s acquisition of Byte LLC in December 2020. On February 21, 2025, the SDNY Court entered an order consolidating the North Collier Action, the Calvin Action, and the Key West Action under the caption In re Dentsply Sirona, Inc. Securities Litigation, No. 24-cv-9083 (the “2024 Securities Litigation”), and appointed lead plaintiffs and lead counsel for the consolidated case. An amended complaint was filed on May 9, 2025. On July 8, 2025, the Company and certain then-current and former officers of the Company filed a motion to dismiss the amended complaint. On January 16, 2026, the SDNY Court granted the motion to dismiss as to Mr. Gomez and granted in part and denied in part the motions to dismiss as to the Company and all other defendants.

Separately, on March 18, 2025, Company stockholder Kevin O’Connor filed a stockholder derivative suit in the SDNY Court captioned Kevin O’Connor, derivatively on behalf of Dentsply Sirona Inc. v. Simon D. Campion, et al. and Dentsply Sirona Inc., No. 1:25-cv-02246 (the “O’Connor Derivative Litigation”). The complaint, filed derivatively on behalf of the Company, asserts claims against current and former members of the Company’s Board of Directors and then-current and former executive officers. The derivative complaint in this case contains allegations similar to those in the 2024 Securities Litigation, and it alleges that during the period from December 1, 2022 through November 6, 2024, various of the defendants breached fiduciary duties by, among other things, causing or allowing the Company to issue or make materially false and misleading statements concerning the Company’s financial condition and business operations as related to the acquisition of Byte LLC.

Additionally, on April 9, 2025, Company stockholder William Andreotti filed a stockholder derivative suit in the SDNY Court captioned William Andreotti, Derivatively on Behalf of Dentsply Sirona, Inc. v. Simon D. Campion, et al. and Dentsply Sirona, Inc., No. 1:25-cv-02931 (the “Andreotti Derivative Litigation”). The complaint, filed derivatively on behalf of the Company, asserts claims against current and former members of the Company’s Board of Directors and then-current and former executive officers. The derivative complaint in this case contains allegations similar to those in the O’Connor Derivative Litigation and the 2024 Securities Litigation, and it alleges that beginning on December 1, 2022, various of the defendants breached fiduciary duties and were unjustly enriched by disseminating or approving materially false and misleading statements or omissions related to the acquisition of Byte LLC.

On April 29, 2025, the SDNY Court issued an order consolidating and staying the O’Connor Derivative Litigation and the Andreotti Derivative Litigation.

Subsequent to December 31, 2025, on February 24, 2026, Company stockholder Derrick Chua filed a stockholder derivative suit in the U.S. District Court for the Western District of North Carolina captioned Derrick Chua, derivatively on behalf of Dentsply Sirona Inc. v. Simon D. Campion, et al. and Dentsply Sirona Inc., No. 3:26-cv-00148. The complaint, filed derivatively on behalf of the Company, asserts claims against current and former members of the Company’s Board of Directors and former executive officers. The derivative complaint in this case contains allegations similar to those in the O’Connor Derivative Litigation, the Andreotti Derivative Litigation, and the 2024 Securities Litigation, and it alleges that during the period from December 1, 2022 through November 6, 2024, various of the defendants violated federal securities laws and breached fiduciary duties by, among other things, causing the Company to repurchase its stock at prices that were artificially inflated due to alleged misrepresentations.

On March 21, 2023, Mr. Carlo Gobbetti filed a claim in the Milan Chamber of Arbitration against Dentsply Sirona Italia S.r.l. (“DSI”), Italy, a wholly owned subsidiary of the Company, seeking a total of €28 million for the alleged failure to pay a portion of the purchase price pursuant to a Share Purchase Agreement, dated October 8, 2012 (the “SPA”), in which Sirona Dental Systems, S.r.l., which at the time of execution of the SPA was a wholly-owned subsidiary of Sirona Dental Systems, Inc., acquired all of the shares of MHT S.p.A., an Italian corporation, from Mr. Gobbetti, and various other sellers. Sirona Dental Systems S.r.l. merged into Dentsply Italia S.r.l. in 2018 (the surviving entity is now DSI). Under the SPA, a portion of the purchase price equal to €7 million was required to be deposited into an escrow account (the “Escrow Account”) and released to Mr. Gobbetti and the other sellers upon the satisfaction of certain conditions, including the delivery by July 2013 of a new prototype of an MHT S.p.A. camera which had to meet certain specifications. In connection with the closing of the share purchase transaction, the SPA was supplemented by a Facility Agreement, also dated October 8, 2012 (the “FA”), which specifically set out the mechanics of payment and release of the proceeds of the Escrow Account. The Austrian notary public, Mr. Gottfried Schachinger, acting as escrow agent, Mr. Gobbetti, and SIRONA Holdings GmbH, an affiliate of Sirona Dental Systems, Inc. which paid the €7 million into the Escrow Account, were parties to the FA. The FA is subject to Austrian law and to the jurisdiction of the Court of Salzburg in Austria.

Mr. Gobbetti claims that he is entitled to receive the €7 million outstanding balance of the purchase price under the SPA, plus €21 million for damages incurred as a consequence of the failure to make the payment. Mr. Gobbetti claims that he has a right to receive the full purchase price under the SPA even if the conditions set out in the SPA to deliver a prototype of the MHT S.p.A. camera by July 2013 were not met. On May 15, 2023, DSI filed its initial statement of defense denying that Mr. Gobbetti and the other sellers were entitled to receive the funds deposited in the Escrow Account and further disputing the allegations. Following the constitution of the arbitral tribunal, hearings were held on September 13, 2023 and January 19, 2024, to illustrate and discuss the positions of the parties. The parties also developed their arguments in several rounds of defensive briefs. The final submissions were completed on April 15, 2024, and the final hearing for discussion took place on May 8, 2024. On July 22, 2024, the arbitral tribunal rejected all of Mr. Gobbetti’s claims, ruling that the Company had met its contractual obligations under the SPA, particularly regarding the balance of the purchase price. The arbitral tribunal also dismissed Mr. Gobbetti’s claims in tort and those pertaining to the FA for lack of jurisdiction and lack of capacity for the Company to be sued. The arbitral tribunal observed that such claims should have been brought against SIRONA Holdings GmbH, which is a party to the FA but not to the SPA, before the Court of Salzburg in Austria based on the jurisdictional clause of the FA.

Mr. Gobbetti appealed the ruling of the arbitral tribunal on December 2, 2024 before the Court of Appeals of Milan, Italy (the “Court of Appeals”) arguing that the ruling is null and void. According to Mr. Gobbetti, the arbitral tribunal did not grant him appropriate defense rights under the Italian Civil Code and did not fully address the merits of his claims, despite acknowledging jurisdiction. Mr. Gobbetti asked the Court of Appeals to directly sentence DSI to pay the €7 million, plus damages of €21 million and interest accruing until the time of payment. On April 17, 2025, DSI filed its statement of defense, asking the Court of Appeals to reject Mr. Gobbetti’s appeal and confirm the arbitral award in its entirety. The first hearing in the appeal proceedings took place on May 7, 2025, and the Court of Appeals concluded that there was no need to take additional evidence. A final hearing was scheduled for February 11, 2026 and was moved by the Court of Appeals to March 4, 2026.

Except as noted above, no specific amounts of damages have been alleged in these lawsuits. The Company will continue to incur legal fees in connection with these pending cases, including expenses for the reimbursement of legal fees of present and former officers and directors under indemnification obligations. The expense of continuing to defend such litigation may be significant. The Company intends to defend these lawsuits vigorously, although the Company may elect to settle certain litigation matters, but there can be no assurance that the Company will be successful in any defense or that matters can be settled on terms favorable to the Company. If any of the lawsuits are decided adversely, the Company may be liable for significant damages directly or under its indemnification obligations, which could adversely affect the Company’s business, results of operations and cash flows. At this stage, the Company has accrued losses which are deemed probable, along with related insurance receivables, but the Company is unable to assess whether any incremental material loss or adverse effect is reasonably possible as a result of these lawsuits or estimate the range of any potential loss.

The Internal Revenue Service (“IRS”) is conducting an examination of the Company’s U.S. federal income tax returns for the tax years 2015 and 2016. The Company received a Notice of Proposed Adjustment in April 2023 and a Revenue Agent Report in January 2024 from the IRS examination team proposing an adjustment related to an internal reorganization completed in 2016 with respect to the integration of certain operations of Sirona Dental Systems, Inc. following its acquisition in 2016. Although the proposed adjustment does not result in any additional federal income tax liability for the internal reorganization, if sustained, the proposed adjustment would result in the Company owing additional federal income taxes on a distribution of $451 million related to a stock redemption that occurred after the internal reorganization was completed in 2016. The proposed adjustment, if sustained, would also result in a loss of foreign tax credits carried forward to later tax years. The Company believes that it accurately reported the federal income tax consequences of the internal restructuring and stock redemption in its

tax returns and in April 2024, submitted an administrative protest with the IRS Independent Office of Appeals contesting the examination team’s proposed adjustments. The IRS examination team provided the Company with a rebuttal to the Company’s administrative protest during August 2024 and informed the Company that the dispute would be forwarded to the IRS Independent Office of Appeals.

The General Public Prosecutor’s Office Frankfurt am Main is investigating a series of intercompany loans implemented in 2016 and 2017 as part of the post-merger integration activities of DENTSPLY International Inc. and Sirona Dental Systems, Inc. The Company is cooperating with the investigation. The Company believes that the transactions at issue complied with all applicable German laws. No charges have been filed against the Company or any individuals.

The Company intends to vigorously defend its positions and pursue related appeals in the above-described pending matters and believes it is more likely than not that its positions will be sustained, although the Company may elect to settle certain matters. Unless otherwise disclosed herein, the Company has not accrued losses for these matters because the Company does not believe the risk of loss is probable and cannot estimate the range of any potential loss with any reasonable degree of accuracy.

In addition to the matters disclosed above, the Company is, from time to time, subject to a variety of litigation and similar proceedings incidental to its business. These legal matters primarily involve claims for damages arising out of the use of the Company’s products and services and claims relating to intellectual property matters including patent infringement, employment matters, tax matters, commercial disputes, competition, sales, and trading practices, personal injury, and insurance coverage. The Company may also become subject to lawsuits as a result of past or future acquisitions or as a result of liabilities retained from, or representations, warranties or indemnities provided in connection with, divested businesses. Some of these lawsuits may include claims for punitive and consequential, as well as compensatory, damages. Except as otherwise noted, the Company generally cannot predict what the eventual outcome of the above-described pending matters will be, what the timing of the ultimate resolution of these matters will be, or what the eventual loss, fines or penalties related to each pending matter may be. Based upon the Company’s experience, current information, and applicable law, it does not believe that these proceedings and claims will have a material adverse effect on its consolidated results of operations, financial position, or liquidity. However, in the event of unexpected further developments, it is possible that the ultimate resolution of these matters, or other similar matters, if unfavorable, may be materially adverse to the Company’s business, financial condition, results of operations, or liquidity.

While the Company maintains general, product, property, workers’ compensation, automobile, cargo, aviation, crime, fiduciary, cyber, and directors’ and officers’ liability insurance up to certain limits that cover certain of these claims, this insurance may be insufficient or unavailable to cover such losses. In addition, while the Company believes it is entitled to indemnification from third parties for some of these claims, these rights may also be insufficient or unavailable to cover such losses.

Commitments

Purchase Commitments


(in millions)


2026	$	141
2027	70
2028	35
2029	—
2030	—
Thereafter	—
Total	$	246

The table above includes commitments under the Company’s agreement with a cloud services provider supporting the Company’s digital platform which requires minimum purchases totaling $69 million through 2028.

Off-Balance Sheet Arrangements

As of December 31, 2025, the Company had no material off-balance sheet arrangements that have, or are reasonably likely to have, a current or future material effect on the Company’s consolidated financial condition, results of operations, liquidity, capital expenditures or capital resources other than certain items disclosed in the sections above.

Indemnification

In the normal course of business to facilitate sales of the Company’s products and services, the Company indemnifies certain parties, including customers, vendors, lessors, services providers, and others, with respect to certain matters, including, but not limited to, services to be provided by or for the Company, and intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with its current and former directors and officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. Several of these agreements limit the time within which an indemnification claim can be made and the amount of the claim.

It is not possible to make a reasonable estimate of the maximum potential amount of indemnification under these indemnification agreements due to the unique facts and circumstances involved in the various matters which give rise to indemnification claims and the particular terms of each agreement. However, to the extent that valid indemnification claims arise in the future, future payments by the Company could be significant and could have a material adverse effect on the Company’s results of operations or cash flows in a particular period.

INVENTORIES, NET - ADDITIONAL INFORMATION (Details) - USD ($) $ in Millions	Dec. 31, 2025	Dec. 31, 2024
Inventory Disclosure [Abstract]
Inventory valuation reserve	$ 95	$ 98

INVENTORIES, NET

12 Months Ended

Dec. 31, 2025

Inventory Disclosure [Abstract]

INVENTORIES, NET

Inventories, net were as follows:


	Year Ended December 31,
(in millions)	2025		2024

Raw materials and supplies	$	199	$	172
Work-in-process	82		72
Finished goods	361		320


Inventories, net	$	642	$	564

The Company’s inventory reserve was $95 million and $98 million at December 31, 2025 and 2024, respectively. Inventories are stated at the lower of cost and net realizable value.

INCOME TAXES - SCHEDULE OF UNRECOGNIZED TAX BENEFITS (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Unrecognized Tax Benefits [Roll Forward]
Unrecognized tax benefits at beginning of period	$ 128	$ 132	$ 49
Gross change for prior-period positions	1	18	1
Gross change for current year positions	1	1	95
Decrease due to settlements and payments	(1)	(13)	(9)
Decrease due to statute expirations	(1)	0	(4)
Increase due to effect of foreign currency translation	15	0	0
Decrease due to effect from foreign currency translation and other	0	(10)	0
Unrecognized tax benefits at end of period	$ 143	$ 128	$ 132

STOCK COMPENSATION - NON-QUALIFIED STOCK OPTION TRANSACTIONS (Details) - Nonqualified Stock Options - USD ($) $ / shares in Units, shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Shares
Beginning balance (in shares)	2.2
Granted (in shares)	6.4
Exercised (in shares)	0.0
Cancelled (in shares)	(0.6)
Forfeited (in shares)	(1.8)
Ending balance (in shares)	6.2
Weighted Average Exercise Price
Beginning balance (in dollars per share)	$ 45.37
Granted (in dollars per share)	13.76
Exercised (in dollars per share)	0
Cancelled (in dollars per share)	47.20
Forfeited (in dollars per share)	19.17
Ending balance (in dollars per share)	$ 19.88
Aggregate Intrinsic Value
Balance	$ 1	$ 0
Exercisable
Shares at year end (in shares)	1.1	1.4
Weighted Average Exercise Price Exercisable (in dollars per share)	$ 48.74	$ 50.27
Aggregate Intrinsic Value	$ 0	$ 0
Expected to Vest
Shares at year end (in shares)	5.1	0.8
Weighted Average Exercise Price Expected to Vest (in dollars per share)	$ 13.91	$ 37.06
Aggregate Intrinsic Value	$ 1	$ 0

FAIR VALUE MEASUREMENT - ADDITIONAL INFORMATION (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Fair Value, Concentration of Risk, Financial Statement Captions [Line Items]
Floating rate senior term loan	$ 2,276
Gain recorded to other income	4
Estimate of Fair Value, Fair Value Disclosure
Fair Value, Concentration of Risk, Financial Statement Captions [Line Items]
Floating rate senior term loan	2,217	$ 2,037
Carrying (Reported) Amount, Fair Value Disclosure
Fair Value, Concentration of Risk, Financial Statement Captions [Line Items]
Floating rate senior term loan	$ 2,329	$ 2,135

- Definition

Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-SubTopic 10
-Topic 210
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 55
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482949/835-30-55-8

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(16))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1D
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 944
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(16)(a)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (b)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-4

+ Details

PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)

12 Months Ended

Dec. 31, 2025

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]

Schedule of Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets were as follows:


	Year Ended December 31,
(in millions)	2025		2024

Prepaid expenses	$	140	$	121
Value-added tax receivable	49		50
Deposits	28		30
Other current assets	150		153
Prepaid expenses and other current assets	$	367	$	354

GOODWILL AND INTANGIBLE ASSETS (Tables)

12 Months Ended

Dec. 31, 2025

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Reconciliation of Changes in the Company's Goodwill

A reconciliation of changes in the Company’s goodwill by reportable segment was as follows:


(in millions)	Connected Technology Solutions		Essential Dental Solutions		Orthodontic and Implant Solutions		Wellspect Healthcare		Total

Balance at December 31, 2024
Goodwill	$	291	$	829	$	1,276	$	265	$	2,661
Accumulated impairment losses	(291)		—		(773)		—		(1,064)
Goodwill, net at December 31, 2024	$	—	$	829	$	503	$	265	$	1,597
Translation	—		31		22		23		76
Impairment	—		—		(525)		—		(525)
Goodwill, net at December 31, 2025	$	—	$	860	$	—	$	288	$	1,148

Accumulated impairment losses at December 31, 2025	(291)		—		(1,298)		—		(1,589)

Schedule of Identifiable Definite-Lived Intangible Assets

Identifiable definite-lived and indefinite-lived intangible assets were as follows:


	Year Ended December 31,
	2025						2024
(in millions)	Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount

Developed technology and patents	$	1,783	$	(1,334)	$	449	$	1,639	$	(1,079)	$	560
Trade names and trademarks	84		(79)		5		79		(73)		6
Licensing agreements	42		(29)		13		29		(28)		1
Customer relationships	1,098		(847)		251		1,019		(716)		303
Total definite-lived	$	3,007	$	(2,289)	$	718	$	2,766	$	(1,896)	$	870

Indefinite-lived trade names and trademarks	251		—		251		332		—		332
In-process R&D (a)	5		—		5		5		—		5
Total indefinite-lived	256		—		256		337		—		337

Total identifiable intangible assets	$	3,263	$	(2,289)	$	974	$	3,103	$	(1,896)	$	1,207

(a) Intangible assets acquired in a business combination that are in-process and used in R&D activities are considered indefinite-lived until the completion or abandonment of the R&D efforts. The useful life and amortization of those assets will be determined once the R&D efforts are completed.

Schedule of Indefinite-Lived Intangible Assets

Identifiable definite-lived and indefinite-lived intangible assets were as follows:


	Year Ended December 31,
	2025						2024
(in millions)	Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount

Developed technology and patents	$	1,783	$	(1,334)	$	449	$	1,639	$	(1,079)	$	560
Trade names and trademarks	84		(79)		5		79		(73)		6
Licensing agreements	42		(29)		13		29		(28)		1
Customer relationships	1,098		(847)		251		1,019		(716)		303
Total definite-lived	$	3,007	$	(2,289)	$	718	$	2,766	$	(1,896)	$	870

Indefinite-lived trade names and trademarks	251		—		251		332		—		332
In-process R&D (a)	5		—		5		5		—		5
Total indefinite-lived	256		—		256		337		—		337

Total identifiable intangible assets	$	3,263	$	(2,289)	$	974	$	3,103	$	(1,896)	$	1,207

- Definition

Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482548/350-20-55-24

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1A

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-2

+ Details

INCOME TAXES - SCHEDULE OF THE DEFERRED TAX ASSETS AND LIABILITIES (Details) - USD ($) $ in Millions	Dec. 31, 2025	Dec. 31, 2024
Schedule Of Deferred Income Tax Assets (Liabilities) [Line Items]
Liabilities	$ 94	$ 129
Other noncurrent assets
Schedule Of Deferred Income Tax Assets (Liabilities) [Line Items]
Assets	211	222
Deferred income taxes
Schedule Of Deferred Income Tax Assets (Liabilities) [Line Items]
Liabilities	$ 94	$ 129

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Income Statement [Abstract]
Net sales	$ 3,680	$ 3,793	$ 3,965
Cost of products sold	1,840	1,835	1,879
Gross profit	1,840	1,958	2,086
Selling, general, and administrative expenses	1,438	1,605	1,613
Research and development expenses	150	165	184
Goodwill and intangible asset impairments	650	1,014	307
Restructuring costs	24	53	67
Operating loss	(422)	(879)	(85)
Other income and expenses:
Interest expense, net	88	69	81
Other (income) expense, net	(24)	(12)	9
Loss before income taxes	(486)	(936)	(175)
Provision (benefit) for income taxes	112	(26)	(43)
Net loss	(598)	(910)	(132)
Less: Net loss attributable to noncontrolling interests	0	0	0
Net loss attributable to Dentsply Sirona	$ (598)	$ (910)	$ (132)
Net (loss) per common share attributable to Dentsply Sirona:
Basic (in dollars per share)	$ (3.00)	$ (4.48)	$ (0.62)
Diluted (in dollars per share)	$ (3.00)	$ (4.48)	$ (0.62)
Weighted average common shares outstanding:
Basic (in shares)	199.4	203.2	212.0
Diluted (in shares)	199.4	203.2	212.0

PROPERTY, PLANT AND EQUIPMENT, NET

12 Months Ended

Dec. 31, 2025

Property, Plant and Equipment [Abstract]

PROPERTY, PLANT AND EQUIPMENT, NET

Property, plant and equipment, net, were as follows:


	Year Ended December 31,
(in millions)	2025		2024

Land	$	52	$	46
Buildings and improvements	638		571
Machinery and equipment	995		887
Capitalized software	614		516
Construction in progress	134		87
	$	2,433	$	2,107
Less: Accumulated depreciation and amortization	1,572		1,341
Property, plant and equipment, net	$	861	$	766

RESTRUCTURING AND OTHER COSTS - SCHEDULE OF TOTAL RESTRUCTURING COSTS (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Restructuring Cost and Reserve [Line Items]
Total Restructuring and other costs	$ 25	$ 95	$ 74
Cost of products sold
Restructuring Cost and Reserve [Line Items]
Total Restructuring and other costs	0	10	4
Selling, general and administrative expenses
Restructuring Cost and Reserve [Line Items]
Total Restructuring and other costs	1	32	3
Restructuring costs
Restructuring Cost and Reserve [Line Items]
Total Restructuring and other costs	$ 24	$ 53	$ 67

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References + Details

RESTRUCTURING AND OTHER COSTS

12 Months Ended

Dec. 31, 2025

Restructuring and Related Activities [Abstract]

RESTRUCTURING AND OTHER COSTS

Restructuring and other costs for the years ended December 31, 2025, 2024 and 2023 were recorded in the Consolidated Statements of Operations as follows:


Affected Line Item in the Consolidated Statements of Operations	Year Ended December 31,
(in millions)	2025		2024		2023

Cost of products sold	$	—	$	10	$	4
Selling, general, and administrative expenses	1		32		3
Restructuring costs	24		53		67

Total Restructuring and other costs	$	25	$	95	$	74

Restructuring and other costs of $25 million were recorded in the year ended December 31, 2025, which consisted primarily of employee severance benefits and other restructuring costs for various restructuring actions, including the continuation of the global supply chain transformation initiatives from prior years and the plan approved by the Board of Directors of the Company on July 29, 2024 (the “2024 Plan”).

Restructuring Plans

With the 2024 Plan, the Company sought to improve operational performance and drive stockholder value creation. The 2024 Plan was substantially completed by the end of 2025. As of December 31, 2025, the Company has incurred $29 million in restructuring charges under the 2024 Plan since its inception, primarily related to employee transition, severance payments and employee benefits. Remaining restructuring charges attributable to the 2024 Plan are not expected to be material.


	Severance
(in millions)	2023 and Prior Plans		2024 Plans		Other Actions		Total

Balance at December 31, 2024	$	13	$	19	$	—	$	32
Provisions and adjustments	1		4		16		21
Amounts applied	(11)		(19)		(7)		(37)
Change in estimates	(2)		(2)		(2)		(6)
Balance at December 31, 2025	$	1	$	2	$	7	$	10


	Other Restructuring Costs
(in millions)	2023 and Prior Plans		2024 Plans		Other Actions		Total

Balance at December 31, 2024	$	1	$	—	$	—	$	1
Provisions and adjustments	1		1		2		4
Amounts applied	(2)		(1)		—		(3)

Balance at December 31, 2025	$	—	$	—	$	2	$	2

The cumulative amounts for the provisions and adjustments and amounts applied for all the plans by segment were as follows:


(in millions)	December 31, 2024		Provisions and Adjustments		Amounts Applied		Change in Estimates		December 31, 2025

Connected Technology Solutions	$	9	$	6	$	(10)	$	(4)	$	1
Essential Dental Solutions	11		3		(9)		(1)		4
Orthodontic and Implant Solutions	9		7		(12)		(1)		3
Wellspect Healthcare	3		1		(2)		—		2
All Other	1		8		(7)		—		2
Total	$	33	$	25	$	(40)	$	(6)	$	12

The Company’s restructuring accruals at December 31, 2024 were as follows:


	Severances
(in millions)	2022 and Prior Plans		2023 Plans		2024 Plans		Total

Balance at December 31, 2023	$	2	$	37	$	—	$	39
Provisions and adjustments	1		23		30		54
Amounts applied	(2)		(44)		(11)		(57)
Change in estimates	—		(4)		—		(4)
Balance at December 31, 2024	$	1	$	12	$	19	$	32


	Other Restructuring Costs
(in millions)	2022 and Prior Plans		2023 Plans		2024 Plans		Total

Balance at December 31, 2023	$	1	$	—	$	—	$	1
Provisions and adjustments	—		3		—		3
Amounts applied	—		(3)		—		(3)
Change in estimates	—		—		—		—
Balance at December 31, 2024	$	1	$	—	$	—	$	1

The cumulative amounts for the provisions and adjustments and amounts applied for all the plans by segment were as follows:


(in millions)	December 31, 2023		Provisions and Adjustments		Amounts Applied		Change in Estimates		December 31, 2024

Connected Technology Solutions	$	13	$	23	$	(25)	$	(2)	$	9
Essential Dental Solutions	17		15		(20)		(1)		11
Orthodontic and Implant Solutions	9		11		(11)		—		9
Wellspect Healthcare	1		5		(2)		(1)		3
All Other	—		3		(2)		—		1
Total	$	40	$	57	$	(60)	$	(4)	$	33

Byte Developments

The changes to the Byte clear aligners business disclosed in Note 6, Segment and Geographic Information, resulted in significant reductions in revenue forecasts. The Company recorded long-term tangible asset charges, which include production equipment and capitalized software, as well as working capital for certain inventory and customer receivables specific to Byte. Additionally, the Company recorded a full impairment of the Byte trademark intangible asset.

In addition to these impairments, for the year ended December 31, 2024, the Company paid $13 million in refunds and recorded a full accrual for remaining expected customer refunds and other reimbursement payments stemming from the cessation of sales, which resulted in a $43 million accrual at December 31, 2024, with $35 million recorded as a reduction to net sales. During the year ended December 31, 2025, the Company paid $16 million of refunds and recorded adjustments resulting from refinements of its estimate of expected customer refunds that increased deferred income by $8 million and increased sales by $14 million. The remainder of the accrual is expected to be paid in 2026.

The impact of the 2024 charges related to changes to the Company’s Byte clear aligners business was as follows:


Location in the Consolidated Statements of Operations
(in millions)	December 31, 2024

Net sales
Change in refund estimate	$	(35)
Cost of products sold
Inventory reserve	(8)
Selling, general, and administrative expenses
Intangible asset impairment - trademark	(152)
Property, plant and equipment write-off	(17)
Accounts receivable reserve and prepaid write-off	(10)
Total impact on operating loss	$	(222)

STOCK COMPENSATION

12 Months Ended

Dec. 31, 2025

Share-Based Payment Arrangement [Abstract]

STOCK COMPENSATION

The Company maintains the 2024 Omnibus Incentive Plan (the “Plan”), which was approved by the Company’s stockholders on May 22, 2024 (the “Effective Date”). The Company’s stockholders previously approved the 2016 Omnibus Incentive Plan (the “Prior Plan”). After the Effective Date, no new awards may be granted under the Prior Plan, although awards granted under the Prior Plan prior to the Effective Date remain outstanding and remain subject to the terms and conditions of, and continue to be governed by, the Prior Plan. Under the Plan, the Company may grant stock options, share appreciation rights, restricted shares, restricted share units, share bonuses, other share-based awards, or cash awards, collectively referred to as “Awards.” The Company’s non-qualified stock options (“NQSOs”) are granted at exercise prices that are at least equal to the closing stock price on the date of grant. Under the Plan, 14.5 million shares are initially available for Awards, less (i) one share for every one share that was subject to an option or share appreciation right granted after March 26,

2024 under the Prior Plan and (ii) 2.7 shares for every one share that was subject to an award other than an option or share appreciation right granted after March 26, 2024 under the Prior Plan (such adjusted amount, the “Share Pool”). Under the Plan, any shares that are subject to options or share appreciation rights shall be counted against the Share Pool as one share for every one share granted, and any shares that are subject to awards other than options or share appreciation rights shall be counted against the Share Pool as 2.7 shares for every one share granted. Shares granted under either the Plan or the Prior Plan which are cancelled or forfeited are added back to the count of shares available for Awards. The number of shares available for grant at December 31, 2025 is 18 million.

The amounts of stock-based compensation expense recorded in the Company’s Consolidated Statements of Operations were as follows:


	Year Ended December 31,
(in millions)	2025		2024		2023

Cost of products sold	$	2	$	3	$	4
Selling, general, and administrative expense	28		35		36
Research and development expense	2		2		4
Restructuring and other costs	—		(1)		2
Total stock-based compensation expense	$	32	$	39	$	46

Related deferred income tax benefit	$	5	$	7	$	8

The Company uses the Black-Scholes option-pricing model to estimate the fair value of each option awarded. The average assumptions used to determine compensation cost for the Company’s NQSOs issued were as follows:


	Year Ended December 31,
	2025			2024			2023

Weighted average fair value per NQSO	$	3.14		$	9.91		$	12.64
Expected dividend yield	4.77		%	1.92		%	1.45		%
Risk-free interest rate	3.81		%	4.28		%	4.27		%
Expected volatility	36.3		%	35.7		%	35.8		%
Expected life (years)	4.12			4.26			4.76

The total intrinsic value of NQSOs exercised for the years ended December 31, 2025, 2024 and 2023 was insignificant.

The NQSO transactions for the year ended December 31, 2025 were as follows:


	Outstanding					Exercisable					Expected to Vest
(in millions, except per share amounts)	Shares	Weighted Average Exercise Price		Aggregate Intrinsic Value		Shares	Weighted Average Exercise Price		Aggregate Intrinsic Value		Shares	Weighted Average Exercise Price		Aggregate Intrinsic Value

December 31, 2024	2.2	$	45.37	$	—	1.4	$	50.27	$	—	0.8	$	37.06	$	—
Granted	6.4	13.76

Exercised	—	—
Cancelled	(0.6)	47.20
Forfeited	(1.8)	19.17
December 31, 2025	6.2	$	19.88	$	1	1.1	$	48.74	$	—	5.1	$	13.91	$	1

There were 5.1 million NQSOs unvested at December 31, 2025. The remaining unamortized compensation cost related to NQSOs is $13 million, which will be expensed over the weighted average remaining vesting period of the options, which is 2.4 years.

The weighted average remaining contractual term of all outstanding options, exercisable options, and options expected to vest are 8.7 years, 4.6 years and 9.5 years, respectively.

Information about NQSOs outstanding as of December 31, 2025 is provided below:


				Outstanding				Exercisable
				Number Outstanding at December 31, 2025	Weighted Average Remaining Contractual Life (in years)	Weighted Average Exercise Price		Number Exercisable at December 31, 2025	Weighted Average Exercise Price
Range of Exercise Prices
(in millions, except per share amounts and life)

$	5.01	-	$10.00	—	0.0	$	—	—	$	—
$	10.01	-	$20.00	5.0	9.6	$	13.09	—	$	—
$	20.01	-	$30.00	—	7.9	$	28.39	—	$	28.39
$	30.01	-	$40.00	0.5	7.7	36.99		0.4	$	37.49
$	40.01	-	$50.00	0.3	3.3	47.53		0.3	$	47.60
$	50.01	-	$60.00	0.3	4.1	55.69		0.3	$	55.69
$	60.01	-	$70.00	0.1	1.0	62.37		0.1	$	62.37
				6.2				1.1

The unvested RSUs for the year ended December 31, 2025 were as follows:


	Unvested Restricted Stock Units
	Shares	Weighted Average Grant Date Fair Value

(in millions, except per share amounts)

Unvested at December 31, 2024	3.9	$	37.11
Granted	4.5	15.64

Vested	(0.7)	35.49
Forfeited	(2.3)	23.50
Unvested at December 31, 2025	5.4	$	19.95

The weighted average grant date fair value of RSUs granted for the year ended December 31, 2023 was $42.95. The unamortized compensation cost related to RSUs is $26 million, which will be expensed over the remaining weighted average restricted period of the RSUs, which is 1.7 years.

The total fair value of shares vested for the years ended December 31, 2025, 2024 and 2023 was $31 million, $46 million and $42 million, respectively.

LEASES - LEASE COSTS (Details) - USD ($) $ in Millions	12 Months Ended
LEASES - LEASE COSTS (Details) - USD ($) $ in Millions	Dec. 31, 2025	Dec. 31, 2024
Leases [Abstract]
Operating lease cost	$ 65	$ 67
Variable lease cost	17	16
Total lease cost	$ 82	$ 83

PREPAID EXPENSES AND OTHER CURRENT ASSETS

12 Months Ended

Dec. 31, 2025

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]

PREPAID EXPENSES AND OTHER CURRENT ASSETS

Prepaid expenses and other current assets were as follows:


	Year Ended December 31,
(in millions)	2025		2024

Prepaid expenses	$	140	$	121
Value-added tax receivable	49		50
Deposits	28		30
Other current assets	150		153
Prepaid expenses and other current assets	$	367	$	354

FAIR VALUE MEASUREMENT (Tables)

12 Months Ended

Dec. 31, 2025

Fair Value Disclosures [Abstract]

Schedule of Assets and Liabilities measured at Fair Value on a Recurring Basis

The Company’s financial assets and liabilities set forth by level within the fair value hierarchy that were accounted for at fair value on a recurring basis were as follows:


	Year Ended December 31, 2025
(in millions)	Total		Level 1		Level 2		Level 3

Assets


Interest rate swap asset related to long-term debt	$	14	$	—	$	14	$	—

Foreign exchange forward contracts	8		—		8		—

Total assets	$	22	$	—	$	22	$	—

Liabilities
Interest rate swaps	$	14	$	—	$	14	$	—

Cross currency basis swaps	31		—		31		—
Foreign exchange forward contracts	67		—		67		—

Contingent considerations on acquisitions	—		—		—		—

Total liabilities	$	112	$	—	$	112	$	—


	Year Ended December 31, 2024
(in millions)	Total		Level 1		Level 2		Level 3

Assets



Cross currency interest rate swaps	$	18	$	—	$	18	$	—
Foreign exchange forward contracts	18		—		18		—


Total assets	$	36	$	—	$	36	$	—

Liabilities
Interest rate swaps	$	21	$	—	$	21	$	—


Foreign exchange forward contracts	9		—		9		—

Contingent considerations on acquisitions	4		—		—		4

Total liabilities	$	34	$	—	$	30	$	4

SEGMENT AND GEOGRAPHIC INFORMATION

12 Months Ended

Dec. 31, 2025

Segment Reporting [Abstract]

SEGMENT AND GEOGRAPHIC INFORMATION

The Company has four operating segments, organized primarily by product, which are also the Company’s reportable segments. These are (i) Connected Technology Solutions, (ii) Essential Dental Solutions, (iii) Orthodontic and Implant Solutions, and (iv) Wellspect Healthcare. They generally have overlapping geographical presence, customer bases, distribution channels, and regulatory oversight with the exception of Wellspect Healthcare, which has a more discrete market and regulatory environment specific to the medical device industry. These operating segments, which also form the Company’s reportable segments, are identified in accordance with how the Company’s chief operating decision maker (“CODM”) regularly reviews financial results and uses this information to evaluate the Company’s performance and allocate resources. The Company’s CODM is the Chief Executive Officer.

The CODM assesses performance of the segments based on the net sales and adjusted operating income. Segment adjusted operating income is defined as operating income before income taxes and before certain unallocated corporate costs, interest expense, net, other (income) expense, net, goodwill and intangible asset impairments, restructuring and other costs, amortization of intangible assets, other acquisition costs, and depreciation resulting from the fair value step-up of property, plant, and equipment from business combinations. Asset and other balance sheet information is not reported to the CODM.

The CODM uses both net sales and segment adjusted operating income for each segment during development of the annual operating plan and the regular forecasting process. Additionally, the CODM considers budget-to-actual variances for these measures on a quarterly basis as well as segment-specific forecasting when making decisions about the allocation of operating and capital resources to each segment.

A description of the products and services provided within each of the Company’s four reportable segments is provided below.

Connected Technology Solutions

This segment includes the design, manufacture and sales of the Company’s dental technology and equipment products. These products include the Equipment & Instruments and CAD/CAM product categories.

Equipment & Instruments

The Equipment & Instruments product category consists of dental equipment products such as imaging equipment, motorized dental handpieces, treatment centers, and other instruments for dental practitioners and specialists. Imaging equipment serves as a key point of entry to the Company’s digital workflow offerings and consists of a broad range of diagnostic imaging systems for 2D or 3D, panoramic, and intraoral applications, as well as cone-beam computed tomography systems (“CBCT”). Treatment centers comprise a broad range of products from basic dental chairs to sophisticated chair-based units with integrated diagnostic, hygienic and ergonomic functionalities, as well as specialist centers used in preventive treatment and for training purposes. This product group also includes other lab equipment, such as amalgamators, mixing machines and porcelain furnaces.

CAD/CAM

Dental CAD/CAM technologies are products designed for dental professionals to support numerous digital workflows for procedures such as dental restorations through integrations with DS Core, our cloud-based platform. This product category includes intraoral scanners, 3-D printers, mills, and certain software and services, as well as a full-chairside economical restoration of esthetic ceramic dentistry offering called CEREC, which enables dentists to practice same-day or single visit dentistry.

Essential Dental Solutions

This segment includes the development, manufacture and sales of the Company’s value-added endodontic, restorative, and preventive consumable products and small equipment used by dental professionals for the treatment of patients. Offerings in this segment also include specialized treatment products including products used in the creation of dental appliances.

Essential Dental Solutions products are designed to operate in an integrated system to provide solutions for high-tech dental procedures. The endodontic products include motorized endodontic handpieces, files, sealers, irrigation needles and other tools or single-use solutions which support root canal procedures. The restorative products include curing light systems, dental ceramics, composites, and other materials used in prosthetic restorations, including crowns and veneers.

The preventive products include small equipment, such as dental diagnostic systems and ultrasonic scalers and polishers, as well as other dental supplies including dental anesthetics, prophylaxis paste, dental sealants, and impression materials.

Orthodontic and Implant Solutions

This segment includes the design, manufacture, and sales of the Company’s various digital implant systems and innovative dental implant products, digital dentures, and digital orthodontic solutions. Offerings in this segment also include application of our digital services and technology, including those provided by DS Core, our cloud-based platform.

Orthodontics

The Orthodontics product category includes the SureSmile brand, a comprehensive digital treatment planning and orthodontic appliance solution. The cloud-based software is used to prescribe SureSmile clear aligners, robotically bent wires, and digital indirect bonding trays. The SureSmile Simulator uses intraoral scanners and our DS Core platform to create a 3D visualization of potential patient outcomes. The category also includes whitening kits and retainers. The Orthodontics product category previously included a direct-to-consumer clear aligner product marketed as Byte, which was no longer offered to new patients after October 24, 2024. The Company continues to provide support to Byte clear aligner patients in treatment, provided they meet certain criteria.

Implants & Prosthetics

The Implants & Prosthetics product category includes a portfolio of innovative dental implant products, supported by the Company’s digital workflow for implant solutions, digital dentures, crown and bridge products, bone regenerative and restorative solutions, treatment planning software and educational programs. The Implants & Prosthetics product category is supported by key technologies including custom abutments, advanced tapered immediate load screws and regenerative bone growth factor. Offerings in this category also include dental prosthetics such as artificial teeth.

Wellspect Healthcare

This segment includes the design, manufacture, and sales of the Company’s innovative continence care solutions for both urinary and bowel management. Wellspect Healthcare is a leading global manufacturer and provider of innovative medical devices, including catheters to help people suffering from urinary retention and advanced irrigation systems to help people suffering from chronic or severe constipation, which combine a high degree of user convenience, clinical effectiveness and connectivity into one smart system.

The Company’s segment financial information was as follows:


	Year Ended December 31,
	2025
(in millions)	Connected Technology Solutions	Essential Dental Solutions	Orthodontic and Implant Solutions	Wellspect Healthcare	Total

Net sales	1,036	1,469	850	325	3,680

Adjusted cost of products sold (a)	614	555	392	131




Adjusted selling expenses (b)	221	301	222	55
Adjusted G&A expenses (b)	81	76	80	27

Adjusted R&D expenses (c)	68	23	48	10

Segment adjusted operating income	52	514	108	102	776

Reconciling items (income) expense:
Unallocated corporate costs (d)					311
Interest expense, net					88
Other (income) expense, net					(24)
Goodwill and intangible asset impairments					650
Restructuring and other costs					24
Amortization of intangibles					211
Depreciation resulting from the fair value step-up of property, plant, and equipment from business combinations					2
Loss before income taxes					(486)

(a) Adjusted cost of products sold represents expenses adjusted to exclude intangible amortization expense, step-up depreciation expense, and other restructuring costs.


	Year Ended December 31,
	2024
(in millions)	Connected Technology Solutions	Essential Dental Solutions	Orthodontic and Implant Solutions	Wellspect Healthcare	Total

Net sales	1,062	1,454	973	304	3,793

Adjusted cost of products sold (a)	602	565	407	117




Adjusted selling expenses (b)	242	313	301	52
Adjusted G&A expenses (b)	74	74	133	27

Adjusted R&D expenses (c)	74	23	52	10

Segment adjusted operating income	70	479	80	98	727

Reconciling items (income) expense:
Unallocated corporate costs (d)					320
Interest expense, net					69
Other (income) expense, net					(12)
Goodwill and intangible asset impairments					1,014
Restructuring and other costs					53
Amortization of intangibles					216
Depreciation resulting from the fair value step-up of property, plant, and equipment from business combinations					3
Loss before income taxes					(936)

(a) Adjusted cost of products sold represents expenses adjusted to exclude intangible amortization expense, step-up depreciation expense, and other restructuring costs.


	Year Ended December 31,
	2023
(in millions)	Connected Technology Solutions	Essential Dental Solutions	Orthodontic and Implant Solutions	Wellspect Healthcare	Total

Net sales	1,169	1,468	1,040	288	3,965

Adjusted cost of products sold (a)	645	560	402	114




Adjusted selling expenses (b)	264	313	305	51
Adjusted G&A expenses (b)	77	94	119	25

Adjusted R&D expenses (c)	82	23	58	11

Segment adjusted operating income	101	478	156	87	822

Reconciling items (income) expense:
Unallocated corporate costs (d)					319
Interest expense, net					81
Other (income) expense, net					9
Goodwill and intangible asset impairments					307
Restructuring and other costs					67
Amortization of intangibles					211
Depreciation resulting from the fair value step-up of property, plant, and equipment from business combinations					3
Loss before income taxes					(175)

(a) Adjusted cost of products sold represents expenses adjusted to exclude intangible amortization expense, step-up depreciation expense, and other restructuring costs.


Depreciation and Amortization	Year Ended December 31,
(in millions)	2025		2024		2023

Connected Technology Solutions	$	186	$	175	$	176
Essential Dental Solutions	34		35		33
Orthodontic and Implant Solutions	90		98		97
Wellspect Healthcare	18		19		18
All Other (a)	24		22		19
Total	$	352	$	349	$	343

(a) Includes unallocated corporate costs for depreciation and amortization

Geographic Information


	Year Ended December 31,
(in millions)	2025		2024		2023

Net sales
United States	$	1,182	$	1,348	$	1,437
Germany	422		410		431

Other Foreign	2,076		2,035		2,097
Total net sales	$	3,680	$	3,793	$	3,965

Property, plant and equipment, net, represents those long-lived assets held by the operating businesses located in the respective geographic areas.


	Year Ended December 31,
(in millions)	2025		2024		2023

Property, plant, and equipment, net
United States	$	206	$	210	$	194
Germany	247		230		260
Sweden	124		101		105
Other Foreign	284		225		241
Total property, plant, and equipment, net	$	861	$	766	$	800

Product and Customer Information

For information on the Company’s net sales by product category comprising each of the reportable segments, see Note 2, Revenue Recognition.

Concentration Risk

Customers that accounted for 10% or more of net sales or accounts receivable for the year ended December 31, 2025 were as follows:


		Year Ended December 31,
	2025
			% of net sales		% of accounts receivable

Henry Schein, Inc.			13	%	Less than 10%
Patterson Companies, Inc.			Less than 10%		11	%

For the year ended December 31, 2024, no customer accounted for 10% or more of consolidated net sales or consolidated accounts receivable.

Customers that accounted for 10% or more of net sales or accounts receivable for the year ended December 31, 2023 were as follows:


		Year Ended December 31,
	2023
			% of net sales		% of accounts receivable

Henry Schein, Inc.			14	%	11	%
Patterson Companies, Inc.			Less than 10%		10	%

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-21

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-21

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-15

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 12: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 13: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 14: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 15: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 16: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 17: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 34
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-34

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/280/tableOfContent

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

+ Details

LOSS PER COMMON SHARE - COMPUTATION OF BASIC AND DILUTED (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Basic Loss Per Common Share
Net loss attributable to Dentsply Sirona	$ (598)	$ (910)	$ (132)
Weighted average common shares outstanding (in shares)	199.4	203.2	212.0
Basic loss per common share (in dollars per share)	$ (3.00)	$ (4.48)	$ (0.62)
Diluted Loss Per Common Share
Net loss attributable to Dentsply Sirona	$ (598)	$ (910)	$ (132)
Weighted average common shares outstanding (in shares)	199.4	203.2	212.0
Incremental weighted average shares from assumed exercise of dilutive options from stock-based compensation awards (in shares)	0.0	0.0	0.0
Total weighted average diluted shares outstanding (in shares)	199.4	203.2	212.0
Diluted loss per common share (in dollars per share)	$ (3.00)	$ (4.48)	$ (0.62)
Weighted average shares excluded from diluted common shares outstanding due to reported net loss (in shares)	0.8	0.6	1.1
Weighted average shares excluded from diluted common shares outstanding due to antidilutive nature (in shares)	4.5	3.7	3.0

BENEFIT PLANS (Tables)

12 Months Ended

Dec. 31, 2025

Retirement Benefits [Abstract]

Schedule of Reconciliations of Changes in the Defined Benefit Obligations, Fair Value of Assets and Statement of Funded Status

Reconciliation of changes in the defined benefit obligations, fair value of assets and statement of funded status were as follows:




	Year Ended December 31,
(in millions)	2025		2024

Change in Benefit Obligation
Benefit obligation at beginning of year	$	478	$	511
Service cost	11		11
Interest cost	12		12
Participant contributions	5		5
Actuarial (gains) losses	(21)		(4)


Effect of exchange rate changes	70		(36)

Plan curtailments and settlements	(13)		—
Benefits paid	(12)		(21)
Benefit obligation at end of year	$	530	$	478

Change in Plan Assets
Fair value of plan assets at beginning of year	$	208	$	207
Actual return on assets	10		16
Plan settlements	(13)		—

Effect of exchange rate changes	30		(15)
Employer contributions	18		16
Participant contributions	5		5
Benefits paid	(12)		(21)
Fair value of plan assets at end of year	$	246	$	208

Funded status at end of year	$	(284)	$	(270)

Schedule of Amounts Recognized in the Accompanying Consolidated Balance Sheets, Net of Tax Effects

The amounts recognized in the accompanying Consolidated Balance Sheets, net of tax effects, were as follows:


	Location In The	Year Ended December 31,
(in millions)	Consolidated Balance Sheets	2025		2024

Other noncurrent assets	Other noncurrent assets	$	17	$	4
Deferred tax asset	Other noncurrent assets	6		8
Total assets		$	23	$	12

Current liabilities	Accrued liabilities	$	(13)	$	(10)
Other noncurrent liabilities	Other noncurrent liabilities	(288)		(264)
Deferred tax liability	Deferred income taxes	(8)		(4)
Total liabilities		$	(309)	$	(278)

Accumulated other comprehensive income	Accumulated other comprehensive loss	5		23
Net amount recognized		$	(281)	$	(243)

Schedule of Amounts Recognized in Accumulated Other Comprehensive Income

Amounts recognized in AOCI were as follows:



	Year Ended December 31,
(in millions)	2025		2024

Net actuarial loss	$	5	$	30
Net prior service cost	(2)		(3)
Before tax AOCI	$	3	$	27
Less: Deferred taxes (benefit)	(2)		4
Net of tax AOCI	$	5	$	23

Schedule of Information for Pension Plans with an Accumulated Benefit Obligation in Excess of Plan Assets

Information for pension plans with a projected or accumulated benefit obligation in excess of plan assets was as follows:


	Year Ended December 31,
(in millions)	2025		2024

Projected benefit obligation	$	300	$	274
Accumulated benefit obligation	290		263

Schedule of Components of Net Periodic Benefit Cost

Components of net periodic benefit cost were as follows:


	Year Ended December 31,						Location in the Consolidated Statements of Operations
(in millions)	2025		2024		2023

Service cost	$	4	$	4	$	4	Cost of products sold
Service cost	7		7		6		Selling, general and administrative expenses
Interest cost	12		12		14		Other (income) expense, net
Expected return on plan assets	(6)		(5)		(6)		Other (income) expense, net

Amortization of prior service credit	(1)		(1)		(1)		Other (income) expense, net
Amortization of net actuarial loss	1		2		—		Other (income) expense, net

Curtailment and settlement gains	2		—		—		Other (income) expense, net

Net periodic benefit cost	$	19	$	19	$	17

Schedule of Other Changes in Plan Assets and Benefit Obligations Recognized in AOCI

Other changes in plan assets and benefit obligations recognized in AOCI were as follows:


	Year Ended December 31,
(in millions)	2025		2024		2023

Net actuarial (gains) losses	$	(24)	$	(17)	$	37


Amortization	—		(1)		1
Total recognized in AOCI	$	(24)	$	(18)	$	38
Total recognized in net periodic benefit cost and AOCI	$	(5)	$	1	$	55

Schedule of Weighted Average Assumptions Used to Determine Benefit Obligations, Principally in Foreign Locations

The weighted average assumptions used to determine benefit obligations for the Company’s plans, principally in foreign locations, were as follows:


	Year Ended December 31,
	2025		2024		2023

Interest crediting rate	2.0	%	2.0	%	2.3	%
Discount rate	3.0	%	2.5	%	2.6	%
Rate of compensation increase	2.4	%	2.4	%	2.5	%

Schedule of Weighted Average Assumptions Used to Determine Net Periodic Benefit Cost

The weighted average assumptions used to determine net periodic benefit cost for the Company’s plans, principally in foreign locations, were as follows:


	Year Ended December 31,
	2025		2024		2023

Interest crediting rate	2.0	%	2.3	%	2.5	%
Discount rate	2.5	%	2.6	%	3.2	%
Expected return on plan assets	2.8	%	2.9	%	3.2	%
Rate of compensation increase	2.4	%	2.5	%	2.6	%
Measurement date	12/31/2025		12/31/2024		12/31/2023

Schedule of Fair Value Measurements of Plan Assets

The fair values of the Company’s pension plan assets at December 31, 2025 and 2024 are presented in the table below by asset category. Approximately 83% of the total plan assets are categorized as Level 1, as the values assigned to these pension assets are based on quoted prices available in active markets. For the other category levels, a description of the valuation is provided in Note 1, Significant Accounting Policies, under the “Fair Value Measurement” heading.


	December 31, 2025
(in millions)	Total		Level 1		Level 2		Level 3

Assets Category
Cash and cash equivalents	$	5	$	5	$	—	$	—
Equity securities:

International	79		79		—		—
Fixed income securities:
Fixed rate bonds (a)	90		90		—		—
Other types of investments:
Mutual funds (b)	31		31		—		—


Insurance contracts	26		—		—		26
Hedge funds	14		—		—		14
Real estate	1		—		—		1
Total	$	246	$	205	$	—	$	41


	December 31, 2024
(in millions)	Total		Level 1		Level 2		Level 3

Assets Category
Cash and cash equivalents	$	6	$	6	$	—	$	—
Equity securities:

International	67		67		—		—
Fixed income securities:
Fixed rate bonds (a)	79		79		—		—
Other types of investments:
Mutual funds (b)	21		21		—		—


Insurance contracts	24		—		—		24
Hedge funds	10		—		—		10
Real estate	1		—		—		1
Total	$	208	$	173	$	—	$	35

(a) This category includes fixed income securities invested primarily in Swiss bonds, foreign bonds denominated in Swiss francs, foreign currency bonds, mortgage notes and pledged letters.

(b) This category includes mutual funds balanced between moderate income generation and moderate capital appreciation with investment allocations of approximately 50% equities and 50% fixed income investments.

Schedule of Reconciliation for the Plans Assets Categorized as Level 3

A reconciliation from December 31, 2023 to December 31, 2025 for the plan assets categorized as Level 3 was as follows:


(in millions)	Insurance Contracts		Hedge Funds		Real Estate		Total

Balance at December 31, 2023	$	26	$	7	$	1	$	34
Actual return on plan assets:
Relating to assets still held at the reporting date	1		1		—		2


Purchases, sales and settlements, net	(1)		3		—		2

Effect of exchange rate changes	(2)		(1)		—		(3)
Balance at December 31, 2024	$	24	$	10	$	1	$	35
Actual return on plan assets:
Relating to assets still held at the reporting date	$	—	$	1	$	—	$	1


Purchases, sales and settlements, net	(1)		1		—		—

Effect of exchange rate changes	3		2		—		5
Balance at December 31, 2025	$	26	$	14	$	1	$	41

Schedule of Estimated Future Benefit Payments

Estimated Future Benefit Payments

Total benefits expected to be paid from the plans in the future are as follows:


(in millions)	Pension Benefits

2026	$	31
2027	31
2028	30
2029	30
2030	30
2031-2035	145

OTHER (INCOME) EXPENSE, NET

12 Months Ended

Dec. 31, 2025

Other Income and Expenses [Abstract]

OTHER (INCOME) EXPENSE, NET

Other (income) expense, net, were as follows:


	Year Ended December 31,
(in millions)	2025		2024		2023

Foreign exchange transaction (gain)	$	(32)	$	(21)	$	(3)
Other expense, net	8		9		12
Total other (income) expense, net	$	(24)	$	(12)	$	9

The Company’s equity-method net losses for the years ended December 31, 2025 and 2024 were not significant. The Company’s equity-method net loss for the year ended December 31, 2023 was $4 million.

GOODWILL AND INTANGIBLE ASSETS - ADDITIONAL INFORMATION (Details)	3 Months Ended								12 Months Ended
	Dec. 31, 2025 USD ($)	Sep. 30, 2025 USD ($)	Jun. 30, 2025 USD ($)	Dec. 31, 2024 USD ($)	Sep. 30, 2024 USD ($) reporting_unit	Mar. 31, 2024 USD ($)	Sep. 30, 2023 USD ($)	Jun. 30, 2021 USD ($)	Dec. 31, 2025 USD ($)	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)
Goodwill [Line Items]
Impairment									$ (525,000,000)	$ (773,000,000)	$ (291,000,000)
Intangible asset impairment			$ 79,000,000						125,000,000	241,000,000	16,000,000
Other intangible assets from the Byte business	$ 3,263,000,000			$ 3,103,000,000					3,263,000,000	3,103,000,000
Goodwill	1,148,000,000			1,597,000,000					1,148,000,000	1,597,000,000
Total indefinite-lived	256,000,000			337,000,000					256,000,000	337,000,000
Number of reporting units \| reporting_unit					2
Amortization of intangible assets									211,000,000	216,000,000	$ 211,000,000
2026	143,000,000								143,000,000
2027	121,000,000								121,000,000
2028	126,000,000								126,000,000
2029	127,000,000								127,000,000
2030	125,000,000								125,000,000
Identifiable intangible assets, net	974,000,000			1,207,000,000					974,000,000	1,207,000,000
Intangible assets	718,000,000			870,000,000					718,000,000	870,000,000
Developed technology
Goodwill [Line Items]
Payments to acquire intangible assets				7,000,000				$ 3,000,000
Asset acquisition, contingent consideration, liability	0			10,000,000					0	10,000,000
Identifiable intangible assets, net	3,800,000								3,800,000
Intangible assets	$ 449,000,000			560,000,000					449,000,000	560,000,000
Licensing agreements
Goodwill [Line Items]
Intangible asset recognized									$ 13,500,000
Intangible asset, useful life (in years)	15 years								15 years
Intangible assets	$ 13,000,000			1,000,000					$ 13,000,000	1,000,000
Byte Aligner Systems \| Selling General And Administrative Expenses, Intangible Asset Impairment , Trade Name
Goodwill [Line Items]
Charges related to the Byte Realignment				(152,000,000)
Maximum \| Developed technology
Goodwill [Line Items]
Intangible asset, useful life (in years)	15 years								15 years
Maximum \| Licensing agreements
Goodwill [Line Items]
Intangible asset, useful life (in years)	20 years								20 years
Connected Technology Solutions
Goodwill [Line Items]
Impairment							$ (291,000,000)		$ 0
Intangible asset impairment	$ 22,000,000	$ 4,000,000	64,000,000	82,000,000			14,000,000
Goodwill	0			0					0	0
Connected Technology Solutions \| Trade Names
Goodwill [Line Items]
Intangible asset impairment						$ 6,000,000
Orthodontic and Implant Solutions
Goodwill [Line Items]
Impairment									(525,000,000)
Intangible asset impairment	15,000,000	5,000,000		1,000,000			$ 2,000,000
Goodwill	0			503,000,000					$ 0	$ 503,000,000
Implants & Prosthetics Reporting Unit
Goodwill [Line Items]
Impairment	$ (116,000,000)	$ (253,000,000)	(156,000,000)	$ (269,000,000)	$ (359,000,000)
Intangible asset impairment			$ 15,000,000
Orthodontic Aligner Solutions Reporting Unit
Goodwill [Line Items]
Impairment					$ (145,000,000)

BENEFIT PLANS - SCHEDULE OF WEIGHTED AVERAGE ASSUMPTIONS USED TO DETERMINE NET PERIODIC BENEFIT COST TREND RATES (Details)	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Retirement Benefits [Abstract]
Interest crediting rate	2.00%	2.30%	2.50%
Discount rate	2.50%	2.60%	3.20%
Expected return on plan assets	2.80%	2.90%	3.20%
Rate of compensation increase	2.40%	2.50%	2.60%

OTHER (INCOME) EXPENSE, NET (Tables)

12 Months Ended

Dec. 31, 2025

Other Income and Expenses [Abstract]

Schedule of Other (Income) Expense, Net

Other (income) expense, net, were as follows:


	Year Ended December 31,
(in millions)	2025		2024		2023

Foreign exchange transaction (gain)	$	(32)	$	(21)	$	(3)
Other expense, net	8		9		12
Total other (income) expense, net	$	(24)	$	(12)	$	9

RESTRUCTURING AND OTHER COSTS - SCHEDULE OF PROVISIONS AND ADJUSTMENTS AND AMOUNTS APPLIED FOR ALL PLANS BY SEGMENT (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Restructuring Reserve
Beginning balance	$ 33	$ 40
Provisions and adjustments	25	57
Amounts applied	(40)	(60)
Change in estimates	(6)	(4)
Ending balance	12	33
Operating Segments \| Connected Technology Solutions
Restructuring Reserve
Beginning balance	9	13
Provisions and adjustments	6	23
Amounts applied	(10)	(25)
Change in estimates	(4)	(2)
Ending balance	1	9
Operating Segments \| Essential Dental Solutions
Restructuring Reserve
Beginning balance	11	17
Provisions and adjustments	3	15
Amounts applied	(9)	(20)
Change in estimates	(1)	(1)
Ending balance	4	11
Operating Segments \| Orthodontic and Implant Solutions
Restructuring Reserve
Beginning balance	9	9
Provisions and adjustments	7	11
Amounts applied	(12)	(11)
Change in estimates	(1)	0
Ending balance	3	9
Operating Segments \| Wellspect Healthcare
Restructuring Reserve
Beginning balance	3	1
Provisions and adjustments	1	5
Amounts applied	(2)	(2)
Change in estimates	0	(1)
Ending balance	2	3
All Other
Restructuring Reserve
Beginning balance	1	0
Provisions and adjustments	8	3
Amounts applied	(7)	(2)
Change in estimates	0	0
Ending balance	$ 2	$ 1

COMPREHENSIVE LOSS - RECLASSIFICATION OUT OF ACCUMULATED OTHER COMPREHENSIVE INCOME (EXPENSE) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Interest expense, net	$ (88)	$ (69)	$ (81)
Cost of products sold	(1,840)	(1,835)	(1,879)
Loss before income taxes	(486)	(936)	(175)
Provision (benefit) for income taxes	(112)	26	43
Net loss	(598)	(910)	(132)
Reclassification out of Accumulated Other Comprehensive Income
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Net loss	(3)	(2)	(3)
Reclassification out of Accumulated Other Comprehensive Income \| (Loss) Gain on Cash Flow Hedges
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Interest expense, net	(3)	(3)	(3)
Cost of products sold	0	0	(1)
Loss before income taxes	(3)	(3)	(4)
Provision (benefit) for income taxes	0	0	0
Net loss	(3)	(3)	(4)
Reclassification out of Accumulated Other Comprehensive Income \| Pension Liability (Loss) Gain
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Loss before income taxes	0	1	1
Provision (benefit) for income taxes	0	0	0
Net loss	0	1	1
Reclassification out of Accumulated Other Comprehensive Income \| Amortization of prior service benefits
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Loss before income taxes	1	1	1
Reclassification out of Accumulated Other Comprehensive Income \| Amortization of net actuarial losses
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Loss before income taxes	$ (1)	$ 0	$ 0

BENEFIT PLANS - SCHEDULE OF PENSION BENEFITS AND OTHER POSTRETIREMENT BENEFITS RECOGNIZED IN THE ACCOMPANYING CONSOLIDATED BALANCE SHEETS (Details) - USD ($) $ in Millions	Dec. 31, 2025	Dec. 31, 2024
Retirement Benefits [Abstract]
Other noncurrent assets	$ 17	$ 4
Deferred tax asset	6	8
Total assets	23	12
Current liabilities	(13)	(10)
Other noncurrent liabilities	(288)	(264)
Deferred tax liability	(8)	(4)
Total liabilities	(309)	(278)
Accumulated other comprehensive income	5	23
Net amount recognized	$ (281)	$ (243)

RESTRUCTURING AND OTHER COSTS - SCHEDULE OF RESTRUCTURING ACCRUALS (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Restructuring Reserve
Beginning balance	$ 33	$ 40
Provisions and adjustments	25	57
Amounts applied	(40)	(60)
Change in estimates	(6)	(4)
Ending balance	12	33
Severance
Restructuring Reserve
Beginning balance	32	39
Provisions and adjustments	21	54
Amounts applied	(37)	(57)
Change in estimates	(6)	(4)
Ending balance	10	32
Severance \| 2023 and Prior Plans
Restructuring Reserve
Beginning balance	13
Provisions and adjustments	1
Amounts applied	(11)
Change in estimates	(2)
Ending balance	1	13
Severance \| 2024 Plans
Restructuring Reserve
Beginning balance	19	0
Provisions and adjustments	4	30
Amounts applied	(19)	(11)
Change in estimates	(2)	0
Ending balance	2	19
Severance \| Other Actions
Restructuring Reserve
Beginning balance	0
Provisions and adjustments	16
Amounts applied	(7)
Change in estimates	(2)
Ending balance	7	0
Severance \| 2022 and Prior Plans
Restructuring Reserve
Beginning balance	1	2
Provisions and adjustments		1
Amounts applied		(2)
Change in estimates		0
Ending balance		1
Severance \| 2023 Plans
Restructuring Reserve
Beginning balance	12	37
Provisions and adjustments		23
Amounts applied		(44)
Change in estimates		(4)
Ending balance		12
Other Restructuring Costs
Restructuring Reserve
Beginning balance	1	1
Provisions and adjustments	4	3
Amounts applied	(3)	(3)
Change in estimates		0
Ending balance	2	1
Other Restructuring Costs \| 2023 and Prior Plans
Restructuring Reserve
Beginning balance	1
Provisions and adjustments	1
Amounts applied	(2)
Ending balance	0	1
Other Restructuring Costs \| 2024 Plans
Restructuring Reserve
Beginning balance	0	0
Provisions and adjustments	1	0
Amounts applied	(1)	0
Change in estimates		0
Ending balance	0	0
Other Restructuring Costs \| Other Actions
Restructuring Reserve
Beginning balance	0
Provisions and adjustments	2
Amounts applied	0
Ending balance	2	0
Other Restructuring Costs \| 2022 and Prior Plans
Restructuring Reserve
Beginning balance	1	1
Provisions and adjustments		0
Amounts applied		0
Change in estimates		0
Ending balance		1
Other Restructuring Costs \| 2023 Plans
Restructuring Reserve
Beginning balance	$ 0	0
Provisions and adjustments		3
Amounts applied		(3)
Change in estimates		0
Ending balance		$ 0

FINANCIAL INSTRUMENTS AND DERIVATIVES - SCHEDULE OF CONSOLIDATED BALANCE SHEETS LOCATION OF DERIVATIVE FAIR VALUES (Details) - USD ($) $ in Millions	Dec. 31, 2025	Dec. 31, 2024
Derivative [Line Items]
Gross asset amount recognized for derivative instruments designated as hedges	$ 50	$ 36
Gross liability amount recognized for derivative instruments designated as hedges	$ 154	$ 30
Derivative Asset, Statement of Financial Position [Extensible Enumeration]	Other noncurrent assets, Prepaid expenses and other current assets	Other noncurrent assets, Prepaid expenses and other current assets
Derivative Liability, Statement of Financial Position [Extensible Enumeration]	Accrued Liabilities, Current, Other Liabilities, Noncurrent	Accrued Liabilities, Current, Other Liabilities, Noncurrent
Interest rate swaps
Derivative [Line Items]
Gross liability amount recognized for derivative instruments designated as hedges	$ 14	$ 21
Cross currency basis swaps
Derivative [Line Items]
Gross asset amount recognized for derivative instruments designated as hedges	42	18
Gross liability amount recognized for derivative instruments designated as hedges	73
Prepaid Expenses and Other Current Assets
Derivative [Line Items]
Gross asset amount recognized for derivative instruments designated as hedges	42	9
Gross asset amount recognized for derivative instruments not designated as hedges	8	4
Prepaid Expenses and Other Current Assets \| Foreign exchange forward contracts \| Designated as Hedging Instrument
Derivative [Line Items]
Gross asset amount recognized for derivative instruments designated as hedges	0	5
Prepaid Expenses and Other Current Assets \| Foreign exchange forward contracts \| Not Designated as Hedging Instrument
Derivative [Line Items]
Gross asset amount recognized for derivative instruments not designated as hedges	8	4
Prepaid Expenses and Other Current Assets \| Interest rate swaps \| Designated as Hedging Instrument
Derivative [Line Items]
Gross asset amount recognized for derivative instruments designated as hedges	0	0
Prepaid Expenses and Other Current Assets \| Cross currency basis swaps \| Designated as Hedging Instrument
Derivative [Line Items]
Gross asset amount recognized for derivative instruments designated as hedges	42	4
Other Noncurrent Assets
Derivative [Line Items]
Gross asset amount recognized for derivative instruments designated as hedges	0	23
Gross asset amount recognized for derivative instruments not designated as hedges	0	0
Other Noncurrent Assets \| Foreign exchange forward contracts \| Designated as Hedging Instrument
Derivative [Line Items]
Gross asset amount recognized for derivative instruments designated as hedges	0	9
Other Noncurrent Assets \| Foreign exchange forward contracts \| Not Designated as Hedging Instrument
Derivative [Line Items]
Gross asset amount recognized for derivative instruments not designated as hedges	0	0
Other Noncurrent Assets \| Interest rate swaps \| Designated as Hedging Instrument
Derivative [Line Items]
Gross asset amount recognized for derivative instruments designated as hedges	0	0
Other Noncurrent Assets \| Cross currency basis swaps \| Designated as Hedging Instrument
Derivative [Line Items]
Gross asset amount recognized for derivative instruments designated as hedges	0	14
Accrued Liabilities
Derivative [Line Items]
Gross liability amount recognized for derivative instruments designated as hedges	24	4
Gross liability amount recognized for derivative instruments not designated as hedges	6	8
Accrued Liabilities \| Foreign exchange forward contracts \| Designated as Hedging Instrument
Derivative [Line Items]
Gross liability amount recognized for derivative instruments designated as hedges	21	0
Accrued Liabilities \| Foreign exchange forward contracts \| Not Designated as Hedging Instrument
Derivative [Line Items]
Gross liability amount recognized for derivative instruments not designated as hedges	6	8
Accrued Liabilities \| Interest rate swaps \| Designated as Hedging Instrument
Derivative [Line Items]
Gross liability amount recognized for derivative instruments designated as hedges	3	4
Accrued Liabilities \| Cross currency basis swaps \| Designated as Hedging Instrument
Derivative [Line Items]
Gross liability amount recognized for derivative instruments designated as hedges	0	0
Other Noncurrent Liabilities
Derivative [Line Items]
Gross liability amount recognized for derivative instruments designated as hedges	124	18
Gross liability amount recognized for derivative instruments not designated as hedges	0	0
Other Noncurrent Liabilities \| Foreign exchange forward contracts \| Designated as Hedging Instrument
Derivative [Line Items]
Gross liability amount recognized for derivative instruments designated as hedges	40	1
Other Noncurrent Liabilities \| Foreign exchange forward contracts \| Not Designated as Hedging Instrument
Derivative [Line Items]
Gross liability amount recognized for derivative instruments not designated as hedges	0	0
Other Noncurrent Liabilities \| Interest rate swaps \| Designated as Hedging Instrument
Derivative [Line Items]
Gross liability amount recognized for derivative instruments designated as hedges	11	17
Other Noncurrent Liabilities \| Cross currency basis swaps \| Designated as Hedging Instrument
Derivative [Line Items]
Gross liability amount recognized for derivative instruments designated as hedges	$ 73	$ 0

LEASES

12 Months Ended

Dec. 31, 2025

Leases [Abstract]

LEASES

The net present value of finance and operating lease right-of-use assets and liabilities was as follows:


		Year Ended December 31,
(in millions, except percentages)	Location in the Consolidated Balance Sheets	2025			2024

Assets
Finance leases	Property, plant, and equipment, net	$	—		$	—
Operating leases	Operating lease right-of-use assets, net	139			136
Total right-of-use assets		$	139		$	136

Liabilities
Current liabilities

Operating leases	Accrued liabilities	47			46
Noncurrent liabilities
Finance leases	Long-term debt	—			—
Operating leases	Operating lease liabilities	93			91
Total lease liabilities		$	140		$	137

Supplemental information:
Weighted-average discount rate

Operating leases		4.6		%	4.1		%

Weighted-average remaining lease term in years

Operating leases		4.0			4.1

The lease costs recognized in the Consolidated Statements of Operations were as follows:


	Year Ended December 31,
(in millions)	2025		2024




Operating lease cost	$	65	$	67

Variable lease cost	17		16
Total lease cost	$	82	$	83

The contractual maturity dates of the remaining lease liabilities as of December 31, 2025 were as follows:


(in millions)	Operating Leases

2026	$	52
2027	38
2028	26
2029	17
2030	9
2031 and beyond	12
Total lease payments	$	154
Less imputed interest	14
Present value of lease liabilities	$	140

The supplemental cash flow information for leases was as follows:


	Year Ended December 31,
(in millions)	2025		2024		2023

Cash paid for amounts included in the measurement of lease liabilities:

Operating cash flows paid for operating leases	$	62	$	67	$	68


Right-of-use assets obtained in exchange for new lease liabilities (non-cash investing activity):

Operating leases	51		19		36

LEASES

The net present value of finance and operating lease right-of-use assets and liabilities was as follows:


		Year Ended December 31,
(in millions, except percentages)	Location in the Consolidated Balance Sheets	2025			2024

Assets
Finance leases	Property, plant, and equipment, net	$	—		$	—
Operating leases	Operating lease right-of-use assets, net	139			136
Total right-of-use assets		$	139		$	136

Liabilities
Current liabilities

Operating leases	Accrued liabilities	47			46
Noncurrent liabilities
Finance leases	Long-term debt	—			—
Operating leases	Operating lease liabilities	93			91
Total lease liabilities		$	140		$	137

Supplemental information:
Weighted-average discount rate

Operating leases		4.6		%	4.1		%

Weighted-average remaining lease term in years

Operating leases		4.0			4.1

The lease costs recognized in the Consolidated Statements of Operations were as follows:


	Year Ended December 31,
(in millions)	2025		2024




Operating lease cost	$	65	$	67

Variable lease cost	17		16
Total lease cost	$	82	$	83

The contractual maturity dates of the remaining lease liabilities as of December 31, 2025 were as follows:


(in millions)	Operating Leases

2026	$	52
2027	38
2028	26
2029	17
2030	9
2031 and beyond	12
Total lease payments	$	154
Less imputed interest	14
Present value of lease liabilities	$	140

The supplemental cash flow information for leases was as follows:


	Year Ended December 31,
(in millions)	2025		2024		2023

Cash paid for amounts included in the measurement of lease liabilities:

Operating cash flows paid for operating leases	$	62	$	67	$	68


Right-of-use assets obtained in exchange for new lease liabilities (non-cash investing activity):

Operating leases	51		19		36

EQUITY

12 Months Ended

Dec. 31, 2025

Equity [Abstract]

EQUITY

On November 7, 2023, the Board of Directors approved an increase to the authorized share repurchase program of $1.0 billion. Share repurchases may be made through open market purchases, Rule 10b5-1 plans, accelerated share repurchases, privately negotiated transactions or other transactions in such amounts and at such times as the Company considers appropriate based upon prevailing market and business conditions and other factors. At December 31, 2025, the Company had authorization to repurchase $1.2 billion in shares of common stock remaining under the share repurchase program.

On March 3, 2023, the Company entered into an Accelerated Share Repurchase Agreement (“ASR Agreement”) with a financial institution to repurchase the Company’s common stock. The Company repurchased shares under the ASR Agreement as part of the share repurchase program described above. In 2023, the Company repurchased approximately 3.1 million shares, which were delivered during March 2023, at a volume-weighted average price of $38.74, representing $120 million of the total anticipated repurchase size. In April 2023, an additional 0.8 million shares were delivered upon the final settlement of the ASR Agreement, resulting in a total of 3.9 million shares repurchased under the agreement.


(in millions, except per share amounts)			Initial Delivery					Final Settlement
Agreement Date	Amount Paid		Shares Received	Price per share		Value of Shares as a % of Contract Value		Settlement Date	Total Shares Received	Average Price per Share
March 3, 2023	$	150	3.1	$	38.74	80	%	April 28, 2023	3.9	$	38.55

The ASR Agreement was accounted for as an initial delivery of common shares in a treasury stock transaction on March 6, 2023 of $121 million and a forward contract indexed to the Company’s common stock for an amount of common shares that was determined on the final settlement date. The forward contract met all applicable criteria for equity classification and was not accounted for as a derivative instrument for the quarter ended March 31, 2023. Therefore, the value of the forward contract of $30 million was recorded in Capital in excess of par value at March 31, 2023. Upon final settlement in April 2023, this amount was subsequently recorded as Treasury Stock in the Consolidated Balance Sheets. The initial delivery and final settlement of common stock reduced the weighted average common shares outstanding for both basic and diluted earnings per share. The forward contract did not impact the weighted average common shares outstanding for diluted earnings per share.

For the year ended December 31, 2025 the Company had no repurchases of shares of common stock. For the years ended December 31, 2024 and 2023, the Company repurchased outstanding shares of common stock at a cost of $250 million and $300 million, respectively.

For the years ended December 31, 2025, 2024, and 2023, stock options exercised and the proceeds received at exercise were not significant. It is the Company’s practice to issue shares from treasury stock when stock options are exercised and RSUs vest. For the year ended December 31, 2024, the treasury stock transactions resulted in an excise tax of $2 million for public company stock repurchases established by the Inflation Reduction Act of 2022.

Total outstanding shares of common stock and treasury stock were as follows:


(in millions)	Shares of Common Stock	Shares of Treasury Stock	Outstanding Shares

Balance at December 31, 2022	264.5	(49.3)	215.2

Shares of treasury stock issued	—	0.8	0.8
Repurchase of common stock at an average cost of $34.20	—	(8.8)	(8.8)

Balance at December 31, 2023	264.5	(57.3)	207.2

Shares of treasury stock issued	—	1.0	1.0
Repurchase of common stock at an average cost of $26.65	—	(9.4)	(9.4)

Balance at December 31, 2024	264.5	(65.7)	198.8
Shares of treasury stock issued	—	0.8	0.8


Balance at December 31, 2025	264.5	(64.9)	199.6

- Definition

The entire disclosure for equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478448/946-505-50-6

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480237/815-40-50-6

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/505/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 16
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-16

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

+ Details

BENEFIT PLANS

12 Months Ended

Dec. 31, 2025

Retirement Benefits [Abstract]

BENEFIT PLANS

Defined Contribution Plans

The Company maintains both U.S. and non-U.S. employee defined contribution plans. The primary U.S. plan, the Dentsply Sirona Inc. 401(k) Savings Plan (the “Plan”), allows eligible employees to contribute a portion of their cash compensation to the Plan on a tax-deferred basis, and the Company provides a matching contribution. The Plan includes various investment funds. Each eligible participant who elects to contribute to the Plan will receive a matching contribution of 100% on the first 4% contributed and 50% on the next 2% contributed for a total maximum matching contribution of 5%. At its discretion, the Company may make additional non-elective cash contributions based on a percentage of compensation to participant accounts. The Company did not make any additional non-elective cash contributions in connection with 2025 compensation. In addition to the Plan, the Company also maintains various other U.S. and non-U.S. defined contribution and non-qualified deferred compensation plans. The annual expenses, net of forfeitures, of these plans were $38 million, $34 million and $43 million for the years ended December 31, 2025, 2024, and 2023, respectively.

Defined Benefit Plans

The Company maintains defined benefit pension plans for certain employees in Austria, France, Germany, Indonesia, Italy, Japan, the Netherlands, Norway, Sweden, Switzerland, Taiwan, and the United States. These plans provide benefits based upon age, years of service and remuneration. Substantially all the German and Swedish plans are unfunded book reserve plans. Most employees and retirees outside the United States are covered by government health plans.

The Company predominantly derives its discount rates by applying the specific spot rates along the yield curve to the relevant projected cash flows; or, in markets where there is an absence of a sufficiently deep corporate bond market, it uses liability durations in establishing its discount rates, which are observed from indices of high-grade corporate or government bond yield in the respective economic regions of a given plan. For the large defined benefits pension plans, the Company uses a spot rate approach for the estimation of the Service cost and Interest cost components of benefit cost by applying the specific spot rates along the yield curve to the relevant projected cash flows.

Significant changes in the retirement plan benefit obligations for the year ended December 31, 2025 include a $34 million actuarial gain primarily attributable to the increase in discount rates in most of the countries with defined benefit pension plans. The changes also include a $13 million actuarial loss due to plan experience being different than anticipated.

Significant changes in the retirement plan benefit obligations for the year ended December 31, 2024 include a $9 million actuarial gain primarily attributable to the increase in discount rates for large defined benefit pension plans in Germany and Sweden, the effect of which is slightly offset by a $1 million loss due to a change in the lump sum withdrawal rate for the Swiss plan. The changes also include a $4 million actuarial loss due to plan experience being different than anticipated.

Defined Benefit Pension Plan Assets

The primary investment strategy is to ensure that the assets of the plans, along with anticipated future contributions, will be invested in order that the benefit entitlements of employees, pensioners and beneficiaries covered under the plan can be met when due with high probability. Pension plan assets consist mainly of common stock and fixed income investments. The target allocations for defined benefit plan assets are 30% to 65% equity securities, 30% to 65% fixed income securities, 0% to 15% real estate, and 0% to 25% in all other types of investments. Equity securities include investments in companies located both in and outside the United States. Equity securities in the defined benefit pension plans do not include Company common stock contributed directly by the Company. Fixed income securities include corporate bonds of companies from diversified industries, government bonds, mortgage notes and pledge letters. Other types of investments include investments in mutual funds, insurance contracts, hedge funds and real estate. These plan assets are not recorded in the Company’s Consolidated Balance Sheet as they are held in trust or other off-balance sheet investment vehicles.

The defined benefit pension plan assets maintained in Austria, Germany, Norway, the Netherlands, Switzerland and Taiwan all have separate investment policies but generally have an objective to achieve a long-term rate of return in excess of 2% while at the same time mitigating the impact of investment risk associated with investment categories that are expected to yield greater than average returns. In accordance with the investment policies, the plans’ assets were invested in the following investment categories: interest-bearing cash, U.S. and foreign equities, foreign fixed income securities (primarily corporate and government bonds), insurance company contracts, real estate and hedge funds.

Reconciliation of changes in the defined benefit obligations, fair value of assets and statement of funded status were as follows:




	Year Ended December 31,
(in millions)	2025		2024

Change in Benefit Obligation
Benefit obligation at beginning of year	$	478	$	511
Service cost	11		11
Interest cost	12		12
Participant contributions	5		5
Actuarial (gains) losses	(21)		(4)


Effect of exchange rate changes	70		(36)

Plan curtailments and settlements	(13)		—
Benefits paid	(12)		(21)
Benefit obligation at end of year	$	530	$	478

Change in Plan Assets
Fair value of plan assets at beginning of year	$	208	$	207
Actual return on assets	10		16
Plan settlements	(13)		—

Effect of exchange rate changes	30		(15)
Employer contributions	18		16
Participant contributions	5		5
Benefits paid	(12)		(21)
Fair value of plan assets at end of year	$	246	$	208

Funded status at end of year	$	(284)	$	(270)

The amounts recognized in the accompanying Consolidated Balance Sheets, net of tax effects, were as follows:


	Location In The	Year Ended December 31,
(in millions)	Consolidated Balance Sheets	2025		2024

Other noncurrent assets	Other noncurrent assets	$	17	$	4
Deferred tax asset	Other noncurrent assets	6		8
Total assets		$	23	$	12

Current liabilities	Accrued liabilities	$	(13)	$	(10)
Other noncurrent liabilities	Other noncurrent liabilities	(288)		(264)
Deferred tax liability	Deferred income taxes	(8)		(4)
Total liabilities		$	(309)	$	(278)

Accumulated other comprehensive income	Accumulated other comprehensive loss	5		23
Net amount recognized		$	(281)	$	(243)

Amounts recognized in AOCI were as follows:



	Year Ended December 31,
(in millions)	2025		2024

Net actuarial loss	$	5	$	30
Net prior service cost	(2)		(3)
Before tax AOCI	$	3	$	27
Less: Deferred taxes (benefit)	(2)		4
Net of tax AOCI	$	5	$	23

Information for pension plans with a projected or accumulated benefit obligation in excess of plan assets was as follows:


	Year Ended December 31,
(in millions)	2025		2024

Projected benefit obligation	$	300	$	274
Accumulated benefit obligation	290		263

Components of net periodic benefit cost were as follows:


	Year Ended December 31,						Location in the Consolidated Statements of Operations
(in millions)	2025		2024		2023

Service cost	$	4	$	4	$	4	Cost of products sold
Service cost	7		7		6		Selling, general and administrative expenses
Interest cost	12		12		14		Other (income) expense, net
Expected return on plan assets	(6)		(5)		(6)		Other (income) expense, net

Amortization of prior service credit	(1)		(1)		(1)		Other (income) expense, net
Amortization of net actuarial loss	1		2		—		Other (income) expense, net

Curtailment and settlement gains	2		—		—		Other (income) expense, net

Net periodic benefit cost	$	19	$	19	$	17

Other changes in plan assets and benefit obligations recognized in AOCI were as follows:


	Year Ended December 31,
(in millions)	2025		2024		2023

Net actuarial (gains) losses	$	(24)	$	(17)	$	37


Amortization	—		(1)		1
Total recognized in AOCI	$	(24)	$	(18)	$	38
Total recognized in net periodic benefit cost and AOCI	$	(5)	$	1	$	55

Assumptions

The weighted average assumptions used to determine benefit obligations for the Company’s plans, principally in foreign locations, were as follows:


	Year Ended December 31,
	2025		2024		2023

Interest crediting rate	2.0	%	2.0	%	2.3	%
Discount rate	3.0	%	2.5	%	2.6	%
Rate of compensation increase	2.4	%	2.4	%	2.5	%

The weighted average assumptions used to determine net periodic benefit cost for the Company’s plans, principally in foreign locations, were as follows:


	Year Ended December 31,
	2025		2024		2023

Interest crediting rate	2.0	%	2.3	%	2.5	%
Discount rate	2.5	%	2.6	%	3.2	%
Expected return on plan assets	2.8	%	2.9	%	3.2	%
Rate of compensation increase	2.4	%	2.5	%	2.6	%
Measurement date	12/31/2025		12/31/2024		12/31/2023

To develop the assumptions for the expected long-term rate of return on assets, the Company considered the current level of expected returns on risk free investments (primarily U.S. government bonds), the historical level of the risk premium associated with the other asset classes in which the assets are invested and the expectations for future returns of each asset class. The expected return for each asset class was then weighted based on the target asset allocations to develop the assumptions for the expected long-term rate of return on assets.

Fair Value Measurements of Plan Assets


	December 31, 2025
(in millions)	Total		Level 1		Level 2		Level 3

Assets Category
Cash and cash equivalents	$	5	$	5	$	—	$	—
Equity securities:

International	79		79		—		—
Fixed income securities:
Fixed rate bonds (a)	90		90		—		—
Other types of investments:
Mutual funds (b)	31		31		—		—


Insurance contracts	26		—		—		26
Hedge funds	14		—		—		14
Real estate	1		—		—		1
Total	$	246	$	205	$	—	$	41


	December 31, 2024
(in millions)	Total		Level 1		Level 2		Level 3

Assets Category
Cash and cash equivalents	$	6	$	6	$	—	$	—
Equity securities:

International	67		67		—		—
Fixed income securities:
Fixed rate bonds (a)	79		79		—		—
Other types of investments:
Mutual funds (b)	21		21		—		—


Insurance contracts	24		—		—		24
Hedge funds	10		—		—		10
Real estate	1		—		—		1
Total	$	208	$	173	$	—	$	35

(a) This category includes fixed income securities invested primarily in Swiss bonds, foreign bonds denominated in Swiss francs, foreign currency bonds, mortgage notes and pledged letters.

A reconciliation from December 31, 2023 to December 31, 2025 for the plan assets categorized as Level 3 was as follows:


(in millions)	Insurance Contracts		Hedge Funds		Real Estate		Total

Balance at December 31, 2023	$	26	$	7	$	1	$	34
Actual return on plan assets:
Relating to assets still held at the reporting date	1		1		—		2


Purchases, sales and settlements, net	(1)		3		—		2

Effect of exchange rate changes	(2)		(1)		—		(3)
Balance at December 31, 2024	$	24	$	10	$	1	$	35
Actual return on plan assets:
Relating to assets still held at the reporting date	$	—	$	1	$	—	$	1


Purchases, sales and settlements, net	(1)		1		—		—

Effect of exchange rate changes	3		2		—		5
Balance at December 31, 2025	$	26	$	14	$	1	$	41

Fair values for Level 3 assets are determined as follows:

Insurance Contracts: The value of the asset represents the mathematical reserve of the insurance policies and is calculated by the insurance firms using their own assumptions.

Hedge Funds: The investments are valued using the net asset value provided by the administrator of the fund, which is based on the fair value of the underlying securities.

Real Estate: Investment is stated by its appraised value.

Cash Flows

In 2026, the Company expects to make employer contributions of $21 million to its defined benefit pension plans.

Estimated Future Benefit Payments

Total benefits expected to be paid from the plans in the future are as follows:


(in millions)	Pension Benefits

2026	$	31
2027	31
2028	30
2029	30
2030	30
2031-2035	145

FINANCING ARRANGEMENTS (Tables)

12 Months Ended

Dec. 31, 2025

Debt Disclosure [Abstract]

Schedule of Short-Term Debt

Notes payable and current portion of long-term debt was as follows:


	Year Ended December 31,
	2025				2024
	Principal		Interest		Principal		Interest
(in millions except percentages)	Balance		Rate		Balance		Rate


Corporate commercial paper facility	$	82	4.4	%	$	410	5.3	%
Other short-term borrowings	3		4.5	%	11		4.9	%
Add: Current portion of long-term debt	228				128

Total notes payable and current portion of long-term debt	$	313			$	549


Average amount of short-term debt outstanding during the year	136				344
Weighted-average interest rate on short-term debt at year-end			4.4	%			5.3	%

Schedule of Long-term Debt

Long-term debt was as follows:


	Year Ended December 31,
	2025			2024
	Principal			Principal		Due
(Principal balances in millions)	Balance		Balance



0.9% Private placement notes 25 million Swiss franc	—			28		December 2025
2.1% Private placement notes 97 million euros	—			100		December 2025
2.1% Private placement notes 26 million euros	31			27		February 2026
1.0% Private placement notes 58 million Swiss franc	73			64		August 2026
2.3% Private placement notes 106 million euros	125			110		August 2026
1.3% Private placement notes 70 million euros	82			72		October 2027
1.0% Private placement notes 8 million Swiss franc	9			8		December 2027
2.2% Private placement notes 15 million euros	18			16		December 2027
1.2% Private placement notes 140 million Swiss franc	177			154		August 2028
1.5% Private placement notes 70 million euros	82			72		October 2029
3.3% Fixed rate senior notes 750 million	749			750		June 2030
1.6% Private placement notes 70 million euros	82			72		October 2030
2.5% Private placement notes 45 million euros	53			47		February 2031
1.3% Private placement notes 65 million Swiss franc	82			72		August 2031
1.0% Private placement notes 12.6 billion Japanese yen	80			80		September 2031
1.7% Private placement notes 70 million euros	82			72		October 2031
8.4% Private placement notes 550 million U.S. dollars	550			—		September 2055
Other borrowings, various currencies and rates	1			4
Hedge accounting fair value adjustment(a)	(19)			(28)
	$	2,257		$	1,720
Less: Current portion
(included in “Notes payable and current portion of long-term debt” in the Consolidated Balance Sheets)	228			128
Less: Long-term portion of deferred financing costs	14			6
Long-term portion	$	2,015		$	1,586

(a) Represents the fair value of interest rate swap agreements entered into on a portion of the outstanding senior notes.

Schedule of Contractual Maturity Dates of Long-term Debt

The contractual maturity dates of the Company’s long-term borrowings as of December 31, 2025 were as follows:


(in millions)
2026	$	228
2027	110
2028	177
2029	82
2030	832
2031 and beyond	847
	$	2,276

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-SubTopic 10
-Topic 210
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69E
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482925/835-30-45-2

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-3

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477734/942-470-50-3

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-8

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-6

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-7

+ Details

STOCK COMPENSATION - STOCK COMPENSATION EXPENSE RECORDED IN CONSOLIDATED STATEMENTS OF OPERATIONS (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 32	$ 39	$ 46
Related deferred income tax benefit	5	7	8
Cost of products sold
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	2	3	4
Selling, general, and administrative expense
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	28	35	36
Research and development expense
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	2	2	4
Restructuring and other costs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 0	$ (1)	$ 2

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

+ Details

REVENUE RECOGNITION - NET SALES DISAGGREGATED BY GEOGRAPHIC AREAS (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Disaggregation of Revenue [Line Items]
Net sales	$ 3,680	$ 3,793	$ 3,965
United States
Disaggregation of Revenue [Line Items]
Net sales	1,182	1,348	1,437
Europe
Disaggregation of Revenue [Line Items]
Net sales	1,576	1,518	1,550
Rest of World
Disaggregation of Revenue [Line Items]
Net sales	$ 922	$ 927	$ 978

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-7

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 91
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 91
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 91
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 91
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 91
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 91
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 91
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91

+ Details

- Definition

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-4

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-7

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 924
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-4

+ Details

STOCK COMPENSATION - UNVESTED RSU TRANSACTIONS (Details) - Restricted Stock Units (RSUs) - $ / shares shares in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2023
Shares
Beginning balance, unvested (in shares)	3.9
Granted (in shares)	4.5
Vested (in shares)	(0.7)
Forfeited (in shares)	(2.3)
Ending balance, unvested (in shares)	5.4
Weighted Average Grant Date Fair Value
Beginning balance, unvested (in dollars per share)	$ 37.11
Granted (in dollars per share)	15.64	$ 42.95
Vested (in dollars per share)	35.49
Forfeited (in dollars per share)	23.50
Ending balance, unvested (in dollars per share)	$ 19.95

BENEFIT PLANS - SCHEDULE OF RECONCILIATION FOR THE PLAN ASSETS CATEGORIZED AS LEVEL 3 (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Change in Plan Assets. Level 3 [Roll Forward]
Fair value of plan assets at beginning of year	$ 208	$ 207
Actual return on plan assets:
Effect of exchange rate changes	30	(15)
Fair value of plan assets at end of year	246	208
Insurance contracts
Change in Plan Assets. Level 3 [Roll Forward]
Fair value of plan assets at beginning of year	24
Actual return on plan assets:
Fair value of plan assets at end of year	26	24
Hedge funds
Change in Plan Assets. Level 3 [Roll Forward]
Fair value of plan assets at beginning of year	10
Actual return on plan assets:
Fair value of plan assets at end of year	14	10
Real Estate
Change in Plan Assets. Level 3 [Roll Forward]
Fair value of plan assets at beginning of year	1
Actual return on plan assets:
Fair value of plan assets at end of year	1	1
Level 3
Change in Plan Assets. Level 3 [Roll Forward]
Fair value of plan assets at beginning of year	35	34
Actual return on plan assets:
Relating to assets still held at the reporting date	1	2
Purchases, sales and settlements, net	0	2
Effect of exchange rate changes	5	(3)
Fair value of plan assets at end of year	41	35
Level 3 \| Insurance contracts
Change in Plan Assets. Level 3 [Roll Forward]
Fair value of plan assets at beginning of year	24	26
Actual return on plan assets:
Relating to assets still held at the reporting date	0	1
Purchases, sales and settlements, net	(1)	(1)
Effect of exchange rate changes	3	(2)
Fair value of plan assets at end of year	26	24
Level 3 \| Hedge funds
Change in Plan Assets. Level 3 [Roll Forward]
Fair value of plan assets at beginning of year	10	7
Actual return on plan assets:
Relating to assets still held at the reporting date	1	1
Purchases, sales and settlements, net	1	3
Effect of exchange rate changes	2	(1)
Fair value of plan assets at end of year	14	10
Level 3 \| Real Estate
Change in Plan Assets. Level 3 [Roll Forward]
Fair value of plan assets at beginning of year	1	1
Actual return on plan assets:
Relating to assets still held at the reporting date	0	0
Purchases, sales and settlements, net	0	0
Effect of exchange rate changes	0	0
Fair value of plan assets at end of year	$ 1	$ 1

BENEFIT PLANS - SCHEDULE OF RECONCILIATION OF CHANGES IN THE DEFINED BENEFIT AND POSTRETIREMENT HEALTHCARE PLANS' BENEFIT OBLIGATIONS, FIAR VALUE OF ASSETS AND FUNDED STATUS (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Change in Benefit Obligation
Benefit obligation at beginning of year	$ 478	$ 511
Service cost	11	11
Interest cost	12	12	$ 14
Participant contributions	5	5
Actuarial (gains) losses	(21)	(4)
Effect of exchange rate changes	70	(36)
Plan curtailments and settlements	(13)	0
Benefits paid	(12)	(21)
Benefit obligation at end of year	530	478	511
Change in Plan Assets
Fair value of plan assets at beginning of year	208	207
Actual return on assets	10	16
Plan settlements	(13)	0
Effect of exchange rate changes	30	(15)
Employer contributions	18	16
Participant contributions	5	5
Benefits paid	(12)	(21)
Fair value of plan assets at end of year	246	208	$ 207
Funded status at end of year	$ (284)	$ (270)

SIGNIFICANT ACCOUNTING POLICIES - SCHEDULE OF INTANGIBLE ASSETS (Details)	Dec. 31, 2025
Trade names and trademarks \| Maximum
Finite-Lived Intangible Assets [Line Items]
Intangible asset, useful life (in years)	20 years
Licensing agreements
Finite-Lived Intangible Assets [Line Items]
Intangible asset, useful life (in years)	15 years
Licensing agreements \| Maximum
Finite-Lived Intangible Assets [Line Items]
Intangible asset, useful life (in years)	20 years
Customer relationships \| Maximum
Finite-Lived Intangible Assets [Line Items]
Intangible asset, useful life (in years)	15 years
Developed technology \| Maximum
Finite-Lived Intangible Assets [Line Items]
Intangible asset, useful life (in years)	15 years

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 31
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-31

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 20
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-20

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 20
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-20

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 38
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-38

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 31
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-31

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 38
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-38

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 38
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-38

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 38
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-38

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 38
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-38

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 38
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-38

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 31
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-31

Reference 12: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 31
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-31

Reference 13: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 31
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-31

Reference 14: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 31
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-31

Reference 15: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 31
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-31

Reference 16: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 31
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-31

Reference 17: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 31
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-31

Reference 18: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-31

Reference 19: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 29
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-29

Reference 20: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 29
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-29

Reference 21: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 20
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-20

Reference 22: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 20
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-20

Reference 23: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-14

Reference 24: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-14

Reference 25: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-14

Reference 26: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-14

Reference 27: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-14

Reference 28: http://www.xbrl.org/2003/role/exampleRef
-Name Accounting Standards Codification
-Section 55
-Paragraph 40
-SubTopic 30
-Topic 350
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482640/350-30-55-40

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482665/350-30-50-2

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482665/350-30-50-2

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482686/350-30-45-1

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482665/350-30-50-2

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482665/350-30-50-3

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 985
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481283/985-20-50-2

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 926
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483154/926-20-50-5

+ Details

STOCK COMPENSATION (Tables)

12 Months Ended

Dec. 31, 2025

Share-Based Payment Arrangement [Abstract]

Schedule of Stock Compensation Expense Recorded in Consolidated Statements of Operations

The amounts of stock-based compensation expense recorded in the Company’s Consolidated Statements of Operations were as follows:


	Year Ended December 31,
(in millions)	2025		2024		2023

Cost of products sold	$	2	$	3	$	4
Selling, general, and administrative expense	28		35		36
Research and development expense	2		2		4
Restructuring and other costs	—		(1)		2
Total stock-based compensation expense	$	32	$	39	$	46

Related deferred income tax benefit	$	5	$	7	$	8

Schedule of Assumptions Used to Determine Compensation Cost for the Company's Non-Qualified Stock Options Issued


	Year Ended December 31,
	2025			2024			2023

Weighted average fair value per NQSO	$	3.14		$	9.91		$	12.64
Expected dividend yield	4.77		%	1.92		%	1.45		%
Risk-free interest rate	3.81		%	4.28		%	4.27		%
Expected volatility	36.3		%	35.7		%	35.8		%
Expected life (years)	4.12			4.26			4.76

Schedule of Non-qualified Stock Option Transactions

The NQSO transactions for the year ended December 31, 2025 were as follows:


	Outstanding					Exercisable					Expected to Vest
(in millions, except per share amounts)	Shares	Weighted Average Exercise Price		Aggregate Intrinsic Value		Shares	Weighted Average Exercise Price		Aggregate Intrinsic Value		Shares	Weighted Average Exercise Price		Aggregate Intrinsic Value

December 31, 2024	2.2	$	45.37	$	—	1.4	$	50.27	$	—	0.8	$	37.06	$	—
Granted	6.4	13.76

Exercised	—	—
Cancelled	(0.6)	47.20
Forfeited	(1.8)	19.17
December 31, 2025	6.2	$	19.88	$	1	1.1	$	48.74	$	—	5.1	$	13.91	$	1

Schedule of Information about Non-qualified Stock Options Outstanding

Information about NQSOs outstanding as of December 31, 2025 is provided below:


				Outstanding				Exercisable
				Number Outstanding at December 31, 2025	Weighted Average Remaining Contractual Life (in years)	Weighted Average Exercise Price		Number Exercisable at December 31, 2025	Weighted Average Exercise Price
Range of Exercise Prices
(in millions, except per share amounts and life)

$	5.01	-	$10.00	—	0.0	$	—	—	$	—
$	10.01	-	$20.00	5.0	9.6	$	13.09	—	$	—
$	20.01	-	$30.00	—	7.9	$	28.39	—	$	28.39
$	30.01	-	$40.00	0.5	7.7	36.99		0.4	$	37.49
$	40.01	-	$50.00	0.3	3.3	47.53		0.3	$	47.60
$	50.01	-	$60.00	0.3	4.1	55.69		0.3	$	55.69
$	60.01	-	$70.00	0.1	1.0	62.37		0.1	$	62.37
				6.2				1.1

Schedule of the Unvested RSU Transactions

The unvested RSUs for the year ended December 31, 2025 were as follows:


	Unvested Restricted Stock Units
	Shares	Weighted Average Grant Date Fair Value

(in millions, except per share amounts)

Unvested at December 31, 2024	3.9	$	37.11
Granted	4.5	15.64

Vested	(0.7)	35.49
Forfeited	(2.3)	23.50
Unvested at December 31, 2025	5.4	$	19.95

STOCK COMPENSATION - ADDITIONAL INFORMATION (Details) $ / shares in Units, shares in Millions, $ in Millions	2 Months Ended	12 Months Ended
	May 22, 2024 shares	Dec. 31, 2025 USD ($) $ / shares shares	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($) $ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Initially available under the plan (in shares) \| shares	14.5
Conversion ratio for option	1
Conversion ratio for other than option	2.7
Number of shares available for grant (in shares) \| shares		18.0
Weighted average remaining contractual life		8 years 8 months 12 days
Weighted average remaining contractual term of exercisable options		4 years 7 months 6 days
Weighted average remaining contractual term options expected to vest		9 years 6 months
Nonqualified Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of unvested stock options (in shares) \| shares		5.1
Unamortized compensation costs \| $		$ 13
Weighted average period for cost recognition		2 years 4 months 24 days
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unamortized compensation costs \| $		$ 26
Weighted average period for cost recognition		1 year 8 months 12 days
Weighted average grant date fair value of RSUs granted (in dollars per share) \| $ / shares		$ 15.64		$ 42.95
Total fair value of share vested during the period \| $		$ 31	$ 46	$ 42

FINANCIAL INSTRUMENTS AND DERIVATIVES - SCHEDULE OF BALANCE SHEET OFFSETTING (Details) - USD ($) $ in Millions	Dec. 31, 2025	Dec. 31, 2024
Assets
Gross Amounts Recognized	$ 50	$ 36
Gross Amounts Offset in the Consolidated Balance Sheets	0	0
Net Amounts Presented in the Consolidated Balance Sheets	50	36
Gross amounts not offset in the consolidated balance sheets, financial instruments	(50)	(11)
Gross amounts not offset in the consolidated balance sheets, cash collateral received/pledged	0	0
Net Amount	0	25
Liabilities
Gross Amounts Recognized	154	30
Gross Amounts Offset in the Consolidated Balance Sheets	0	0
Net Amounts Presented in the Consolidated Balance Sheets	154	30
Gross amounts not offset in the consolidated balance sheets, financial instruments	(50)	(11)
Gross amounts not offset in the consolidated balance sheets, cash collateral received/pledged	0	0
Net Amount	104	19
Foreign exchange forward contracts
Assets
Gross Amounts Recognized	8	18
Gross Amounts Offset in the Consolidated Balance Sheets	0	0
Net Amounts Presented in the Consolidated Balance Sheets	8	18
Gross amounts not offset in the consolidated balance sheets, financial instruments	(8)	(5)
Gross amounts not offset in the consolidated balance sheets, cash collateral received/pledged	0	0
Net Amount	0	13
Liabilities
Gross Amounts Recognized	67	9
Gross Amounts Offset in the Consolidated Balance Sheets	0	0
Net Amounts Presented in the Consolidated Balance Sheets	67	9
Gross amounts not offset in the consolidated balance sheets, financial instruments	(18)	(4)
Gross amounts not offset in the consolidated balance sheets, cash collateral received/pledged	0	0
Net Amount	49	5
Cross currency basis swaps
Assets
Gross Amounts Recognized	42	18
Gross Amounts Offset in the Consolidated Balance Sheets	0	0
Net Amounts Presented in the Consolidated Balance Sheets	42	18
Gross amounts not offset in the consolidated balance sheets, financial instruments	(42)	(6)
Gross amounts not offset in the consolidated balance sheets, cash collateral received/pledged	0	0
Net Amount	0	12
Liabilities
Gross Amounts Recognized	73
Gross Amounts Offset in the Consolidated Balance Sheets	0
Net Amounts Presented in the Consolidated Balance Sheets	73
Gross amounts not offset in the consolidated balance sheets, financial instruments	(32)
Gross amounts not offset in the consolidated balance sheets, cash collateral received/pledged	0
Net Amount	41
Interest rate swaps
Liabilities
Gross Amounts Recognized	14	21
Gross Amounts Offset in the Consolidated Balance Sheets	0	0
Net Amounts Presented in the Consolidated Balance Sheets	14	21
Gross amounts not offset in the consolidated balance sheets, financial instruments	0	(7)
Gross amounts not offset in the consolidated balance sheets, cash collateral received/pledged	0	0
Net Amount	$ 14	$ 14

LEASES - ASSETS AND LIABILITIES (Details) - USD ($) $ in Millions	Dec. 31, 2025	Dec. 31, 2024
Assets
Finance leases	$ 0	$ 0
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Property, plant and equipment, net	Property, plant and equipment, net
Operating leases	$ 139	$ 136
Total right-of-use assets	139	136
Current Liabilities:
Operating leases	$ 47	$ 46
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]	Accrued Liabilities, Current	Accrued Liabilities, Current
Noncurrent liabilities
Finance leases	$ 0	$ 0
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Long-term debt	Long-term debt
Operating leases	$ 93	$ 91
Total lease liabilities	$ 140	$ 137
Weighted-average discount rate
Operating leases	4.60%	4.10%
Weighted-average remaining lease term in years
Operating leases	4 years	4 years 1 month 6 days

AUDIT INFORMATION	12 Months Ended
AUDIT INFORMATION	Dec. 31, 2025
Audit Information [Abstract]
Auditor Name	Deloitte & Touche LLP
Auditor Location	Charlotte, North Carolina
Auditor Firm ID	34

FAIR VALUE MEASUREMENT

12 Months Ended

Dec. 31, 2025

Fair Value Disclosures [Abstract]

FAIR VALUE MEASUREMENT

The estimated fair and carrying values of the Company’s total debt were $2,217 million and $2,329 million, respectively, at December 31, 2025. At December 31, 2024, the estimated fair and carrying values were $2,037 million and $2,135 million, respectively. The fair value of long-term debt is determined by discounting future cash flows using interest rates available at December 31, 2025 to companies with similar credit ratings for issuances with similar terms and maturities. It is considered a Level 2 fair value measurement for disclosure purposes.

Assets and liabilities measured at fair value on a recurring basis

The Company’s financial assets and liabilities set forth by level within the fair value hierarchy that were accounted for at fair value on a recurring basis were as follows:


	Year Ended December 31, 2025
(in millions)	Total		Level 1		Level 2		Level 3

Assets


Interest rate swap asset related to long-term debt	$	14	$	—	$	14	$	—

Foreign exchange forward contracts	8		—		8		—

Total assets	$	22	$	—	$	22	$	—

Liabilities
Interest rate swaps	$	14	$	—	$	14	$	—

Cross currency basis swaps	31		—		31		—
Foreign exchange forward contracts	67		—		67		—

Contingent considerations on acquisitions	—		—		—		—

Total liabilities	$	112	$	—	$	112	$	—


	Year Ended December 31, 2024
(in millions)	Total		Level 1		Level 2		Level 3

Assets



Cross currency interest rate swaps	$	18	$	—	$	18	$	—
Foreign exchange forward contracts	18		—		18		—


Total assets	$	36	$	—	$	36	$	—

Liabilities
Interest rate swaps	$	21	$	—	$	21	$	—


Foreign exchange forward contracts	9		—		9		—

Contingent considerations on acquisitions	4		—		—		4

Total liabilities	$	34	$	—	$	30	$	4

Derivative valuations are based on observable inputs to the valuation model including interest rates, foreign currency exchange rates, and credit risks.

There were no transfers between fair value measurement levels during the years ended December 31, 2025 and 2024.

Assets and liabilities measured at fair value on a recurring basis using significant unobservable inputs (level 3)

The Company’s Level 3 liabilities at December 31, 2024 are related to earn-out obligations from acquisitions and licensing arrangements.

For the year ended December 31, 2025, there was a gain of $4 million recorded to other income in relation to a release of contingent consideration related to a prior acquisition. There were no additional purchases or transfers of Level 3 financial instruments in 2025 and 2024.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (bbb)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 107
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-107

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 100
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-100

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2E
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 940
-SubTopic 820
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478119/940-820-50-1

+ Details

FINANCIAL INSTRUMENTS AND DERIVATIVES - SCHEDULE OF NOTIONAL AMOUNTS OF OUTSTANDING DERIVATIVE POSITIONS (Details) € in Millions, $ in Millions	Dec. 31, 2025 USD ($)	Dec. 31, 2025 EUR (€)	Jul. 01, 2025 EUR (€)	Jul. 01, 2021 USD ($)
Not Designated as Hedging Instrument
Derivative [Line Items]
Aggregate Notional Amount	$ 1,026
Aggregate Notional Amount Maturing within 12 Months	1,026
Hedges of Net Investments \| Designated as Hedging Instrument
Derivative [Line Items]
Aggregate Notional Amount	2,217
Aggregate Notional Amount Maturing within 12 Months	299
Fair Value Hedges \| Designated as Hedging Instrument
Derivative [Line Items]
Aggregate Notional Amount	150
Aggregate Notional Amount Maturing within 12 Months	0
Foreign exchange forward contracts \| Not Designated as Hedging Instrument
Derivative [Line Items]
Aggregate Notional Amount	1,026
Aggregate Notional Amount Maturing within 12 Months	1,026
Foreign exchange forward contracts \| Hedges of Net Investments \| Designated as Hedging Instrument
Derivative [Line Items]
Aggregate Notional Amount \| €		€ 804
Aggregate Notional Amount Maturing within 12 Months \| €		€ 299
Cross currency basis swaps \| Hedges of Net Investments \| Designated as Hedging Instrument
Derivative [Line Items]
Aggregate Notional Amount	1,413		€ 1,100
Aggregate Notional Amount Maturing within 12 Months	0
Interest rate swaps
Derivative [Line Items]
Aggregate Notional Amount				$ 250
Interest rate swaps \| Fair Value Hedges \| Designated as Hedging Instrument
Derivative [Line Items]
Aggregate Notional Amount	150
Aggregate Notional Amount Maturing within 12 Months	$ 0

SIGNIFICANT ACCOUNTING POLICIES

12 Months Ended

Dec. 31, 2025

Accounting Policies [Abstract]

SIGNIFICANT ACCOUNTING POLICIES

Description of Business

DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the “Company”), is the world’s largest diversified manufacturer of dental products and technologies, with a 139-year history of innovation and service to the dental industry and patients worldwide. The Company’s principal product categories include dental consumable products, dental equipment, dental technologies and continence care consumable products. The Company sells its products in approximately 140 countries under some of the most well-established brand names in the industry.

Basis of Presentation

Use of Estimates

Cash and Cash Equivalents

Accounts Receivable

Inventories

Inventories are stated at the lower of cost and net realizable value. The cost of inventories is based upon the first-in, first-out method (“FIFO”) or average cost methods.

The Company establishes reserves for inventory estimated to be excess, obsolete or unmarketable based upon assumptions about future demand, market conditions, and expiration of products.

Valuation of Goodwill and Indefinite-Lived and Definite-Lived Intangible Assets

Goodwill

Indefinite-Lived Intangible Assets

Definite-Lived Intangible Assets


Definite-Lived Intangible Asset Type						Useful Life

Patents						Up to the date the patent expires
Trade names and trademarks						Up to 20 years
Licensing agreements						Up to 20 years
Customer relationships						Up to 15 years
Developed technology						Up to 15 years

Property, Plant and Equipment


Property, Plant and Equipment Assets Type						Useful Life

Buildings						25 to 40 years
Machinery and Equipment						2 to 20 years
Capitalized Software						3 to 10 years
Leasehold Improvements						Shorter of the estimated useful life or the term of the lease

Leases

Derivative Financial Instruments

Pension and Other Postemployment Benefits

Accruals for Self-Insured Losses

Litigation

Foreign Currency Translation

Foreign currency gains and losses arising from transactions denominated in a currency other than the functional currency of the entity involved are included within Other (income) expense, net in the Consolidated Statements of Operations. During the years ended December 31, 2025, 2024, and 2023, the Company had a net foreign currency gain of $32 million, gain of $21 million, and gain of $3 million, respectively.

Revenue Recognition

Cost of Products Sold

Warranties


	December 31,
(in millions)	2025		2024		2023

Warranty Expense	$	28	$	32	$	48
Warranty Accrual	18		21		24

Selling, General and Administrative Expenses

Research and Development Costs

Stock-Based Compensation

Income Taxes

Earnings Per Share

Investments in Unconsolidated Affiliates

On December 7, 2023, the Company sold its minority interest in a UK-based, privately-held provider of healthcare consumables for $13 million. Prior to the sale, the Company recorded a loss of $4 million in Other (income) expense, net due to a forfeiture of accumulated earnings on the investment for declining its option to purchase the remaining ownership interest.

Noncontrolling Interests

Fair Value Measurement

Recurring Basis

Level 1 - Quoted prices are available in active markets for identical assets or liabilities as of the reported date.

Non-Recurring Basis

Recently Adopted Accounting Pronouncements

Accounting Pronouncements Not Yet Adopted

SEGMENT AND GEOGRAPHIC INFORMATION - SEGMENT REPORTING (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Revenue, Major Customer [Line Items]
Net sales	$ 3,680	$ 3,793	$ 3,965
Operating loss	(422)	(879)	(85)
Interest expense, net	88	69	81
Other (income) expense, net	(24)	(12)	9
Goodwill and intangible asset impairments	650	1,014	307
Restructuring and other costs	24	53	67
Amortization of intangible assets	211	216	211
Loss before income taxes	(486)	(936)	(175)
Total Depreciation and Amortization	352	349	343
Operating Segments
Revenue, Major Customer [Line Items]
Net sales	3,680	3,793	3,965
Operating loss	776	727	822
Unallocated corporate costs
Revenue, Major Customer [Line Items]
Unallocated corporate costs	311	320	319
Total Depreciation and Amortization	24	22	19
Reconciling items (income) expense:, excluding corporate costs
Revenue, Major Customer [Line Items]
Interest expense, net	88	69	81
Other (income) expense, net	(24)	(12)	9
Goodwill and intangible asset impairments	650	1,014	307
Restructuring and other costs	24	53	67
Amortization of intangible assets	211	216	211
Depreciation resulting from the fair value step-up of property, plant, and equipment from business combinations	2	3	3
Connected Technology Solutions \| Operating Segments
Revenue, Major Customer [Line Items]
Net sales	1,036	1,062	1,169
Adjusted cost of products sold	614	602	645
Adjusted selling expenses	221	242	264
Adjusted G&A expenses	81	74	77
Adjusted R&D expenses	68	74	82
Operating loss	52	70	101
Total Depreciation and Amortization	186	175	176
Essential Dental Solutions \| Operating Segments
Revenue, Major Customer [Line Items]
Net sales	1,469	1,454	1,468
Adjusted cost of products sold	555	565	560
Adjusted selling expenses	301	313	313
Adjusted G&A expenses	76	74	94
Adjusted R&D expenses	23	23	23
Operating loss	514	479	478
Total Depreciation and Amortization	34	35	33
Orthodontic and Implant Solutions \| Operating Segments
Revenue, Major Customer [Line Items]
Net sales	850	973	1,040
Adjusted cost of products sold	392	407	402
Adjusted selling expenses	222	301	305
Adjusted G&A expenses	80	133	119
Adjusted R&D expenses	48	52	58
Operating loss	108	80	156
Total Depreciation and Amortization	90	98	97
Wellspect Healthcare \| Operating Segments
Revenue, Major Customer [Line Items]
Net sales	325	304	288
Adjusted cost of products sold	131	117	114
Adjusted selling expenses	55	52	51
Adjusted G&A expenses	27	27	25
Adjusted R&D expenses	10	10	11
Operating loss	102	98	87
Total Depreciation and Amortization	$ 18	$ 19	$ 18

FINANCING ARRANGEMENTS - SCHEDULE OF CONTRACTUAL MATURITY DATES OF THE VAIROUS BORROWINGS (Details) $ in Millions	Dec. 31, 2025 USD ($)
Debt Disclosure [Abstract]
2026	$ 228
2027	110
2028	177
2029	82
2030	832
2031 and beyond	847
Floating rate senior term loan	$ 2,276

- Definition

Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.

+ References

+ Details

BENEFIT PLANS - SCHEDULE OF FAIR VALUE MEASUREMENTS OF PLAN ASSETS (Details) - USD ($) $ in Millions	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Defined Benefit Plan Disclosure [Line Items]
Plan assets	$ 246	$ 208	$ 207
Cash and cash equivalents
Defined Benefit Plan Disclosure [Line Items]
Plan assets	5	6
Equity securities, International
Defined Benefit Plan Disclosure [Line Items]
Plan assets	79	67
Fixed income securities, Fixed rate bonds
Defined Benefit Plan Disclosure [Line Items]
Plan assets	90	79
Mutual funds
Defined Benefit Plan Disclosure [Line Items]
Plan assets	31	21
Insurance contracts
Defined Benefit Plan Disclosure [Line Items]
Plan assets	26	24
Hedge funds
Defined Benefit Plan Disclosure [Line Items]
Plan assets	14	10
Real Estate
Defined Benefit Plan Disclosure [Line Items]
Plan assets	$ 1	1
Equity \| Mutual funds
Defined Benefit Plan Disclosure [Line Items]
Percentage of investments	50.00%
Fixed Income Investments \| Mutual funds
Defined Benefit Plan Disclosure [Line Items]
Percentage of investments	50.00%
Level 1
Defined Benefit Plan Disclosure [Line Items]
Plan assets	$ 205	173
Level 1 \| Cash and cash equivalents
Defined Benefit Plan Disclosure [Line Items]
Plan assets	5	6
Level 1 \| Equity securities, International
Defined Benefit Plan Disclosure [Line Items]
Plan assets	79	67
Level 1 \| Fixed income securities, Fixed rate bonds
Defined Benefit Plan Disclosure [Line Items]
Plan assets	90	79
Level 1 \| Mutual funds
Defined Benefit Plan Disclosure [Line Items]
Plan assets	31	21
Level 1 \| Insurance contracts
Defined Benefit Plan Disclosure [Line Items]
Plan assets	0	0
Level 1 \| Hedge funds
Defined Benefit Plan Disclosure [Line Items]
Plan assets	0	0
Level 1 \| Real Estate
Defined Benefit Plan Disclosure [Line Items]
Plan assets	0	0
Level 2
Defined Benefit Plan Disclosure [Line Items]
Plan assets	0	0
Level 2 \| Cash and cash equivalents
Defined Benefit Plan Disclosure [Line Items]
Plan assets	0	0
Level 2 \| Equity securities, International
Defined Benefit Plan Disclosure [Line Items]
Plan assets	0	0
Level 2 \| Fixed income securities, Fixed rate bonds
Defined Benefit Plan Disclosure [Line Items]
Plan assets	0	0
Level 2 \| Mutual funds
Defined Benefit Plan Disclosure [Line Items]
Plan assets	0	0
Level 2 \| Insurance contracts
Defined Benefit Plan Disclosure [Line Items]
Plan assets	0	0
Level 2 \| Hedge funds
Defined Benefit Plan Disclosure [Line Items]
Plan assets	0	0
Level 2 \| Real Estate
Defined Benefit Plan Disclosure [Line Items]
Plan assets	0	0
Level 3
Defined Benefit Plan Disclosure [Line Items]
Plan assets	41	35	34
Level 3 \| Cash and cash equivalents
Defined Benefit Plan Disclosure [Line Items]
Plan assets	0	0
Level 3 \| Equity securities, International
Defined Benefit Plan Disclosure [Line Items]
Plan assets	0	0
Level 3 \| Fixed income securities, Fixed rate bonds
Defined Benefit Plan Disclosure [Line Items]
Plan assets	0	0
Level 3 \| Mutual funds
Defined Benefit Plan Disclosure [Line Items]
Plan assets	0	0
Level 3 \| Insurance contracts
Defined Benefit Plan Disclosure [Line Items]
Plan assets	26	24	26
Level 3 \| Hedge funds
Defined Benefit Plan Disclosure [Line Items]
Plan assets	14	10	7
Level 3 \| Real Estate
Defined Benefit Plan Disclosure [Line Items]
Plan assets	$ 1	$ 1	$ 1

GOODWILL AND INTANGIBLE ASSETS

12 Months Ended

Dec. 31, 2025

Goodwill and Intangible Assets Disclosure [Abstract]

GOODWILL AND INTANGIBLE ASSETS

The Company’s policy is to assess goodwill and indefinite-lived intangible assets for impairment annually as of April 1, with more frequent assessments if events or changes in circumstances indicate an asset might be impaired. Impairment charges are recorded in Goodwill and intangible asset impairment in the Consolidated Statement of Operations.

Impairment during the Three Months Ended June 30, 2025

For the three months ended June 30, 2025, the Company assessed the goodwill of its reporting units and its indefinite-lived intangible assets for impairment as of April 1, 2025. As a result of the Company’s April 1 impairment test, it was determined that the fair values of its Implant & Prosthetic Solutions reporting unit and certain indefinite-lived intangible assets, including trade names and trademarks within the Connected Technology Solutions segment, and certain trade names within the Implant & Prosthetic Solutions reporting unit within the Orthodontic and Implant Solutions segment were below their carrying values.

The reduction in fair value for the Implant & Prosthetic Solutions reporting unit determined by this model was primarily driven by the impact of tariffs and lower projected volumes, due partly to competitive pressures, particularly in the United States and European markets. These factors contributed to reduced forecasted revenues, lower operating margins, and reduced expectations for future cash flows in the near term. As a result of this test, the Company recorded a pre-tax goodwill impairment charge as of June 30, 2025 of $156 million for the Implant & Prosthetic Solutions reporting unit within the Orthodontic and Implant Solutions segment.

As a result of the annual test of indefinite-lived intangible assets, the Company identified impairments of certain trade names and trademarks within the Connected Technology Solutions segment, and certain trade names within the Implant & Prosthetic Solutions reporting unit within the Orthodontic and Implant Solutions segment. The decline in fair value of these assets was driven by the impact of tariffs, which reduced the royalty rates used to value these assets, and lower volumes for the Company’s premium equipment and implant products due partly to competitive pressure, which contributed to reduced forecasted revenues. As a result of this test, the Company recorded pre-tax charges of $79 million to intangible assets as of June 30, 2025, consisting of $64 million within the Connected Technology Solutions segment and $15 million within the Implant & Prosthetic Solutions reporting unit, which were recorded in Goodwill and intangible asset impairment in the Consolidated Statement of Operations.

Impairment during the Three Months Ended September 30, 2025

For the three months ended September 30, 2025, the Company considered additional qualitative and quantitative factors to determine whether any events or changes in circumstances had resulted in indicators of additional impairment of goodwill or indefinite-lived intangible assets. Due to the lower-than-expected results for Implant & Prosthetic Solutions, it was determined that the fair value of this reporting unit had declined below its carrying value. The updated fair value was computed in a manner consistent with the annual test described above, with the decline primarily driven by lower-than-expected volumes, particularly in the United States, and the impact of tariffs. As a result of the updated impairment testing, as of September 30, 2025, the Company recorded a pre-tax goodwill impairment charge of $253 million for the Implant & Prosthetic Solutions reporting unit. Additionally, review of the indefinite-lived intangible assets previously impaired as of June 30, 2025, using a consistent methodology as that which was used for the annual test, indicated a further decline in fair value as of September 30, 2025 due to lower volumes for the Company’s equipment and implant products. As a result, the Company recorded indefinite-lived

intangible asset pre-tax impairment charges of $4 million and $5 million for the Connected Technology Solutions and Orthodontic and Implant Solutions segments, respectively, for the three months ended September 30, 2025.

Impairment during the Three Months Ended December 31, 2025

For the three months ended December 31, 2025, the Company considered additional qualitative and quantitative factors to determine whether any events or changes in circumstances had resulted in indicators of additional impairment of goodwill or indefinite-lived intangible assets. Due to the lower-than-expected results and lowered near-term forecasts for Implant & Prosthetic Solutions, it was determined that the fair value of this reporting unit had declined below its carrying value. The updated fair value was computed in a manner consistent with the annual test described above, with the decline primarily driven by lower-than-expected volumes and lowered near-term forecasts, particularly in the United States. As a result of the updated impairment testing, as of December 31, 2025, the Company recorded a pre-tax goodwill impairment charge of $116 million for the Implant & Prosthetic Solutions reporting unit. This impairment charge resulted in a full impairment of all remaining goodwill within the reporting unit. Additionally, review of the indefinite-lived intangible assets previously impaired as of September 30, 2025, using a consistent methodology as that which was used for the annual test, indicated a further decline in fair value as of December 31, 2025 due to lower volumes for the Company’s equipment and implant products and lower volumes in near-term forecasts. As a result, the Company recorded indefinite-lived intangible asset pre-tax impairment charges of $22 million and $15 million for the Connected Technology Solutions and Orthodontic and Implant Solutions segments, respectively, for the three months ended December 31, 2025.

2024 Goodwill and Indefinite-Lived Intangibles Impairment and Testing

In the three months ended March 31, 2024, the Company identified indicators of a more likely than not impairment related to certain indefinite-lived imaging product trade names within the Connected Technology Solutions segment. The decline in fair value of these indefinite-lived trade names was driven by declines in volumes during the three months ended March 31, 2024. As a result, the Company recorded an indefinite-lived intangible asset impairment charge of $6 million for the three months ended March 31, 2024.

In the three months ended September 30, 2024, the Company identified indicators of a more likely than not impairment for two of its reporting units, Orthodontic Aligner Solutions and Implant & Prosthetic Solutions, which together comprise all of the Orthodontic and Implant Solutions segment. As a result, the Company recorded pre-tax goodwill impairment charges of $145 million for the Orthodontic Aligner Solutions reporting unit and $359 million for the Implant & Prosthetic Solutions reporting unit, both within the Orthodontic and Implant Solutions segment. The impairment charge related to the Orthodontic Aligner Solutions reporting unit resulted in a full write-off of the remaining goodwill balance for this reporting unit.

In the three months ended December 31, 2024, the Company identified indicators of a more likely than not impairment for its Implant & Prosthetic Solutions reporting unit within the Orthodontic and Implant Solutions segment. The decline in fair value of this reporting unit was driven by a weaker trend in sales volumes, particularly in North America, increased competition from lower-priced alternatives impacting global markets, and adverse macroeconomic pressures impacting demand for elective dental procedures and premium implant solutions. As a result, the Company recorded a pre-tax goodwill impairment charge of $269 million for the Implant & Prosthetic Solutions reporting unit within the Orthodontic and Implant Solutions segment. Additionally, in the three months ended December 31, 2024, the Company also identified indicators of more likely than not impairments for certain indefinite-lived intangible assets including trade names and trademarks within the Connected Technology Solutions segment, and certain trade names within the Implant & Prosthetic Solutions reporting unit within the Orthodontic and Implant Solutions segment. As a result, the Company recorded indefinite-lived intangible asset impairment charges of $82 million and $1 million for the Connected Technology Solutions and Orthodontic and Implant Solutions segments, respectively, for the three months ended December 31, 2024. As a result of suspending sales of Byte clear aligner and impression kits during the fourth quarter of 2024, and subsequently announcing plans that Byte aligners would no longer be offered to new patients, the Company recorded a full write-off of the Byte trademark intangible asset within the Orthodontic and Implant Solutions segment, resulting in a charge of $152 million based on a determination that the trademark will not be used in the future operating model for aligners.

2023 Goodwill and Indefinite-Lived Intangibles Impairment and Testing

In the three months ended September 30, 2023, the Company identified indicators of a more likely than not impairment related to its Connected Technology Solutions reporting unit, which comprises all the Connected Technology Solutions segment. The decline in fair value for this reporting unit was driven by adverse macroeconomic factors because of weakened demand, particularly in European markets, and increased discount rates. These factors contributed to reduced forecasted revenues, lower operating margins, and reduced expectations for future cash flows in the near term, particularly in relation to demand for products which are commonly financed by end customers and are therefore adversely impacted by an environment of higher interest rates. The reporting unit was evaluated for impairment using an income approach, specifically a discounted cash flow model. As a result, the Company recorded a pre-tax goodwill impairment charge for the three months ended September 30, 2023 related to the Connected Technology Solutions reporting unit of $291 million, resulting in a full write-off of the remaining goodwill balance for the Connected Technology Solutions segment.

Additionally, in conjunction with the third quarter test in 2023, the Company conducted an impairment test on the indefinite-lived intangible assets related to the businesses within the Connected Technology Solutions reporting unit within the Connected Technology Solutions segment. The Company also identified an indicator of impairment for the indefinite-lived intangible assets within the Implant & Prosthetic Solutions reporting unit within the Orthodontic and Implant Solutions segment and determined certain trade names and trademarks were impaired. These indefinite-lived intangible assets were evaluated for impairment using an income approach, specifically a relief from royalty method. As a result, the Company recorded indefinite-lived intangible asset impairment charges of $14 million and $2 million for the Connected Technology Solutions and Orthodontic and Implant Solutions segments, respectively, for the three months ended September 30, 2023. The impairment charge was primarily driven by macroeconomic factors such as weakened demand, higher cost of capital, and cost inflation, which are contributing to reduced forecasted revenues.

A reconciliation of changes in the Company’s goodwill by reportable segment was as follows:


(in millions)	Connected Technology Solutions		Essential Dental Solutions		Orthodontic and Implant Solutions		Wellspect Healthcare		Total

Balance at December 31, 2024
Goodwill	$	291	$	829	$	1,276	$	265	$	2,661
Accumulated impairment losses	(291)		—		(773)		—		(1,064)
Goodwill, net at December 31, 2024	$	—	$	829	$	503	$	265	$	1,597
Translation	—		31		22		23		76
Impairment	—		—		(525)		—		(525)
Goodwill, net at December 31, 2025	$	—	$	860	$	—	$	288	$	1,148

Accumulated impairment losses at December 31, 2025	(291)		—		(1,298)		—		(1,589)

Identifiable definite-lived and indefinite-lived intangible assets were as follows:


	Year Ended December 31,
	2025						2024
(in millions)	Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount

Developed technology and patents	$	1,783	$	(1,334)	$	449	$	1,639	$	(1,079)	$	560
Trade names and trademarks	84		(79)		5		79		(73)		6
Licensing agreements	42		(29)		13		29		(28)		1
Customer relationships	1,098		(847)		251		1,019		(716)		303
Total definite-lived	$	3,007	$	(2,289)	$	718	$	2,766	$	(1,896)	$	870

Indefinite-lived trade names and trademarks	251		—		251		332		—		332
In-process R&D (a)	5		—		5		5		—		5
Total indefinite-lived	256		—		256		337		—		337

Total identifiable intangible assets	$	3,263	$	(2,289)	$	974	$	3,103	$	(1,896)	$	1,207

Amortization expense for definite-lived intangible assets for the years ended December 31, 2025, 2024 and 2023 was $211 million, $216 million and $211 million, respectively. The estimated annual amortization expense related to these intangible assets for each of the five succeeding calendar years is $143 million, $121 million, $126 million, $127 million and $125 million for 2026, 2027, 2028, 2029 and 2030, respectively.

During the second quarter of 2021, the Company acquired certain developed technology rights for an initial payment of $3 million. During the fourth quarter of 2024, regulatory and commercial milestones related to the acquisition were achieved, triggering an additional payment of $7 million. As of December 31, 2024, the Company recognized a liability of $10 million for contractual future payments associated with this acquisition that were deemed probable. Both the payment and future obligation were recorded as increases to the developed technology asset for the year ended December 31, 2024. As of December 31, 2025 there is no liability remaining and the net carrying amount of the related intangible asset is $3.8 million related to the developed technology rights. During fiscal year 2025, the Company entered into a long-term licensing and naming rights agreement and recognized an intangible asset of $13.5 million. The asset has a contractual term of 15 years and is being amortized on a straight-line basis over that period. Amortization expense is recorded within selling, general and administrative expenses. As of December 31, 2025, the carrying amount of the intangible asset was $13 million.

BENEFIT PLANS - SCHEDULE OF PENSION PLANS WITH AN ACCUMULATED BENEFIT OBLIGATION IN EXCESS OF PLAN ASSETS (Details) - USD ($) $ in Millions	Dec. 31, 2025	Dec. 31, 2024
Retirement Benefits [Abstract]
Projected benefit obligation	$ 300	$ 274
Accumulated benefit obligation	$ 290	$ 263

EQUITY - SCHEDULE OF ACCELERATED SHARE REPURCHASE PROGRAM (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions			1 Months Ended	2 Months Ended	12 Months Ended
	Apr. 28, 2023	Mar. 03, 2023	Mar. 31, 2023	Apr. 30, 2023	Dec. 31, 2024	Dec. 31, 2023
Equity [Abstract]
Amount Paid	$ 150		$ 120
Initial Delivery
Shares Received (in shares)		3.1	3.1	0.8
Price per share (in dollars per share)		$ 38.74	$ 38.74
Value of Shares as a % of Contract Value		80.00%
Final Settlement
Total Shares Received (in shares)	3.9			3.9	9.4	8.8
Average Price per Share (in dollars per share)	$ 38.55

INCOME TAXES - SCHEDULE OF COMPONENTS OF THE EXPENSE (BENEFIT) FOR INCOME TAXES FROM OPERATIONS (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Current:
U.S. federal	$ (1)	$ (6)	$ 1
U.S. state	2	1	0
Foreign	81	115	86
Total	82	110	87
Deferred:
U.S. federal	36	(61)	4
U.S. state	2	(1)	(3)
Foreign	(8)	(74)	(131)
Total	30	(136)	(130)
Total expense (benefit) for income taxes	$ 112	$ (26)	$ (43)

REVENUE RECOGNITION (Tables)

12 Months Ended

Dec. 31, 2025

Revenue from Contract with Customer [Abstract]

Schedule of Net Sales Disaggregated by Product Category

Net sales disaggregated by product category were as follows:


	Year Ended December 31,
(in millions)	2025		2024		2023

Equipment & Instruments	$	578	$	553	$	628
CAD/CAM	458		509		541
Connected Technology Solutions	$	1,036	$	1,062	$	1,169



Essential Dental Solutions	$	1,469	$	1,454	$	1,468

Orthodontics	$	227	$	299	$	339
Implants & Prosthetics	623		674		701
Orthodontic and Implant Solutions	$	850	$	973	$	1,040

Wellspect Healthcare	$	325	$	304	$	288

Total net sales	$	3,680	$	3,793	$	3,965

Schedule of Net Sales Disaggregated by Geographic Region

Net sales disaggregated by geographic region were as follows:


	Year Ended December 31,
(in millions)	2025		2024		2023

United States	$	1,182	$	1,348	$	1,437
Europe	1,576		1,518		1,550
Rest of World	922		927		978

Total net sales	$	3,680	$	3,793	$	3,965

INCOME TAXES (Tables)

12 Months Ended

Dec. 31, 2025

Income Tax Disclosure [Abstract]

Schedule of Components of (Loss) Income Before Income Taxes from Operations

The components of loss before income taxes were as follows:


	Year Ended December 31,
(in millions)	2025		2024		2023

United States	$	(120)	$	(307)	$	(6)
Foreign	(366)		(629)		(169)
Total loss before income taxes	$	(486)	$	(936)	$	(175)

Schedule of Components of the Expense (Benefit) for Income Taxes from Operations

The components of the expense (benefit) for income taxes from operations were as follows:


	Year Ended December 31,
(in millions)	2025		2024		2023

Current:
U.S. federal	$	(1)	$	(6)	$	1
U.S. state	2		1		—
Foreign	81		115		86
Total	$	82	$	110	$	87

Deferred:
U.S. federal	$	36	$	(61)	$	4
U.S. state	2		(1)		(3)
Foreign	(8)		(74)		(131)
Total	$	30	$	(136)	$	(130)

Total expense (benefit) for income taxes	$	112	$	(26)	$	(43)

Schedule of Reconciliation of the U.S. Federal Statutory Tax Rate to the Effective Rate

For the year ended December 31, 2025, the reconciliation of the U.S. federal statutory tax rate to the effective rate was as follows:


	Year Ended December 31,
(in millions, except percentages)	2025

Statutory U.S. federal income tax rate	$	(102)	21.0	%
Effect of:
State income taxes, net of federal benefit(a)	3		(0.6)	%
Foreign tax effects
Germany
Statutory income tax rate differential	16		(3.3)	%
Trade tax	(18)		3.7	%
Changes in valuation allowances	16		(3.3)	%
Goodwill impairment	8		(1.6)	%
Other	2		(0.4)	%
Israel
Statutory income tax rate differential	16		(3.3)	%
Goodwill impairment	18		(3.7)	%
Other	(4)		0.8	%
Luxembourg
Changes in valuation allowance	238		(48.9)	%
Local impairment losses	(250)		51.3	%
Foreign exchange differences	11		(2.3)	%
Other	3		(0.6)	%
Sweden
Goodwill impairment	26		(5.3)	%
Other	2		(0.4)	%
Switzerland
Statutory income tax rate differential	(21)		4.3	%
Cantonal tax	28		(5.7)	%
Changes in valuation allowances	55		(11.3)	%
Foreign exchange differences	(4)		0.8	%
Local impairment losses	(38)		7.8	%
Other foreign jurisdictions and consolidated eliminations	39		(8.0)	%

Effect of cross-border tax laws
Global Intangible Low Taxed Income (GILTI)	7		(1.5)	%
Subpart F	8		(1.7)	%
Other cross-border	2		(0.4)	%
Tax credits	2		(0.4)	%

Non-taxable or non-deductible items
Goodwill impairment	24		(4.9)	%
Share-based payment awards	6		(1.2)	%
Other non-taxable or non-deductible items	7		(1.5)	%
Changes in unrecognized tax benefits	2		(0.4)	%
Other	10		(2.1)	%
Total tax provision and effective tax rate	$	112	(23.1)	%

(a) State taxes in California, New York, Minnesota, Texas, and Florida made up the majority (greater than 50%) of the tax effect in this category.

As previously disclosed for the years ended December 31, 2024 and 2023, prior to the adoption of ASU 2023-09, the reconciliations of the U.S. federal statutory tax rate to the effective rate were as follows:


	Year Ended December 31,
(in millions, except percentages)	2024				2023

Statutory U.S. federal income tax rate	$	(197)	21.0	%	$	(37)	21.0	%
Effect of:
State income taxes, net of federal benefit	—		—		(2)		1.4
Federal benefit of R&D and foreign tax credits	(7)		0.8		(17)		10.0
U.S. other permanent differences	3		(0.3)		5		(2.7)
Tax effect of international operations	42		(4.5)		(65)		37.2
Global Intangible Low Taxed Income (GILTI)	9		(1.0)		12		(7.0)
Foreign Derived Intangible Income (FDII)	—		—		(9)		5.2
Net effect of tax audit activity	23		(2.5)		(6)		3.2
Tax effect of enacted statutory rate changes on Non-U.S. jurisdictions	3		(0.3)		1		(0.4)
Federal tax on unremitted earnings of certain foreign subsidiaries	(1)		0.1		2		(0.9)
Valuation allowance adjustments	(13)		1.3		5		(3.2)
Tax effect of impairment of goodwill and intangibles	106		(11.3)		60		(34.6)
Other	6		(0.5)		8		(4.4)

Effective income tax rate on operations	$	(26)	2.8	%	$	(43)	24.8	%

Schedule of Tax Effect of Significant Temporary Differences Giving Rise to Deferred Tax Assets and Liabilities

The tax effects of significant temporary differences giving rise to deferred tax assets and liabilities were as follows:


	Year Ended December 31,
(in millions)	2025		2024

Deferred tax assets
Employee benefit accruals	$	38	$	40
Inventory	12		19
Miscellaneous accruals	36		50
Other	35		44
Lease right-of-use liability	33		39
Net unrealized gains/losses included in AOCI	57		—
Foreign tax credit and R&D carryforward	11		41
Tax loss carryforwards and other tax attributes	2,132		1,554
Total deferred tax assets	$	2,354	$	1,787
Less: Valuation allowances	(2,103)		(1,503)
Total deferred tax assets, net	$	251	$	284

Deferred tax liabilities
Identifiable intangible assets	$	(60)	$	(110)
Property, plant and equipment	(35)		(28)
Lease right-of-use asset	(32)		(38)
Net unrealized gains/losses included in AOCI	—		(9)
Taxes on unremitted earnings of foreign subsidiaries	(7)		(6)
Total deferred tax liabilities	(134)		(191)
Net deferred tax assets (liabilities)	$	117	$	93

Schedule of Deferred Tax Assets and Liabilities Included in the Consolidated Balance Sheet

Deferred tax assets and liabilities included in the following Consolidated Balance Sheets line items at December 31 were as follows:


	Year Ended December 31,
(in millions)	2025		2024

Assets
Other noncurrent assets	$	211	$	222
Liabilities
Deferred income taxes	$	94	$	129

Schedule of Unrecognized Tax Benefits

The activity recorded for unrecognized tax benefits were as follows:


	Year Ended December 31,
(in millions)	2025		2024		2023

Unrecognized tax benefits at beginning of period	$	128	$	132	$	49
Gross change for prior-period positions	1		18		1
Gross change for current year positions	1		1		95
Decrease due to settlements and payments	(1)		(13)		(9)
Decrease due to statute expirations	(1)		—		(4)
Increase due to effect of foreign currency translation	15		—		—
Decrease due to effect from foreign currency translation and other	—		(10)		—

Unrecognized tax benefits at end of period	$	143	$	128	$	132

Schedule of Cash Paid During the Period for Taxes, Net of Refunds

Cash paid during the year ended December 31, 2025 for income taxes, net of refunds after adoption of ASU 2023-09 is as follows:


	Year Ended December 31,
(in millions)	2025

Federal	$	(6)
State and local jurisdictions	—
Foreign:
Brazil	4
France	5
Germany	(6)
Italy	11
Russia	5
Sweden	30
Switzerland	10
Other	18
Total	$	71

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Dec. 31, 2025
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

INCOME TAXES - SCHEDULE OF CASH PAID FOR INCOME TAXES (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Effective Income Tax Rate Reconciliation [Line Items]
Federal	$ (6)
State and local jurisdictions	0
Foreign:
Total	71	$ 74	$ 177
Brazil
Foreign:
Income tax paid, foreign	4
France
Foreign:
Income tax paid, foreign	5
Germany
Foreign:
Income tax paid, foreign	(6)
Italy
Foreign:
Income tax paid, foreign	11
Russia
Foreign:
Income tax paid, foreign	5
Sweden
Foreign:
Income tax paid, foreign	30
Switzerland
Foreign:
Income tax paid, foreign	10
Other
Foreign:
Income tax paid, foreign	$ 18

COMPREHENSIVE LOSS

12 Months Ended

Dec. 31, 2025

Other Comprehensive Income (Loss), Net of Tax [Abstract]

COMPREHENSIVE LOSS

Accumulated Other Comprehensive Income (“AOCI”) includes cumulative foreign currency translation adjustments related to consolidation of the Company’s foreign subsidiaries, fair value adjustments related to the Company’s derivative financial instruments, and actuarial gains and losses related to the Company’s pension plans. These changes are recorded in AOCI, net of tax. For the years ended December 31, 2025, 2024 and 2023, these tax adjustments were $178 million, $118 million and $166 million, respectively, primarily related to foreign currency translation adjustments.

The cumulative foreign currency translation adjustments included translation losses of $289 million and $552 million at December 31, 2025 and 2024, respectively, and included losses of $145 million and $67 million, at December 31, 2025 and 2024, respectively, on loans designated as hedges of net investments.

Changes in AOCI, net of tax, by component for the years ended December 31, 2025 and 2024 were as follows:


(in millions)	Foreign Currency Translation Loss		(Loss) Gain on Cash Flow Hedges		(Loss) Gain on Net Investment and Fair Value Hedges		Pension Liability (Loss) Gain		Total

Balance, net of tax, at December 31, 2024	$	(619)	$	(10)	$	(70)	$	(31)	$	(730)
Other comprehensive income (loss) before reclassifications and tax impact	152		—		(151)		26		27
Tax benefit	33		—		33		(6)		60
Other comprehensive income (loss), net of tax, before reclassifications	$	185	$	—	$	(118)	$	20	$	87
Amounts reclassified from accumulated other comprehensive income, net of tax	—		3		—		1		4
Net increase (decrease) in other comprehensive income	185		3		(118)		21		91

Balance, net of tax, at December 31, 2025	$	(434)	$	(7)	$	(188)	$	(10)	$	(639)


(in millions)	Foreign Currency Translation (Loss) Gain		(Loss) Gain on Cash Flow Hedges		(Loss) Gain on Net Investment and Fair Value Hedges		Pension Liability (Loss) Gain		Total

Balance, net of tax, at December 31, 2023	$	(473)	$	(13)	$	(107)	$	(43)	$	(636)
Other comprehensive (loss) income before reclassifications and tax impact	(113)		—		48		15		(50)
Tax expense	(33)		—		(11)		(4)		(48)
Other comprehensive (loss) income, net of tax, before reclassifications	$	(146)	$	—	$	37	$	11	$	(98)
Amounts reclassified from accumulated other comprehensive income, net of tax	—		3		—		1		4
Net (decrease) increase in other comprehensive income	(146)		3		37		12		(94)

Balance, net of tax, at December 31, 2024	$	(619)	$	(10)	$	(70)	$	(31)	$	(730)

Reclassification out of AOCI to the Consolidated Statements of Operations for the years ended December 31, 2025, 2024 and 2023 were as follows:



	Amounts Reclassified from AOCI						Affected Line Item in the Consolidated Statements of Operations
	Year Ended December 31,
(in millions)	2025		2024		2023




(Loss) Gain on derivative financial instruments:
Interest rate swaps	$	(3)	(3)		(3)		Interest expense, net
Foreign exchange forward contracts	—		—		(1)		Cost of products sold


Net loss before tax	$	(3)	$	(3)	$	(4)
Tax impact	—		—		—		Provision (benefit) for income taxes
Net loss after tax	$	(3)	$	(3)	$	(4)






Amortization of defined benefit pension and other postemployment benefit items: (a)
Amortization of prior service benefits	$	1	1		1

Amortization of net actuarial losses	(1)		—		—
Net income (loss) before tax	$	—	$	1	$	1
Tax impact	—		—		—		Provision (benefit) for income taxes
Net income (loss) after tax	$	—	$	1	$	1

Total reclassifications for the period	$	(3)	$	(2)	$	(3)

(a) These AOCI components are included in the computation of net periodic benefit cost for the years ended December 31, 2025, 2024 and 2023, respectively.

SIGNIFICANT ACCOUNTING POLICIES - SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT (Details)	Dec. 31, 2025
Minimum \| Buildings
Property, Plant and Equipment [Line Items]
Useful life (in years)	25 years
Minimum \| Machinery and Equipment
Property, Plant and Equipment [Line Items]
Useful life (in years)	2 years
Minimum \| Capitalized Software
Property, Plant and Equipment [Line Items]
Useful life (in years)	3 years
Maximum \| Buildings
Property, Plant and Equipment [Line Items]
Useful life (in years)	40 years
Maximum \| Machinery and Equipment
Property, Plant and Equipment [Line Items]
Useful life (in years)	20 years
Maximum \| Capitalized Software
Property, Plant and Equipment [Line Items]
Useful life (in years)	10 years

PROPERTY, PLANT AND EQUIPMENT, NET (Tables)

12 Months Ended

Dec. 31, 2025

Property, Plant and Equipment [Abstract]

Schedule of Property, Plant and Equipment, Net

Except for leasehold improvements, depreciation and amortization is computed by the straight-line method over the assets estimated useful lives:


Property, Plant and Equipment Assets Type						Useful Life

Buildings						25 to 40 years
Machinery and Equipment						2 to 20 years
Capitalized Software						3 to 10 years
Leasehold Improvements						Shorter of the estimated useful life or the term of the lease

Property, plant and equipment, net, were as follows:


	Year Ended December 31,
(in millions)	2025		2024

Land	$	52	$	46
Buildings and improvements	638		571
Machinery and equipment	995		887
Capitalized software	614		516
Construction in progress	134		87
	$	2,433	$	2,107
Less: Accumulated depreciation and amortization	1,572		1,341
Property, plant and equipment, net	$	861	$	766

COMPREHENSIVE LOSS - ADDITIONAL INFORMATION (Details) - USD ($) $ in Millions	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Accumulated Other Comprehensive Income (Loss) [Line Items]
Foreign currency tax adjustments	$ 178	$ 118	$ 166
Stockholders' equity	(1,340)	(1,943)	$ (3,294)	$ (3,812)
Accumulated foreign currency adjustment, translation gain (loss)
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stockholders' equity	289	552
Accumulated foreign currency adjustment, net investments hedges
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stockholders' equity	$ 145	$ 67

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480870/815-30-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480870/815-30-50-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480870/815-30-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480870/815-30-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482765/220-10-50-4

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482765/220-10-50-5

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481674/830-30-50-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 17
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481694/830-30-45-17

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 20
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481694/830-30-45-20

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 20
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481694/830-30-45-20

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 20
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481694/830-30-45-20

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 20
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481694/830-30-45-20

+ Details

- Definition

Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 9
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479343/105-10-65-9

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 9
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479343/105-10-65-9

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 17
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480336/718-10-65-17

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 944
-SubTopic 605
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477548/944-605-55-14

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 944
-SubTopic 605
-Name Accounting Standards Codification
-Section 55
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477548/944-605-55-11

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 848
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (a)(3)(iii)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483550/848-10-65-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 842
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 8
-Subparagraph (c)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479832/842-10-65-8

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483421/250-10-45-24

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 23
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483421/250-10-45-23

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 5
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483421/250-10-45-5

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 326
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 5
-Subparagraph (c)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479654/326-10-65-5

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480528/815-20-65-6

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (h)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480528/815-20-65-6

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (h)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480528/815-20-65-6

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (h)(1)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480528/815-20-65-6

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (h)(1)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480528/815-20-65-6

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (i)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480528/815-20-65-6

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479343/105-10-65-6

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479343/105-10-65-6

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (f)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (f)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 8
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482615/740-10-65-8

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 8
-Subparagraph (d)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482615/740-10-65-8

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 326
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479654/326-10-65-4

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-7

Reference 38: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482765/220-10-50-5

Reference 39: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481674/830-30-50-1

Reference 40: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 17
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481694/830-30-45-17

Reference 41: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 20
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481694/830-30-45-20

Reference 42: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-11

Reference 43: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 205
-Name Accounting Standards Codification
-Section 45
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478009/946-205-45-3

Reference 44: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478448/946-505-50-3

Reference 45: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(19))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

Reference 46: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.6-05(4))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2

Reference 47: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(4)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 48: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(6))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 49: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(7))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 50: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

Reference 51: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 52: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 53: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481231/810-10-45-15

Reference 54: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 16
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481231/810-10-45-16

Reference 55: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4I
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I

Reference 56: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476166/350-60-65-1

Reference 57: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (f)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481538/470-20-65-4

+ Details

BENEFIT PLANS - SCHEDULE OF AMOUNTS RECOGNIZED IN ACCUMULATED OTHER COMPREHENSIVE INCOME (Details) - USD ($) $ in Millions	Dec. 31, 2025	Dec. 31, 2024
Retirement Benefits [Abstract]
Net actuarial loss	$ 5	$ 30
Net prior service cost	(2)	(3)
Before tax AOCI	3	27
Less: Deferred taxes (benefit)	(2)	4
Net of tax AOCI	$ 5	$ 23

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Statement of Comprehensive Income [Abstract]
Net loss	$ (598)	$ (910)	$ (132)
Other comprehensive income (loss), net of tax:
Foreign currency translation adjustments	185	(146)	49
Net (loss) gain on derivative financial instruments	(115)	40	(30)
Pension liability adjustments	21	12	(27)
Total other comprehensive income (loss)	91	(94)	(8)
Total comprehensive loss	(507)	(1,004)	(140)
Less: Comprehensive (loss) income attributable to noncontrolling interests	0	0	0
Total comprehensive loss attributable to Dentsply Sirona	$ (507)	$ (1,004)	$ (140)

PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details) - USD ($) $ in Millions	Dec. 31, 2025	Dec. 31, 2024
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid expenses	$ 140	$ 121
Value-added tax receivable	49	50
Deposits	28	30
Other current assets	150	153
Prepaid expenses and other current assets	$ 367	$ 354

INVENTORIES, NET - SCHEDULE OF INVENTORIES, NET (Details) - USD ($) $ in Millions	Dec. 31, 2025	Dec. 31, 2024
Inventory Disclosure [Abstract]
Raw materials and supplies	$ 199	$ 172
Work-in-process	82	72
Finished goods	361	320
Inventories, net	$ 642	$ 564

SIGNIFICANT ACCOUNTING POLICIES - SCHEDULE OF WARRANTIES (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Accounting Policies [Abstract]
Warranty Expense	$ 28	$ 32	$ 48
Warranty Accrual	$ 18	$ 21	$ 24

SEGMENT AND GEOGRAPHIC INFORMATION - CONCENTRATION RISK (Details) - Customer Concentration Risk	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2023
Henry Schein, Inc. \| % of net sales
Concentration Risk [Line Items]
Concentration risk, percentage	13.00%	14.00%
Henry Schein, Inc. \| % of accounts receivable
Concentration Risk [Line Items]
Concentration risk, percentage		11.00%
Patterson Companies, Inc. \| % of accounts receivable
Concentration Risk [Line Items]
Concentration risk, percentage	11.00%	10.00%

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 275
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-18

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 275
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-18

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 275
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 20
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-20

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 275
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-18

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 275
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-18

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 275
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-18

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 275
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 18
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482836/275-10-55-18

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 275
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 20
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-20

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 954
-SubTopic 310
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478785/954-310-50-2

+ Details

- Definition

For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.

+ References + Details

INVENTORIES, NET (Tables)

12 Months Ended

Dec. 31, 2025

Inventory Disclosure [Abstract]

Schedule of Inventories, Net

Inventories, net were as follows:


	Year Ended December 31,
(in millions)	2025		2024

Raw materials and supplies	$	199	$	172
Work-in-process	82		72
Finished goods	361		320


Inventories, net	$	642	$	564

INCOME TAXES - ADDITIONAL INFORMATION (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Income Taxes [Line Items]
Tax credit carryforwards	$ 11
Tax loss carryforward	10,187
Deferred tax assets, operating loss carryforward	2,015	$ 1,458
Deferred tax asset, interest carryforward	117	96
Translation Adjustment	1,992
Change in valuation allowance for deferred tax asset	106
Withholding taxes on undistributed earnings of foreign subsidiaries	7
The total gross unrecognized tax benefits	152
Unrecognized tax benefits, if recognized, would affect the effective income tax rate	52
The total amount of accrued interest and penalties	9	9
Recognized income tax expense, interest and penalties	2	5
Income taxes paid, net of refunds	71	$ 74	$ 177
Foreign Tax Credits Expiring Future Years
Income Taxes [Line Items]
Tax credit carryforwards	9,775
Without Expiry Date
Income Taxes [Line Items]
Tax credit carryforwards	412
Foreign
Income Taxes [Line Items]
Tax credit valuation allowance	$ 5

COMPREHENSIVE LOSS (Tables)

12 Months Ended

Dec. 31, 2025

Other Comprehensive Income (Loss), Net of Tax [Abstract]

Schedule of Accumulated Other Comprehensive Income (Loss)

Changes in AOCI, net of tax, by component for the years ended December 31, 2025 and 2024 were as follows:


(in millions)	Foreign Currency Translation Loss		(Loss) Gain on Cash Flow Hedges		(Loss) Gain on Net Investment and Fair Value Hedges		Pension Liability (Loss) Gain		Total

Balance, net of tax, at December 31, 2024	$	(619)	$	(10)	$	(70)	$	(31)	$	(730)
Other comprehensive income (loss) before reclassifications and tax impact	152		—		(151)		26		27
Tax benefit	33		—		33		(6)		60
Other comprehensive income (loss), net of tax, before reclassifications	$	185	$	—	$	(118)	$	20	$	87
Amounts reclassified from accumulated other comprehensive income, net of tax	—		3		—		1		4
Net increase (decrease) in other comprehensive income	185		3		(118)		21		91

Balance, net of tax, at December 31, 2025	$	(434)	$	(7)	$	(188)	$	(10)	$	(639)


(in millions)	Foreign Currency Translation (Loss) Gain		(Loss) Gain on Cash Flow Hedges		(Loss) Gain on Net Investment and Fair Value Hedges		Pension Liability (Loss) Gain		Total

Balance, net of tax, at December 31, 2023	$	(473)	$	(13)	$	(107)	$	(43)	$	(636)
Other comprehensive (loss) income before reclassifications and tax impact	(113)		—		48		15		(50)
Tax expense	(33)		—		(11)		(4)		(48)
Other comprehensive (loss) income, net of tax, before reclassifications	$	(146)	$	—	$	37	$	11	$	(98)
Amounts reclassified from accumulated other comprehensive income, net of tax	—		3		—		1		4
Net (decrease) increase in other comprehensive income	(146)		3		37		12		(94)

Balance, net of tax, at December 31, 2024	$	(619)	$	(10)	$	(70)	$	(31)	$	(730)

Schedule of Reclassification out of Accumulated Other Comprehensive Income

Reclassification out of AOCI to the Consolidated Statements of Operations for the years ended December 31, 2025, 2024 and 2023 were as follows:



	Amounts Reclassified from AOCI						Affected Line Item in the Consolidated Statements of Operations
	Year Ended December 31,
(in millions)	2025		2024		2023




(Loss) Gain on derivative financial instruments:
Interest rate swaps	$	(3)	(3)		(3)		Interest expense, net
Foreign exchange forward contracts	—		—		(1)		Cost of products sold


Net loss before tax	$	(3)	$	(3)	$	(4)
Tax impact	—		—		—		Provision (benefit) for income taxes
Net loss after tax	$	(3)	$	(3)	$	(4)






Amortization of defined benefit pension and other postemployment benefit items: (a)
Amortization of prior service benefits	$	1	1		1

Amortization of net actuarial losses	(1)		—		—
Net income (loss) before tax	$	—	$	1	$	1
Tax impact	—		—		—		Provision (benefit) for income taxes
Net income (loss) after tax	$	—	$	1	$	1

Total reclassifications for the period	$	(3)	$	(2)	$	(3)

(a) These AOCI components are included in the computation of net periodic benefit cost for the years ended December 31, 2025, 2024 and 2023, respectively.

Subsequent Events (Details) - Subsequent Event $ in Millions	Feb. 24, 2026 USD ($)
Minimum
Subsequent Event [Line Items]
Expected cost	$ 55
Maximum
Subsequent Event [Line Items]
Expected cost	$ 65

EQUITY (Tables)

12 Months Ended

Dec. 31, 2025

Equity [Abstract]

Schedule of Accelerated Share Repurchases


(in millions, except per share amounts)			Initial Delivery					Final Settlement
Agreement Date	Amount Paid		Shares Received	Price per share		Value of Shares as a % of Contract Value		Settlement Date	Total Shares Received	Average Price per Share
March 3, 2023	$	150	3.1	$	38.74	80	%	April 28, 2023	3.9	$	38.55

Schedule of Total Outstanding Shares

Total outstanding shares of common stock and treasury stock were as follows:


(in millions)	Shares of Common Stock	Shares of Treasury Stock	Outstanding Shares

Balance at December 31, 2022	264.5	(49.3)	215.2

Shares of treasury stock issued	—	0.8	0.8
Repurchase of common stock at an average cost of $34.20	—	(8.8)	(8.8)

Balance at December 31, 2023	264.5	(57.3)	207.2

Shares of treasury stock issued	—	1.0	1.0
Repurchase of common stock at an average cost of $26.65	—	(9.4)	(9.4)

Balance at December 31, 2024	264.5	(65.7)	198.8
Shares of treasury stock issued	—	0.8	0.8


Balance at December 31, 2025	264.5	(64.9)	199.6

SIGNIFICANT ACCOUNTING POLICIES (Tables)

12 Months Ended

Dec. 31, 2025

Accounting Policies [Abstract]

Schedule of Intangible Assets

The Company uses the following useful lives for its definite-lived intangible assets:


Definite-Lived Intangible Asset Type						Useful Life

Patents						Up to the date the patent expires
Trade names and trademarks						Up to 20 years
Licensing agreements						Up to 20 years
Customer relationships						Up to 15 years
Developed technology						Up to 15 years

Schedule of Property, Plant and Equipment

Except for leasehold improvements, depreciation and amortization is computed by the straight-line method over the assets estimated useful lives:


Property, Plant and Equipment Assets Type						Useful Life

Buildings						25 to 40 years
Machinery and Equipment						2 to 20 years
Capitalized Software						3 to 10 years
Leasehold Improvements						Shorter of the estimated useful life or the term of the lease

Property, plant and equipment, net, were as follows:


	Year Ended December 31,
(in millions)	2025		2024

Land	$	52	$	46
Buildings and improvements	638		571
Machinery and equipment	995		887
Capitalized software	614		516
Construction in progress	134		87
	$	2,433	$	2,107
Less: Accumulated depreciation and amortization	1,572		1,341
Property, plant and equipment, net	$	861	$	766

Schedule of Warranty Expense and Accrual

The Company’s warranty expense and warranty accrual were as follows:


	December 31,
(in millions)	2025		2024		2023

Warranty Expense	$	28	$	32	$	48
Warranty Accrual	18		21		24

LEASES - CONTRACTUAL MATURITY DATES (Details) $ in Millions	Dec. 31, 2025 USD ($)
Operating Leases
2026	$ 52
2027	38
2028	26
2029	17
2030	9
2031 and beyond	12
Total lease payments	154
Less imputed interest	14
Present value of lease liabilities	$ 140

FINANCIAL INSTRUMENTS AND DERIVATIVES

12 Months Ended

Dec. 31, 2025

Derivative Instruments and Hedging Activities Disclosure [Abstract]

FINANCIAL INSTRUMENTS AND DERIVATIVES

Derivative Instruments and Hedging Activities

The Company’s activities expose it to a variety of market risks, which primarily include the risks related to the effects of changes in foreign currency exchange rates and interest rates. These financial exposures are monitored and managed by the Company as part of its overall risk management program. The objective of this risk management program is to reduce the volatility that these market risks may have on the Company’s operating results. The Company employs derivative financial instruments to hedge certain anticipated transactions, firm commitments, or assets and liabilities denominated in foreign currencies. Additionally, the Company utilizes interest rate swaps to convert fixed rate debt into variable rate debt or vice versa. The Company does not hold derivative instruments for trading or speculative purposes.

The following summarizes the notional amounts of hedges of net investments, fair value hedges, and derivative instruments not designated as hedges for accounting purposes by derivative instrument type at December 31, 2025 and the notional amounts expected to mature during the next 12 months.


	Aggregate Notional Amount		Aggregate Notional Amount Maturing within 12 Months

(in millions)







Hedges of Net Investments
Foreign exchange forward contracts	$	804	$	299
Cross currency basis swaps	1,413		—
Total derivative instruments designated as hedges of net investments	$	2,217	$	299

Fair Value Hedges

Interest rate swaps	150		—
Total derivative instruments designated as fair value hedges	$	150	$	—

Derivative Instruments not Designated as Hedges
Foreign exchange forward contracts	$	1,026	$	1,026

Total derivative instruments not designated as hedges	$	1,026	$	1,026

Hedges of Net Investments in Foreign Operations

The Company has significant investments in foreign subsidiaries. The net assets of these subsidiaries are exposed to volatility in foreign currency exchange rates. The Company employs both derivative and non-derivative financial instruments to hedge a portion of these exposures. The derivative instruments consist of foreign exchange forward contracts and cross-currency basis swaps. The non-derivative instruments consist of foreign currency-denominated debt held at the parent company level. Translation gains and losses related to the net assets of the foreign subsidiaries are offset by gains and losses in the aforementioned instruments, which are designated as hedges of net investments, and the intrinsic value changes in these instruments are recorded on AOCI, net of tax effects. The time-value component of the fair value of the derivative instrument is amortized on a straight-line basis in Other (income) expense, net in the Consolidated Statements of Operations in the applicable period. Any cash flows associated with these instruments are included in investing activities in the Consolidated Statements of Cash Flows, except for derivative instruments that include an other-than-insignificant financing element, for which all cash flows are classified as financing activities in the Consolidated Statements of Cash Flows.

The fair value of the foreign currency exchange forward contracts and cross-currency basis swaps is the estimated amount the Company would receive or pay at the reporting date, taking into account the effective interest rates and foreign exchange rates. The effective portion of the change in the value of these derivatives is recorded in AOCI, net of tax effects.

On July 2, 2021, the Company entered into a cross-currency basis swap of a notional amount of $300 million, which matures on June 3, 2030. The cross-currency basis swap is designated as a hedge of net investments. This contract effectively converts a portion of the $750 million bond coupon from 3.3% to 1.7%.

On May 25, 2021, the Company re-established its euro net investment hedge portfolio by entering into eight foreign exchange forward contracts, each with a notional amount of 10 million euro. The original contracts have quarterly maturity dates through March 2023, and the Company entered into additional foreign exchange contracts as individual contracts within the portfolio matured. As of December 31, 2025, the euro net investment hedge portfolio has an aggregate notional value of 40 million euro with maturity dates through December 2026.

On July 20, 2023, the Company entered into a Swiss franc foreign exchange forward contract designated as a net investment hedge. The foreign exchange forward contract had a notional amount of 600 million Swiss francs. This net investment hedge was settled in September 2023 which resulted in cash receipts totaling $32 million. The Company subsequently entered into Swiss franc foreign exchange contracts designated as net investment hedges with a total notional amount of 600 million Swiss francs. This portfolio of contracts has semi-annual maturity dates through July 2028.

On July 1, 2025, the Company entered into a series of USD to CHF cross-currency basis swaps with a total notional

amount of $1.1 billion. The cross-currency basis swaps were designated as a hedge of net investments at inception. The maturity dates are $550 million in 2030, $275 million in 2032, and $275 million in 2035.

Fair Value Hedges

Interest Rate Risk Management

On July 1, 2021, the Company entered into variable interest rate swaps with a notional amount of $250 million, which effectively converted a portion of the underlying fixed rate of 3.3% on the $750 million Senior Notes due June 2030 to a variable interest rate. Of the $250 million notional amount, $100 million has a term of five-years maturing on June 1, 2026 and $150 million has a term of nine years maturing on March 1, 2030.

On February 13, 2024, the Company paid $9 million to settle the variable interest rate swap with a notional amount of $100 million which was originally set to mature on June 1, 2026. This closure of the interest rate swap will result in a loss of $8 million being amortized over the remaining life of the Senior Notes due June 2030.

Derivative Instruments Not Designated as Hedges

The Company enters into derivative instruments with the intent to partially mitigate the foreign exchange revaluation risk associated with recorded assets and liabilities that are denominated in a non-functional currency. The Company primarily uses foreign exchange forward contracts to hedge these risks. The gains and losses on these derivative transactions offset the gains and losses generated by the revaluation of the underlying non-functional currency balances and are recorded in Other (income) expense, net in the Consolidated Statements of Operations. Any cash flows associated with these instruments are included in operating activities in the Consolidated Statements of Cash Flows.

Derivative Instrument Activity

The effects of derivative hedging instruments on the Consolidated Statements of Operations and Consolidated Statements of Comprehensive Loss were as follows:


	Year Ended December 31, 2025						Year Ended December 31, 2024						Year Ended December 31, 2023
(in millions)	Cost of products sold		Interest expense, net		Other (income) expense, net		Cost of products sold		Interest expense, net		Other (income) expense, net		Cost of products sold		Interest expense, net		Other (income) expense, net

Total amounts of line items presented in the Consolidated Statements of Operations in which the effects of cash flow, net investment or fair value hedges are recorded	$	1,840	$	88	$	(24)	$	1,835	$	69	$	(12)	$	1,879	$	81	$	9





Gain on Hedges of Net Investment
Cross currency basis swaps	$	—	$	—	$	(23)	$	—	$	—	$	(5)	$	—	$	—	$	(5)
Foreign exchange forward contracts	—		—		(25)		—		—		(25)		—		—		(12)

Loss on Fair Value Hedges:
Interest rate swaps	$	—	$	6	$	—	$	—	$	8	$	—	$	—	$	11	$	—
Foreign exchange forward contracts	—		—		—		—		—		—		—		—		—

Loss on Derivative Instruments not Designated as Hedges
Foreign exchange forward contracts	$	—	$	—	$	12	$	—	$	—	$	2	$	—	$	—	$	8


	Amount of Gain or (Loss) Recognized in AOCI							Amount of Gain or (Loss) Reclassified from AOCI into Income
	Year Ended December 31,						Consolidated Statements of Operations Location	Year Ended December 31,
(in millions)	2025		2024		2023			2025		2024		2023







Hedges of Net Investments
Cross currency basis swaps	$	(49)	$	11	$	(18)	Other (income) expense, net	$	—	$	—	$	—
Foreign exchange forward contracts	(102)		37		(29)		Other (income) expense, net	—		—		—


Fair Value Hedges
Interest rate swaps	$	—	$	—	$	—	Other (income) expense, net	$	—	$	—	$	—
Foreign exchange forward contracts	—		—		2		Interest expense, net	—		—		—

Consolidated Balance Sheets Location of Derivative Fair Values

The fair value and the location of the Company’s derivatives in the Consolidated Balance Sheets were as follows:


	Year Ended December 31, 2025
(in millions)	Prepaid Expenses and Other Current Assets		Other Noncurrent Assets		Accrued Liabilities		Other Noncurrent Liabilities

Designated as Hedges:
Foreign exchange forward contracts	$	—	$	—	$	21	$	40

Interest rate swaps	—		—		3		11
Cross currency basis swaps	42		—		—		73
Total	$	42	$	—	$	24	$	124

Not Designated as Hedges:
Foreign exchange forward contracts	$	8	$	—	$	6	$	—



Total	$	8	$	—	$	6	$	—


	Year Ended December 31, 2024
(in millions)	Prepaid Expenses and Other Current Assets		Other Noncurrent Assets		Accrued Liabilities		Other Noncurrent Liabilities

Designated as Hedges:
Foreign exchange forward contracts	$	5	$	9	$	—	$	1

Interest rate swaps	—		—		4		17
Cross currency basis swaps	4		14		—		—
Total	$	9	$	23	$	4	$	18

Not Designated as Hedges:
Foreign exchange forward contracts	$	4	$	—	$	8	$	—



Total	$	4	$	—	$	8	$	—

Balance Sheet Offsetting

Substantially all of the Company’s derivative contracts are subject to netting arrangements, whereby the right to offset occurs in the event of default or termination in accordance with the terms of the arrangements with the counterparty. While these contracts contain the enforceable right to offset through netting arrangements with the same counterparty, the Company elects to present them on a gross basis in the Consolidated Balance Sheets.

Offsetting of financial assets and liabilities under netting arrangements at December 31, 2025 was as follows:


							Gross Amounts Not Offset in the Consolidated Balance Sheets
(in millions)	Gross Amounts Recognized		Gross Amounts Offset in the Consolidated Balance Sheets		Net Amounts Presented in the Consolidated Balance Sheets		Financial Instruments		Cash Collateral Received/Pledged		Net Amount

Assets
Foreign exchange forward contracts	$	8	$	—	$	8	$	(8)	$	—	$	—


Cross currency basis swaps	42		—		42		(42)		—		—

Total assets	$	50	$	—	$	50	$	(50)	$	—	$	—

Liabilities
Foreign exchange forward contracts	$	67	$	—	$	67	$	(18)	$	—	$	49


Interest rate swaps	14		—		14		—		—		14
Cross currency basis swaps	73		—		73		(32)		—		41
Total liabilities	$	154	$	—	$	154	$	(50)	$	—	$	104

Offsetting of financial assets and liabilities under netting arrangements at December 31, 2024 were as follows:


							Gross Amounts Not Offset in the Consolidated Balance Sheets
(in millions)	Gross Amounts Recognized		Gross Amounts Offset in the Consolidated Balance Sheets		Net Amounts Presented in the Consolidated Balance Sheets		Financial Instruments		Cash Collateral Received/Pledged		Net Amount

Assets
Foreign exchange forward contracts	$	18	$	—	$	18	$	(5)	$	—	$	13


Cross currency basis swaps	18		—		18		(6)		—		12
Total assets	$	36	$	—	$	36	$	(11)	$	—	$	25

Liabilities
Foreign exchange forward contracts	$	9	$	—	$	9	$	(4)	$	—	$	5
Interest rate swaps	21		—		21		(7)		—		14



Total liabilities	$	30	$	—	$	30	$	(11)	$	—	$	19

- Definition

The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 182
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480401/815-10-55-182

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 185
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480401/815-10-55-185

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 184
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480401/815-10-55-184

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 181
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480401/815-10-55-181

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4K
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4K

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4K
-Subparagraph (a)(5)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4K

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4K
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4K

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4K
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4K

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4K
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4K

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4H
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4H

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4H
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4H

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 15
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480960/815-15-50-3

Reference 13: http://www.xbrl.org/2003/role/exampleRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 183
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480401/815-10-55-183

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4K
-Subparagraph (a)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4K

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4K
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4K

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4K
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4K

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4I
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4I

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4F
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4F

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-2

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-2

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-2

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-2

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-1B

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/815/tableOfContent

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480237/815-40-50-5

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5C
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-5C

+ Details

RESTRUCTURING AND OTHER COSTS - SCHEDULE OF IMPACT OF THESE CHARGES RELATED TO BYTE REALIGNMENT (Details) - Byte Aligner Systems - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2025	Dec. 31, 2024
Total impact on operating loss
Restructuring Cost and Reserve [Line Items]
Charges related to the Byte Realignment	$ (222)
Net sales
Restructuring Cost and Reserve [Line Items]
Charges related to the Byte Realignment	(35)	$ 14	$ (35)
Cost of products sold
Restructuring Cost and Reserve [Line Items]
Charges related to the Byte Realignment	(8)
Selling, general, and administrative expenses, Intangible asset impairment - trademark
Restructuring Cost and Reserve [Line Items]
Charges related to the Byte Realignment	(152)
Selling, general, and administrative expenses, Property, plant and equipment write-off
Restructuring Cost and Reserve [Line Items]
Charges related to the Byte Realignment	(17)
Selling, general, and administrative expenses, Accounts receivable reserve and prepaid write-off
Restructuring Cost and Reserve [Line Items]
Charges related to the Byte Realignment	$ (10)

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References + Details

SEGMENT AND GEOGRAPHIC INFORMATION - ADDITIONAL INFORMATION (Details)	12 Months Ended
	Dec. 31, 2025 segment
Segment Reporting [Abstract]
Number of operating segments	4
Number of reportable segments	4

OTHER (INCOME) EXPENSE, NET - SCHEDULE OF OTHER (INCOME) EXPENSE, NET (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Other Income and Expenses [Abstract]
Foreign exchange transaction (gain)	$ (32)	$ (21)	$ (3)
Other expense, net	8	9	12
Total other (income) expense, net	$ (24)	$ (12)	$ 9

REVENUE RECOGNITION - ADDITIONAL INFORMATION (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Revenue from Contract with Customer [Abstract]
Deferred income	$ 74	$ 95
Deferred revenue, noncurrent	33	49
Deferred revenue recognized during the year	111	79
Allowances for doubtful accounts and trade discounts	$ 12	$ 14

INCOME TAXES

12 Months Ended

Dec. 31, 2025

Income Tax Disclosure [Abstract]

INCOME TAXES

The components of loss before income taxes were as follows:


	Year Ended December 31,
(in millions)	2025		2024		2023

United States	$	(120)	$	(307)	$	(6)
Foreign	(366)		(629)		(169)
Total loss before income taxes	$	(486)	$	(936)	$	(175)

The components of the expense (benefit) for income taxes from operations were as follows:


	Year Ended December 31,
(in millions)	2025		2024		2023

Current:
U.S. federal	$	(1)	$	(6)	$	1
U.S. state	2		1		—
Foreign	81		115		86
Total	$	82	$	110	$	87

Deferred:
U.S. federal	$	36	$	(61)	$	4
U.S. state	2		(1)		(3)
Foreign	(8)		(74)		(131)
Total	$	30	$	(136)	$	(130)

Total expense (benefit) for income taxes	$	112	$	(26)	$	(43)

For the year ended December 31, 2025, the reconciliation of the U.S. federal statutory tax rate to the effective rate was as follows:


	Year Ended December 31,
(in millions, except percentages)	2025

Statutory U.S. federal income tax rate	$	(102)	21.0	%
Effect of:
State income taxes, net of federal benefit(a)	3		(0.6)	%
Foreign tax effects
Germany
Statutory income tax rate differential	16		(3.3)	%
Trade tax	(18)		3.7	%
Changes in valuation allowances	16		(3.3)	%
Goodwill impairment	8		(1.6)	%
Other	2		(0.4)	%
Israel
Statutory income tax rate differential	16		(3.3)	%
Goodwill impairment	18		(3.7)	%
Other	(4)		0.8	%
Luxembourg
Changes in valuation allowance	238		(48.9)	%
Local impairment losses	(250)		51.3	%
Foreign exchange differences	11		(2.3)	%
Other	3		(0.6)	%
Sweden
Goodwill impairment	26		(5.3)	%
Other	2		(0.4)	%
Switzerland
Statutory income tax rate differential	(21)		4.3	%
Cantonal tax	28		(5.7)	%
Changes in valuation allowances	55		(11.3)	%
Foreign exchange differences	(4)		0.8	%
Local impairment losses	(38)		7.8	%
Other foreign jurisdictions and consolidated eliminations	39		(8.0)	%

Effect of cross-border tax laws
Global Intangible Low Taxed Income (GILTI)	7		(1.5)	%
Subpart F	8		(1.7)	%
Other cross-border	2		(0.4)	%
Tax credits	2		(0.4)	%

Non-taxable or non-deductible items
Goodwill impairment	24		(4.9)	%
Share-based payment awards	6		(1.2)	%
Other non-taxable or non-deductible items	7		(1.5)	%
Changes in unrecognized tax benefits	2		(0.4)	%
Other	10		(2.1)	%
Total tax provision and effective tax rate	$	112	(23.1)	%

(a) State taxes in California, New York, Minnesota, Texas, and Florida made up the majority (greater than 50%) of the tax effect in this category.


	Year Ended December 31,
(in millions, except percentages)	2024				2023

Statutory U.S. federal income tax rate	$	(197)	21.0	%	$	(37)	21.0	%
Effect of:
State income taxes, net of federal benefit	—		—		(2)		1.4
Federal benefit of R&D and foreign tax credits	(7)		0.8		(17)		10.0
U.S. other permanent differences	3		(0.3)		5		(2.7)
Tax effect of international operations	42		(4.5)		(65)		37.2
Global Intangible Low Taxed Income (GILTI)	9		(1.0)		12		(7.0)
Foreign Derived Intangible Income (FDII)	—		—		(9)		5.2
Net effect of tax audit activity	23		(2.5)		(6)		3.2
Tax effect of enacted statutory rate changes on Non-U.S. jurisdictions	3		(0.3)		1		(0.4)
Federal tax on unremitted earnings of certain foreign subsidiaries	(1)		0.1		2		(0.9)
Valuation allowance adjustments	(13)		1.3		5		(3.2)
Tax effect of impairment of goodwill and intangibles	106		(11.3)		60		(34.6)
Other	6		(0.5)		8		(4.4)

Effective income tax rate on operations	$	(26)	2.8	%	$	(43)	24.8	%

On July 4, 2025, the One Big Beautiful Bill Act (“OBBBA”) was signed into law in the United States. The OBBBA includes significant provisions, including tax cut extensions and modifications to the international tax framework. The Company evaluated the impact of the OBBBA and concluded that its effect was not material to the financial results of the year ended December 31, 2025.

The tax effects of significant temporary differences giving rise to deferred tax assets and liabilities were as follows:


	Year Ended December 31,
(in millions)	2025		2024

Deferred tax assets
Employee benefit accruals	$	38	$	40
Inventory	12		19
Miscellaneous accruals	36		50
Other	35		44
Lease right-of-use liability	33		39
Net unrealized gains/losses included in AOCI	57		—
Foreign tax credit and R&D carryforward	11		41
Tax loss carryforwards and other tax attributes	2,132		1,554
Total deferred tax assets	$	2,354	$	1,787
Less: Valuation allowances	(2,103)		(1,503)
Total deferred tax assets, net	$	251	$	284

Deferred tax liabilities
Identifiable intangible assets	$	(60)	$	(110)
Property, plant and equipment	(35)		(28)
Lease right-of-use asset	(32)		(38)
Net unrealized gains/losses included in AOCI	—		(9)
Taxes on unremitted earnings of foreign subsidiaries	(7)		(6)
Total deferred tax liabilities	(134)		(191)
Net deferred tax assets (liabilities)	$	117	$	93

Deferred tax assets and liabilities included in the following Consolidated Balance Sheets line items at December 31 were as follows:


	Year Ended December 31,
(in millions)	2025		2024

Assets
Other noncurrent assets	$	211	$	222
Liabilities
Deferred income taxes	$	94	$	129

The Company has $11 million of tax credit carryforwards at December 31, 2025 which will expire at various times from 2028 through 2045.

The Company has tax loss carryforwards related to certain foreign and domestic subsidiaries of approximately $10,187 million at December 31, 2025, of which $9,775 million expires at various times through 2045 and $412 million may be carried forward indefinitely. These are reflected as deferred income tax assets at December 31, 2025, and are comprised of future tax benefits of $2,015 million and $117 million, before valuation allowances, related to tax loss carryforwards and disallowed interest carryforwards, respectively. As of December 31, 2024 the Company’s deferred tax assets included $1,458 million of tax loss carryforwards and $96 million of disallowed interest carryforwards. The increase in tax loss carryforwards in 2025 is primarily the result of impairment losses.

At December 31, 2025, the Company has recorded $1,992 million of valuation allowance to offset the future tax benefit of net operating losses, $5 million to offset the future tax benefit of foreign tax credits, and $106 million of valuation allowance for other deferred tax assets. The Company has recorded these valuation allowances due to the uncertainty that these assets can be realized in the future. The increase in the valuation allowance is attributable to the increase in the tax loss carryforwards as there is uncertainty that these assets can be realized in the future.

The Company has recorded $7 million of withholding taxes on certain undistributed earnings of its foreign subsidiaries that the Company anticipates will be repatriated.

Tax Contingencies

The total amount of gross unrecognized tax benefits at December 31, 2025 is approximately $152 million, including interest, of which approximately $52 million represents the amount of unrecognized tax benefits that, if recognized, would affect the effective income tax rate. It is reasonably possible that certain amounts of unrecognized tax benefits will significantly increase or decrease within twelve months of the reporting date of the Company’s consolidated financial statements.

The total amount of accrued interest and penalties was $9 million at December 31, 2025 and 2024. The Company has consistently classified interest and penalties recognized in its consolidated financial statements as income taxes based on the accounting policy election of the Company. The Company recognized a tax expense of $2 million for the year ended December 31, 2025, and a tax expense of $5 million in 2024 related to interest and penalties.

The Company is subject to U.S. federal income tax as well as income tax of multiple state and foreign jurisdictions. The significant jurisdictions include the United States and Germany. The Company has concluded all U.S. federal income tax matters for years through 2014 with the Internal Revenue Service (“IRS”). The Company is currently under IRS audit for the tax years 2015 and 2016. The Company is under audit in Germany for the tax years 2014 through 2021. For additional information on the IRS and German audits, see Note 21, Commitments and Contingencies.

The activity recorded for unrecognized tax benefits were as follows:


	Year Ended December 31,
(in millions)	2025		2024		2023

Unrecognized tax benefits at beginning of period	$	128	$	132	$	49
Gross change for prior-period positions	1		18		1
Gross change for current year positions	1		1		95
Decrease due to settlements and payments	(1)		(13)		(9)
Decrease due to statute expirations	(1)		—		(4)
Increase due to effect of foreign currency translation	15		—		—
Decrease due to effect from foreign currency translation and other	—		(10)		—

Unrecognized tax benefits at end of period	$	143	$	128	$	132

Cash Taxes

Cash paid for income taxes, net of refunds, for the years ended December 31, 2024 and 2023 prior to adoption of ASU 2023-09 was $74 million and $177 million, respectively. Cash paid during the year ended December 31, 2025 for income taxes, net of refunds after adoption of ASU 2023-09 is as follows:


	Year Ended December 31,
(in millions)	2025

Federal	$	(6)
State and local jurisdictions	—
Foreign:
Brazil	4
France	5
Germany	(6)
Italy	11
Russia	5
Sweden	30
Switzerland	10
Other	18
Total	$	71

- Definition

The entire disclosure for income tax.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 740
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477617/942-740-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 740
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478822/944-740-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 231
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482663/740-10-55-231

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 270
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477891/740-270-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.5.Q1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-13

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/740/tableOfContent

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-14

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-21

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-17

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482603/740-30-50-2

+ Details

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Dec. 31, 2025	Dec. 31, 2024
Statement of Financial Position [Abstract]
Preferred stock, par or stated value per share (in dollars per share)	$ 1.00	$ 1.00
Preferred stock, shares authorized (in shares)	250,000	250,000
Preferred stock, shares issued (in shares)	0	0
Common stock, par or stated value per share (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	400,000,000.0	400,000,000.0
Common stock, shares issued (in shares)	264,500,000	264,500,000
Common stock, shares outstanding (in shares)	199,600,000	198,800,000
Treasury stock, shares (in shares)	64,900,000	65,700,000

GOODWILL AND INTANGIBLE ASSETS - SCHEDULE OF RECONCILIATION OF CHANGES IN GOODWILL (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Goodwill [Roll Forward]
Goodwill			$ 2,661
Accumulated impairment losses		$ (1,589)	(1,064)
Balance, beginning of the year		1,597
Translation		76
Impairment		(525)	(773)	$ (291)
Balance, end of the year		1,148	1,597
Connected Technology Solutions
Goodwill [Roll Forward]
Goodwill			291
Accumulated impairment losses		(291)	(291)
Balance, beginning of the year		0
Translation		0
Impairment	$ (291)	0
Balance, end of the year		0	0
Essential Dental Solutions
Goodwill [Roll Forward]
Goodwill			829
Accumulated impairment losses		0	0
Balance, beginning of the year		829
Translation		31
Impairment		0
Balance, end of the year		860	829
Orthodontic and Implant Solutions
Goodwill [Roll Forward]
Goodwill			1,276
Accumulated impairment losses		(1,298)	(773)
Balance, beginning of the year		503
Translation		22
Impairment		(525)
Balance, end of the year		0	503
Wellspect Healthcare
Goodwill [Roll Forward]
Goodwill			265
Accumulated impairment losses		0	0
Balance, beginning of the year		265
Translation		23
Impairment		0
Balance, end of the year		$ 288	$ 265

BENEFIT PLANS - SCHEDULE OF WEIGHTED AVERAGE ASSUMPTIONS USED TO DETERMINE BENEFIT OBLIGATIONS (Details)	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Retirement Benefits [Abstract]
Interest crediting rate	2.00%	2.00%	2.30%
Discount rate	3.00%	2.50%	2.60%
Rate of compensation increase	2.40%	2.40%	2.50%

FAIR VALUE MEASUREMENT - SCHEDULE OF FINANCIAL ASSETS AND LIABILITIES THAT ARE RECORDED AT FAIR VALUE AND CLASSIFIED BASED ON THE LOWEST LEVEL OF INPUT (Details) - USD ($) $ in Millions	Dec. 31, 2025	Dec. 31, 2024
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative asset	$ 50	$ 36
Derivative liability	154	30
Recurring
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total assets	22	36
Contingent considerations on acquisitions	0	4
Total liabilities	112	34
Level 1 \| Recurring
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total assets	0	0
Contingent considerations on acquisitions	0	0
Total liabilities	0	0
Level 2 \| Recurring
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total assets	22	36
Contingent considerations on acquisitions	0	0
Total liabilities	112	30
Level 3 \| Recurring
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total assets	0	0
Contingent considerations on acquisitions	0	4
Total liabilities	0	4
Interest rate swaps
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative liability	14	21
Interest rate swaps \| Recurring
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative asset	14
Derivative liability	14	21
Interest rate swaps \| Level 1 \| Recurring
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative asset	0
Derivative liability	0	0
Interest rate swaps \| Level 2 \| Recurring
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative asset	14
Derivative liability	14	21
Interest rate swaps \| Level 3 \| Recurring
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative asset	0
Derivative liability	0	0
Foreign exchange forward contracts \| Recurring
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative asset	8	18
Derivative liability	67	9
Foreign exchange forward contracts \| Level 1 \| Recurring
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative asset	0	0
Derivative liability	0	0
Foreign exchange forward contracts \| Level 2 \| Recurring
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative asset	8	18
Derivative liability	67	9
Foreign exchange forward contracts \| Level 3 \| Recurring
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative asset	0	0
Derivative liability	0	0
Cross currency basis swaps
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative asset	42	18
Derivative liability	73
Cross currency basis swaps \| Recurring
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative asset		18
Derivative liability	31
Cross currency basis swaps \| Level 1 \| Recurring
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative asset		0
Derivative liability	0
Cross currency basis swaps \| Level 2 \| Recurring
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative asset		18
Derivative liability	31
Cross currency basis swaps \| Level 3 \| Recurring
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative asset		$ 0
Derivative liability	$ 0

FINANCIAL INSTRUMENTS AND DERIVATIVES (Tables)

12 Months Ended

Dec. 31, 2025

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of Notional Amounts of Outstanding Derivative Positions


	Aggregate Notional Amount		Aggregate Notional Amount Maturing within 12 Months

(in millions)







Hedges of Net Investments
Foreign exchange forward contracts	$	804	$	299
Cross currency basis swaps	1,413		—
Total derivative instruments designated as hedges of net investments	$	2,217	$	299

Fair Value Hedges

Interest rate swaps	150		—
Total derivative instruments designated as fair value hedges	$	150	$	—

Derivative Instruments not Designated as Hedges
Foreign exchange forward contracts	$	1,026	$	1,026

Total derivative instruments not designated as hedges	$	1,026	$	1,026

Schedule of Derivative Instruments

The effects of derivative hedging instruments on the Consolidated Statements of Operations and Consolidated Statements of Comprehensive Loss were as follows:


	Year Ended December 31, 2025						Year Ended December 31, 2024						Year Ended December 31, 2023
(in millions)	Cost of products sold		Interest expense, net		Other (income) expense, net		Cost of products sold		Interest expense, net		Other (income) expense, net		Cost of products sold		Interest expense, net		Other (income) expense, net

Total amounts of line items presented in the Consolidated Statements of Operations in which the effects of cash flow, net investment or fair value hedges are recorded	$	1,840	$	88	$	(24)	$	1,835	$	69	$	(12)	$	1,879	$	81	$	9





Gain on Hedges of Net Investment
Cross currency basis swaps	$	—	$	—	$	(23)	$	—	$	—	$	(5)	$	—	$	—	$	(5)
Foreign exchange forward contracts	—		—		(25)		—		—		(25)		—		—		(12)

Loss on Fair Value Hedges:
Interest rate swaps	$	—	$	6	$	—	$	—	$	8	$	—	$	—	$	11	$	—
Foreign exchange forward contracts	—		—		—		—		—		—		—		—		—

Loss on Derivative Instruments not Designated as Hedges
Foreign exchange forward contracts	$	—	$	—	$	12	$	—	$	—	$	2	$	—	$	—	$	8


	Amount of Gain or (Loss) Recognized in AOCI							Amount of Gain or (Loss) Reclassified from AOCI into Income
	Year Ended December 31,						Consolidated Statements of Operations Location	Year Ended December 31,
(in millions)	2025		2024		2023			2025		2024		2023







Hedges of Net Investments
Cross currency basis swaps	$	(49)	$	11	$	(18)	Other (income) expense, net	$	—	$	—	$	—
Foreign exchange forward contracts	(102)		37		(29)		Other (income) expense, net	—		—		—


Fair Value Hedges
Interest rate swaps	$	—	$	—	$	—	Other (income) expense, net	$	—	$	—	$	—
Foreign exchange forward contracts	—		—		2		Interest expense, net	—		—		—

Schedule of Consolidated Balance Sheets Location of Derivative Fair Values

The fair value and the location of the Company’s derivatives in the Consolidated Balance Sheets were as follows:


	Year Ended December 31, 2025
(in millions)	Prepaid Expenses and Other Current Assets		Other Noncurrent Assets		Accrued Liabilities		Other Noncurrent Liabilities

Designated as Hedges:
Foreign exchange forward contracts	$	—	$	—	$	21	$	40

Interest rate swaps	—		—		3		11
Cross currency basis swaps	42		—		—		73
Total	$	42	$	—	$	24	$	124

Not Designated as Hedges:
Foreign exchange forward contracts	$	8	$	—	$	6	$	—



Total	$	8	$	—	$	6	$	—


	Year Ended December 31, 2024
(in millions)	Prepaid Expenses and Other Current Assets		Other Noncurrent Assets		Accrued Liabilities		Other Noncurrent Liabilities

Designated as Hedges:
Foreign exchange forward contracts	$	5	$	9	$	—	$	1

Interest rate swaps	—		—		4		17
Cross currency basis swaps	4		14		—		—
Total	$	9	$	23	$	4	$	18

Not Designated as Hedges:
Foreign exchange forward contracts	$	4	$	—	$	8	$	—



Total	$	4	$	—	$	8	$	—

Schedule of Balance Sheet Offsetting

Offsetting of financial assets and liabilities under netting arrangements at December 31, 2025 was as follows:


							Gross Amounts Not Offset in the Consolidated Balance Sheets
(in millions)	Gross Amounts Recognized		Gross Amounts Offset in the Consolidated Balance Sheets		Net Amounts Presented in the Consolidated Balance Sheets		Financial Instruments		Cash Collateral Received/Pledged		Net Amount

Assets
Foreign exchange forward contracts	$	8	$	—	$	8	$	(8)	$	—	$	—


Cross currency basis swaps	42		—		42		(42)		—		—

Total assets	$	50	$	—	$	50	$	(50)	$	—	$	—

Liabilities
Foreign exchange forward contracts	$	67	$	—	$	67	$	(18)	$	—	$	49


Interest rate swaps	14		—		14		—		—		14
Cross currency basis swaps	73		—		73		(32)		—		41
Total liabilities	$	154	$	—	$	154	$	(50)	$	—	$	104

Offsetting of financial assets and liabilities under netting arrangements at December 31, 2024 were as follows:


							Gross Amounts Not Offset in the Consolidated Balance Sheets
(in millions)	Gross Amounts Recognized		Gross Amounts Offset in the Consolidated Balance Sheets		Net Amounts Presented in the Consolidated Balance Sheets		Financial Instruments		Cash Collateral Received/Pledged		Net Amount

Assets
Foreign exchange forward contracts	$	18	$	—	$	18	$	(5)	$	—	$	13


Cross currency basis swaps	18		—		18		(6)		—		12
Total assets	$	36	$	—	$	36	$	(11)	$	—	$	25

Liabilities
Foreign exchange forward contracts	$	9	$	—	$	9	$	(4)	$	—	$	5
Interest rate swaps	21		—		21		(7)		—		14



Total liabilities	$	30	$	—	$	30	$	(11)	$	—	$	19

SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS

12 Months Ended

Dec. 31, 2025

SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]

SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS

SCHEDULE II

DENTSPLY SIRONA INC. AND SUBSIDIARIES

VALUATION AND QUALIFYING ACCOUNTS

FOR THE YEARS ENDED DECEMBER 31, 2025, 2024, and 2023


			Additions
Description	Balance at Beginning of Period		Charged To Costs And Expenses		Charged to Other Accounts		Write-offs Net of Recoveries		Translation Adjustment		Balance at End of Period

(in millions)

Allowance for doubtful accounts:

For the Year Ended December 31,
2023	$	14	$	6	$	(1)	$	(3)	$	1	$	17
2024	17		14		(9)		(6)		(2)		14
2025	14		1		(2)		(3)		2		12

Inventory valuation reserve:

For the Year Ended December 31,
2023	$	82	$	39	$	—	$	(18)	$	4	$	107
2024	107		26		—		(22)		(13)		98
2025	98		17		—		(27)		7		95

Deferred tax asset valuation allowance:

For the Year Ended December 31,
2023	$	645	$	279	$	4	$	(70)	$	5	$	863
2024	863		691		—		(39)		(12)		1,503
2025	1,503		634		5		(61)		22		2,103

SIGNIFICANT ACCOUNTING POLICIES - ADDITIONAL INFORMATION (Details) $ in Millions			12 Months Ended
	Dec. 07, 2023 USD ($)	Dec. 06, 2023 USD ($)	Dec. 31, 2025 USD ($) year country	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)
Significant Accounting Policies [Line Items]
Company years in innovation and service \| year			139
Number of countries in which entity operates \| country			140
Cash and cash equivalents			$ 326	$ 272
Foreign currency translation gain (loss)			185	(146)	$ 49
Stockholders' equity (deficit)			1,340	1,943	3,294	$ 3,812
Foreign exchange transaction gain (loss)			32	21	3
Sale of minority interest	$ 13
Equity-method net losses		$ 4	$ 0	0	4
Employee Stock Option
Significant Accounting Policies [Line Items]
Award expiration period			10 years
Hedges of Net Investments
Significant Accounting Policies [Line Items]
Foreign currency translation gain (loss)			$ 263	(192)	78
Stockholders' equity (deficit)			$ (78)	$ 46	$ (29)
Minimum
Significant Accounting Policies [Line Items]
Lease, remaining lease term			1 year
Lessee, lease, renewal term			1 year
Maximum
Significant Accounting Policies [Line Items]
Lease, remaining lease term			8 years
Lessee, lease, renewal term			3 years
Russia
Significant Accounting Policies [Line Items]
Cash and cash equivalents			$ 56

SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Translation Adjustment	$ 1,992
Allowance for doubtful accounts:
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Period	14	$ 17	$ 14
Charged To Costs And Expenses	1	14	6
Charged to Other Accounts	(2)	(9)	(1)
Write-offs Net of Recoveries	(3)	(6)	(3)
Translation Adjustment	2	(2)	1
Balance at End of Period	12	14	17
Inventory valuation reserve:
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Period	98	107	82
Charged To Costs And Expenses	17	26	39
Charged to Other Accounts	0	0	0
Write-offs Net of Recoveries	(27)	(22)	(18)
Translation Adjustment	7	(13)	4
Balance at End of Period	95	98	107
Deferred tax asset valuation allowance:
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Period	1,503	863	645
Charged To Costs And Expenses	634	691	279
Charged to Other Accounts	5	0	4
Write-offs Net of Recoveries	(61)	(39)	(70)
Translation Adjustment	22	(12)	5
Balance at End of Period	$ 2,103	$ 1,503	$ 863

COVER PAGE - USD ($)	12 Months Ended
COVER PAGE - USD ($)	Dec. 31, 2025	Feb. 20, 2026	Jun. 30, 2025
Cover [Abstract]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2025
Current Fiscal Year End Date	--12-31
Document Transition Report	false
Entity File Number	0-16211
Entity Registrant Name	DENTSPLY SIRONA Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	39-1434669
Entity Address, Address Line One	13320 Ballantyne Corporate Place
Entity Address, City or Town	Charlotte
Entity Address, State or Province	NC
Entity Address, Postal Zip Code	28277-3607
City Area Code	844
Local Phone Number	848-0137
Title of 12(b) Security	Common Stock, par value $.01 per share
Trading Symbol	XRAY
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Document Financial Statement Error Correction	false
Entity Shell Company	false
Entity Public Float			$ 3,158,220,816
Entity Common Stock, Shares Outstanding		199,749,333
Documents Incorporated by Reference	DOCUMENTS INCORPORATED BY REFERENCE Certain portions of the definitive Proxy Statement of DENTSPLY SIRONA Inc. (the “Proxy Statement”) to be used in connection with the 2026 Annual Meeting of Stockholders are incorporated by reference into Part III of this Form 10-K to the extent provided herein. Except as specifically incorporated by reference herein the Proxy Statement is not deemed to be filed as part of this Form 10-K.
Entity Central Index Key	0000818479
Document Fiscal Year Focus	2025
Document Fiscal Period Focus	FY
Amendment Flag	false

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Cash flows from operating activities:
Net loss	$ (598)	$ (910)	$ (132)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation	141	133	132
Amortization of intangible assets	211	216	211
Goodwill impairment	525	773	291
Intangible asset impairment	125	241	16
Deferred income taxes	30	(136)	(130)
Stock-based compensation expense	33	39	46
Other non-cash (income) expense	(10)	(9)	2
Loss (gain) on disposal of property, plant and equipment	0	19	(3)
Changes in operating assets and liabilities:
Accounts and notes receivable-trade, net	(91)	104	(58)
Inventories, net	(17)	17	6
Prepaid expenses and other current assets	(7)	38	(58)
Other noncurrent assets	(7)	(5)	4
Accounts payable	11	(30)	14
Accrued liabilities	(74)	(39)	17
Income taxes	(32)	38	(11)
Other noncurrent liabilities	(5)	(28)	30
Net cash provided by operating activities	235	461	377
Cash flows from investing activities:
Cash received on sale of non-strategic businesses or product lines	0	0	13
Capital expenditures	(131)	(180)	(149)
Cash received on derivative contracts	10	1	39
Cash paid on derivative contracts	(14)	(12)	0
Other investing activities, net	3	(6)	8
Net cash used in investing activities	(132)	(197)	(89)
Cash flows from financing activities:
Proceeds from long-term borrowings	553	1	0
Cash paid for deferred financing costs	(16)	0	0
Repayments on long-term borrowings	(147)	(88)	(7)
Proceeds from 364-day bridge loan	435	0	0
Repayment of 364-day bridge loan	(435)	0	0
(Repayments) proceeds on other short-term borrowings, net	(336)	177	126
Cash paid for treasury stock	0	(250)	(300)
Cash dividends paid	(128)	(126)	(116)
Other financing activities, net	(6)	(16)	(10)
Net cash used in financing activities	(80)	(302)	(307)
Effect of exchange rate changes on cash and cash equivalents	31	(24)	(12)
Net (decrease) increase in cash and cash equivalents	54	(62)	(31)
Cash and cash equivalents at beginning of period	272	334	365
Cash and cash equivalents at end of period	326	272	334
Supplemental disclosures of cash flow information:
Interest paid, net of amounts capitalized	66	91	97
Income taxes paid, net of refunds	71	74	177
Non-cash investing activities:
Change in accounts payable related to capital expenditures	37	8	6
Exchange of inventory for naming rights	$ 14	$ 0	$ 0

FINANCING ARRANGEMENTS

12 Months Ended

Dec. 31, 2025

Debt Disclosure [Abstract]

FINANCING ARRANGEMENTS

Notes Payable and Current Portion of Long-Term Debt

Notes payable and current portion of long-term debt was as follows:


	Year Ended December 31,
	2025				2024
	Principal		Interest		Principal		Interest
(in millions except percentages)	Balance		Rate		Balance		Rate


Corporate commercial paper facility	$	82	4.4	%	$	410	5.3	%
Other short-term borrowings	3		4.5	%	11		4.9	%
Add: Current portion of long-term debt	228				128

Total notes payable and current portion of long-term debt	$	313			$	549


Average amount of short-term debt outstanding during the year	136				344
Weighted-average interest rate on short-term debt at year-end			4.4	%			5.3	%

Short-Term Financing

The Company has a five-year senior unsecured multi-currency revolving facility, for an aggregate principal amount of $700 million, that expires on May 12, 2028. The Company also has a $700 million commercial paper program. The $700 million multi-currency revolving credit facility serves as a back-up to the commercial paper facility, resulting in an aggregate of $700 million total available credit under the commercial paper facility and the multi-currency revolving credit facility. The Company had outstanding borrowings of $82 million and $410 million under the commercial paper facility at December 31, 2025 and December 31, 2024, respectively, and no outstanding borrowings under the multi-currency revolving credit facility. The Company also has access to $22 million in uncommitted short-term financing available under lines of credit from various financial institutions, which is reduced by outstanding short-term borrowings of $3 million.

At December 31, 2025, the Company had $637 million borrowings available under unused lines of credit, including lines available under its short-term arrangements and revolving credit facility.

Long-Term Debt

Long-term debt was as follows:


	Year Ended December 31,
	2025			2024
	Principal			Principal		Due
(Principal balances in millions)	Balance		Balance



0.9% Private placement notes 25 million Swiss franc	—			28		December 2025
2.1% Private placement notes 97 million euros	—			100		December 2025
2.1% Private placement notes 26 million euros	31			27		February 2026
1.0% Private placement notes 58 million Swiss franc	73			64		August 2026
2.3% Private placement notes 106 million euros	125			110		August 2026
1.3% Private placement notes 70 million euros	82			72		October 2027
1.0% Private placement notes 8 million Swiss franc	9			8		December 2027
2.2% Private placement notes 15 million euros	18			16		December 2027
1.2% Private placement notes 140 million Swiss franc	177			154		August 2028
1.5% Private placement notes 70 million euros	82			72		October 2029
3.3% Fixed rate senior notes 750 million	749			750		June 2030
1.6% Private placement notes 70 million euros	82			72		October 2030
2.5% Private placement notes 45 million euros	53			47		February 2031
1.3% Private placement notes 65 million Swiss franc	82			72		August 2031
1.0% Private placement notes 12.6 billion Japanese yen	80			80		September 2031
1.7% Private placement notes 70 million euros	82			72		October 2031
8.4% Private placement notes 550 million U.S. dollars	550			—		September 2055
Other borrowings, various currencies and rates	1			4
Hedge accounting fair value adjustment(a)	(19)			(28)
	$	2,257		$	1,720
Less: Current portion
(included in “Notes payable and current portion of long-term debt” in the Consolidated Balance Sheets)	228			128
Less: Long-term portion of deferred financing costs	14			6
Long-term portion	$	2,015		$	1,586

(a) Represents the fair value of interest rate swap agreements entered into on a portion of the outstanding senior notes.

Our private placement notes and revolving credit facility contain financial covenants, including maximum Total Leverage Ratio and maximum Senior Leverage Ratio requirements. On December 24, 2025, these covenants were amended to permit higher leverage levels that step down over time from 4.25 to 1.00 for the four fiscal quarter period ended December 31, 2025 to 2.50 to 1.00 in the quarter ended December 31, 2027 and thereafter. The amendments also added restrictions on certain restricted payments, revised the definition of EBITDA to allow limited addbacks for efficiency‑initiative costs through 2026, and excluded swap obligations from the definition of debt for covenant calculations. At December 31, 2025, we were in compliance with all covenants.

The contractual maturity dates of the Company’s long-term borrowings as of December 31, 2025 were as follows:


(in millions)
2026	$	228
2027	110
2028	177
2029	82
2030	832
2031 and beyond	847
	$	2,276

Interest expense, net includes interest income of $14 million, $20 million and $16 million for the years ended December 31, 2025, 2024 and 2023, respectively. Interest income primarily relates to interest-bearing cash and cash equivalents.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481544/470-10-50-6

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481544/470-10-50-6

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 470
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/470/tableOfContent

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482925/835-30-45-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

+ Details

EQUITY - SCHEDULE OF TOTAL OUTSTANDING SHARES (Details) - $ / shares shares in Millions		2 Months Ended	12 Months Ended
	Apr. 28, 2023	Apr. 30, 2023	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shares of common stock, beginning balance (in shares)			198.8	207.2	215.2
Shares of Treasury Stock, beginning balance (in shares)			(65.7)
Shares of treasury stock issued (in shares)			0.8	1.0	0.8
Repurchase of common stock (in shares)	(3.9)	(3.9)		(9.4)	(8.8)
Shares of common stock, ending balance (in shares)			199.6	198.8	207.2
Shares of Treasury Stock, ending balance (in shares)			(64.9)	(65.7)
Stock repurchased under the repurchase program, average price (in dollars per share)				$ 26.65	$ 34.20
Common Stock
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shares of common stock, beginning balance (in shares)			264.5	264.5	264.5
Shares of common stock, ending balance (in shares)			264.5	264.5	264.5
Treasury Stock
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shares of Treasury Stock, beginning balance (in shares)			(65.7)	(57.3)	(49.3)
Shares of treasury stock issued (in shares)			0.8	1.0	0.8
Repurchase of common stock (in shares)				(9.4)	(8.8)
Shares of Treasury Stock, ending balance (in shares)			(64.9)	(65.7)	(57.3)